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 SCIENTIFIC REPORT 1 INTRODUCTION, OBJECTIVE AND RESEARCH QUESTIONS 
1.1 Introduction 
The diagnosis and treatment of cancer patients is a complex, rapidly and 
continuously evolving science. While the number of available therapeutic 
options is getting larger, the number of different health professionals to treat 
the patient is also expanding. A “typical” patient with cancer will be in contact 
with numerous specialists: a medical internist of the organ affected, a 
surgeon specialized in the surgical treatment of the organ affected, a 
medical oncologist, a specialist in medical imaging (perhaps two if nuclear 
imaging is involved), a specialist in pathology, a specialist in radiotherapy 
and sometimes a specialist in genetics. In addition to these physicians, the 
patient may also benefit from the support of other health professionals: a 
nurse specialised in oncology, a psychologist, a social worker, a dietician. 
And ideally, this staff should keep in touch with the patient’s general 
practitioner. As a consequence, when the number of actors around the 
patient increases, the potential for miscommunication, poor coordination 
between healthcare providers and fragmentation of services increases 
accordingly. This constitutes a major challenge for caregivers and for 
patients.1 
Multidisciplinary teams (MDTs) meetings were created as a response to this 
challenge. MDT meetings, as the name suggests, allow specialists from 
different disciplines to form and to unite the best possible team to achieve 
optimal care for a cancer patient. The purpose of the MDT meetings is to 
develop a strategic plan of diagnosis, treatment and follow-up and to discuss 
the overall care of an individual patient.2 MDT meetings were identified as 
the best approach to organise cancer care in a way that consistently brings 
together all healthcare professionals involved in cancer diagnosis and 
treatment3 and in 2014, the European Partnership Action Against Cancer 
(EPAAC) published a policy statement on multidisciplinary cancer care 
which was endorsed by the majority of European scientific societies, patient 
organisations and stakeholders. In this policy statement, MDT meetings are 
described as follows: 
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What are MDT meetings in oncology?  
Multidisciplinary team (MDT) meetings are an alliance of all medical and 
healthcare professionals related to a specific tumour disease whose 
approach to cancer care is guided by their willingness to agree on evidence-
based clinical decisions and to coordinate the delivery of care at all stages 
of the process, encouraging patients in turn to take an active role in their 
care.1 
In Belgium, MDT meetings have been reimbursed since 2003 by the RIZIV-
INAMI for all cancer types. It was one of the first examples of the 
reimbursement of shared intellectual activity involving different specialties. 
It acknowledged the added value of multidisciplinary work to the quality of 
care.4 In 2008 the Belgian Cancer Plan identified the MDT meeting as an 
essential step in the clinical pathway of each new cancer patient,5 and extra 
financial fees were added for the oncologist attending or coordinating the 
meeting. Nevertheless, the requirement has not been translated officially 
into legal texts,6 and in daily practice there is quite some variability as some 
cancer types are not systematically discussed during a MDT meeting.7 
There are, however, financial incentives to do so: the financing of supportive 
staff members in the oncological centres (i.e. psychologists, nurses, social 
workers, dieticians and data managers) is directly based on the number of 
MDT meetings reimbursed in the centre.5 
Today, there is a consensus that the MDT meetings do improve the quality 
of cancer care by strengthening the communication between different health 
professionals, and that this practice should be facilitated as much as 
possible. At present, however, there is not much known about the variability 
between hospitals in the organisation of the MDT meetings. Little information 
is available to which extent all new cancer patients are effectively discussed, 
and to which extent these discussions are really efficient, specific and 
patient-centred. This report aims to provide answers to these questions. 
1.2 Objectives and research questions 
The objectives of this report, which has been commissioned by the RIZIV-
INAMI, are to provide a global picture of the use of MDT meetings in 
Belgium, ten years after the start of their reimbursement, to identify areas of 
improvement and formulate recommendations to policy makers accordingly. 
This objective has been elaborated around the 4 following research 
questions:  
1. What is the evolution in the practice of MDT meetings? What is the 
corresponding evolution in the costs for the RIZIV-INAMI budget?  
2. Are all cancer patients equally benefiting from the MDT meeting? Which 
factors influence the chances of a case being discussed during a MDT 
meeting?  
3. Today, how are these meetings organized in the hospitals? What are 
the barriers and opportunities for a more efficient organization of the 
MDT meetings?  
4. What are the role and expectations of the GPs with regard to the MDT 
meeting? How can GP participation at the MDT meetings be improved?  
1.3 Structure of this report 
The first chapter presents the general context of the study, the objectives 
and research questions.  
The second chapter describes background information about MDT 
meetings in Belgium: the legislation, the Cancer Plan, and the evolution of 
use and charges at a national macro level.  
The third chapter presents a detailed analysis of Belgian Cancer Registry 
data linked to sickness funds billing data for 7 cancers (breast, prostate, 
rectum, lung, soft tissue sarcoma, malignant melanoma and acute 
leukaemia). The number of patients discussed at MDT meeting, timing of 
the discussion, number and qualification of participants are described. This 
chapter is exclusively based on nationally available administrative data, with 
their inherent limitations (mainly the fact that they represent only what was 
billed to the sickness funds).  
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The fourth chapter presents an analysis performed by experts at RIZIV-
INAMI, who have analysed how administrative billing data can be used to 
identify outlying patterns in the use of MDT meetings.  
To enrich the analysis with the views and perceptions of actors in the field, 
a national web survey has been carried out during the spring 2014. More 
than 1000 health professionals, mainly medical specialists, have provided 
information on how the MDT meetings are being organised in their hospitals, 
and their perception of the MDT meetings’ functioning. The results of this 
web survey are presented in the fifth chapter.  
In the sixth chapter, the (lack of) attendance of GPs in the MDT meetings 
is further investigated, by a series of extended interviews of GPs who did 
attend MDT meetings. These interviews and analyses have been performed 
by a consortium of 2 university teams from UGent and ULG.  
The discussion of the above chapters, the conclusions and the policy 
recommendations are not presented in this report, but can be found in the 
scientific summary which accompanies this report, and which is also 
available on the KCE website.  
 
2 BACKGROUND INFORMATION  
2.1 The Belgian context 
2.1.1 Evolution of billing codes and accessory legislation 
The billing codes concerning the MDT meetings have been developed in 
2003 and adapted in 2010, as summarized below and detailed in appendix 
A (description of billing codes and list of Royal Decrees referring to 
oncology).  
In 2003, three billing codes (one for the coordination, 2 for the participation) 
were created, concomitantly with the creation of the programs of care in 
oncology. A MDT meeting can only be billed once per calendar year, and is 
composed of minimum 3 specialists, with a maximum 4 specialists (intra-
muros, including the coordinator of the MDT meeting) who can receive 
reimbursement for attendance at the MDT meeting. 
In 2010 an important change was introduced in the billing codes. It concerns 
the specification of 3 different MDT meeting types: the first MDT meeting, 
which can be billed once at the diagnosis phase, the follow-up MDT 
meeting which can be billed “if required by the evolution of the disease and 
treatment plan” and gets a lower reimbursement (K50 instead of K80), and 
a second advice MDT meeting (supplementary MDT meeting), which can 
be billed by a hospital where the patient is referred to. The restriction of one 
MDT meeting per calendar year disappeared in 2010, and the maximum 
number of intra-muros specialists reimbursed increased from 4 to 5 
(including the coordinator of the MDT meeting). Also in 2010, a new billing 
code was introduced, and allowed some specialists (medical oncology, 
haematology, paediatric oncology and paediatric haematology) to receive a 
supplementary fee when attending or coordinating the MDT meeting.  
More details are presented in the following section.  
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2.1.1.1 Legal specification for the reimbursement of MDT 
meetings  
Who initiates/asks for the MDT meeting?  
To be discussed at the MDT meeting, a written request has first to be sent 
by the treating specialist of the patient, or possibly by his/her GP. Specialists 
in pathology, clinical biology or radiology cannot initiate a MDT meeting. 
What is the role of the coordinator of the MDT meeting?  
One of the attending physicians takes the role of coordinator of the MDT 
meeting. S/he writes the report of the MDT meeting, which describes the 
diagnosis, the prognosis, and the treatment plan, on the short and long term, 
taking into account medical aspects, but also psycho-social aspects. This 
report also contains the names of all participants (even if their number 
exceeds 5), and the name of the requesting physician. 
This written report, signed by the coordinator of the MDT meeting, has to be 
transmitted to  
 All physicians who attended the meeting 
 The requesting physician 
 The GP of the patient (if s/he was not the requesting physician) 
 The advisory doctor from the patient’s sickness fund 
Who attends the MDT meeting?  
At least 4 specialists from different specialities need to physically attend the 
meeting. At least one of them has to 
 have surgical expertise in oncology 
 or have the recognition in medical oncology 
 or have the recognition in radiotherapy 
 or have the recognition of clinical haematology or paediatric 
haematology and oncology  
One of the attending physicians takes the role of coordinator of the MDT 
meeting (see below) and the others are “participating” physicians. More than 
4 participants can be present, but reimbursement will be limited to 4.  
In addition to these participants, there is a specific code for a specialist from 
another hospital or for the GP of the patient. Specialists from another 
hospital who usually attend the MDT meeting (e.g. radiotherapist, medical 
oncologist) are already counted in the participating physicians above.  
Attendance at the MDT meetings 
From 2010 on a maximum of 6 physicians can attest the attendance of 
the MDT meeting:  
- 1 coordinator  
- 4 participants who belong to the hospital staff (intra-muros participants) 
- 1 participant extra-muros (the GP or the treating specialist of the patient, if 
s/he’s not part of the hospital team) 
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Table 1 – Maximal reimbursement of a first MDT meeting per discussed case 
What? Qualification K Max N Fee 01/02/2014 Total 
Coordination  Specialist K80 1 95.11 € € 95.11 
Participation Specialist K17 4 20.21 € € 80.84 
Total   5  € 175.95 
In the case of 
attendance by…  
Specialist outside 
hospital or GP 
K25 1 29.72 €  
If additional fee Coordination by 
oncologist 
K15  17.83 €  
Total   6  € 223.5 
Which MDT meeting types are specified?  
First MDT meeting 
A first MDT meeting is mandatory in some specific situations well described 
in the AR-KB. Only in the specific case of patients with breast cancer treated 
in a recognized breast clinic is the practice of a MDT meeting mandatory.6 
Mandatory, and eligible for reimbursement 
 For every oncological treatment which deviates from the written 
guidelines of the oncological centre (manual of oncology). 
 For a repetition of a series of irradiations in the same target zone, 
starting within 12 months after the start of the first series of irradiations 
 For chemotherapy with a drug which, in its first reimbursement phase, 
has been designated by the CTG to be monitored by the MDT meeting  
Not mandatory, but eligible for reimbursement 
 For every patient with a new diagnosis of cancer, except the cases 
mentioned below. 
Not eligible for reimbursement  
 uncomplicated basal cell carcinoma of skin (BCC)  
 uncomplicated squamous cell carcinoma of the skin (SCC). 
Follow-up MDT meeting  
A follow up COM can be billed when 
 The follow-up of the treatment requests the revision of the diagnosis 
and/or a change in the treatment plan 
And/or 
 To repeat a series of irradiations within 12 months after the start of the 
first series of irradiation  
The “change in the treatment plan” has to be interpreted in a restricted way 
and used with parsimony: it only refers to a change in the treatment plan 
where a multidisciplinary decision is required. Changes in the chemotherapy 
or radiotherapy plan treatment or in palliative care is the responsibility of the 
treating specialist, and does not necessarily require a follow-up MDT 
meeting.  
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Supplementary MDT meeting 
If the result of the MDT meeting cannot lead to a definitive diagnosis or to a 
concrete treatment plan, the team can decide to refer the patient to a hospital 
with more expertise (and with a care program in oncology). The name of this 
hospital has to be mentioned in the MDT meeting report. If the patient 
decides to go to another hospital (e.g. for referral or for second opinion), and 
the name of that hospital is not explicitly mentioned on the MDT meeting 
report, this hospital will not be reimbursed for the supplementary MDT 
meeting. 
2.1.1.2 Medico-legal issues related to MDT meeting  
Traditionally, a doctor-patient relationship reflects a one to one relation, 
where mostly face-to-face interactions occur. The shift towards a team 
approach, such as in multidisciplinary oncological team discussions, where 
patient cases are jointly discussed raise some concerns about the medico-
legal implications. In Belgium as well as internationally, lawsuits involving 
medico-legal liability related to the outcome or the process of MDT meetings 
are unknown, which suggest that probably the risk for lawsuits in this matter 
is rather low. Yet, clarity on which patients should be discussed at the MDT 
meetings, the status of the decisions of the MDT meetings and the 
accountability of the participants for the decisions that were taken and about 
the implementation of these decisions is important to avoid defensive 
behaviour creating a barrier to this kind of multidisciplinary approach.  
Referral of patient cases to MDT meetings 
Today MDT meetings are not obligatory for Belgian hospitals. If MDT 
meetings are organized it is usually the treating physician who will decide 
on the referral of the patient to a MDT meeting. There are no uniform criteria 
for which patients should be discussed. Therefore, the documentation of the 
reason of non-referral of a patient to a MDT meeting could help to streamline 
a uniform approach and could serve as evidence in possible lawsuits. 
Patients’ informed consent  
Patient consent needs to be obtained for every intervention of a healthcare 
professional (art. 8 Belgian Patients’ Rights Act8). When considering the 
referral of a patient case to a MDT meeting, patients (or their legal 
representative) need to understand the purpose of the MDT meeting, the 
possible disciplines present (observational or participating in discussion) 
and the medical and non-medical information that will be shared within the 
team.9 Patients discussed during the MDT meetings are protected by the 
principles of confidentiality of the doctor-patient relationship (professional 
secrecy – art. 458 Belgian Penal Code). Traditionally professional secrecy 
applies in the doctor-patient relationship or in the relationship patient-
medical team (shared professional secrecy).10, 11 During the MDT meeting, 
however, several participants -in particular in general MDT meetings- will 
possibly be involved or attending discussions on patients they have no 
medical relation with and/or where the patient is personally known by a team 
member. Therefore it is of utmost importance that patients are informed on 
the team that will be present at the MDT meeting. Patients should be offered 
the option to indicate the information they do not wish to share.9 A possible 
option for the healthcare professionals concerned to avoid conflicts of 
interest is the possibility not to take part in the decision making or not to 
attend when the case of the patient they are familiar with is discussed.9  
Accountability for MDT meeting decisions 
The fundamental legal principle underlying a professional patient-doctor 
relationship is the duty to take reasonable care for the patient. The lack of 
reasonable care can lead to medical liability if this has caused an injury or 
other damage to the patient. As patient cases in MDT meetings are 
discussed in team, the question arises if and with whom the patient has a 
doctor-patient relationship. Furthermore, as the MDT meeting team has no 
legal personality the question arises who can be held liable in case of 
malpractice. According to the literature, each doctor is individually 
responsible and potentially liable for the decisions within his/her area of 
expertise.12, 13 This implies that if MDT meeting participants do not agree 
with the proposed recommendation resulting from the MDT meeting 
discussion, this should be noted in the MDT meeting report. Possibly an 
alternative recommendation could be documented. Overall, the 
documentation of the treatment plan, the participating members and 
possible dissenting opinions are of utmost importance. In that scope the 
availability of sound systems and tools to support the process are primordial 
(cfr. supra).  
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2.1.2 The Cancer Plan and the financing of extra manpower in 
oncological centres  
Since July 1st 2008, the Cancer Plan offers financial support to hospitals 
having a certified oncological care programa by financing extra manpower to 
support patients with cancer: nurses in oncology (a recognized function 
since 2009, Cancer Plan Action 1414), onco-psychologists, social workers 
(Cancer Plan Action 10), data managers (Cancer Plan Action 11) and since 
January 2011 also dieticians. The FTE of the extra manpower are calculated 
based on the number of MDT meetings reimbursed in the hospital. 
In 2012, 1 070 full time equivalents (FTE) were financed: 330 nurses in 
oncology, 330 onco-psychologists, 165 social workers, 163 dieticians and 
82 data managers. 14For a medium size hospital which would perform 500 
MDT meetings per year, this corresponds to 6.5 FTEs (see Table 2).  
Computation of FTEs 
There has been an evolution in the way FTE were calculated. For the period 
2008-2010, the number of FTE were calculated each year based on the last 
available number of MDT meetings reimbursed (usually 2 years before, so 
FTE financed in 2008 were calculated based on number of MDT meeting 
reimbursed in 2006). From 2011 onwards, the computation was not done 
per year, but was valid for a period of 3 years. Thus for 2011, 2012 and 
2013, reimbursement data from 2009 have been used, without taking into 
account the change in billing codes from 2010. For 2014 (and 2015-2016), 
a new way of computation will be put in place, but this is not yet known at 
the moment.  
Function Description  
The role of the data manager is described in the law: the data manager is 
responsible for collecting and sending the required data to the Belgian 
Cancer Registry, for the evaluation of adherence to the recommendations of 
the hospital manual of oncology and also for the evaluation of the good 
implementation of the decisions of the MDT meeting where he/she assists.  
                                                     
a  This encompasses the care programme for basic oncological care (le 
programme de soins de base en oncologie - het zorgprogramma voor 
The exact function of the nurses in oncology, psychologists, social workers 
and dieticians are not legally described, and interpretations of the role of the 
different actors vary across hospitals.15  
Table 2 – Financing of manpower based on number of MDT meetings 
(Cancer Plan) 
Specialty  Manpower In 2012, FTE 
financed  
by Cancer 
Plan 
Example FTE  
for 500 MDT 
meetings/year 
Supportive staff oncological centre 
Onco nurse  1 FTE/250 MDT 
meetings 
330 2 
Onco 
psychologist 
 1 FTE/250 MDT 
meetings 
330 2 
Social worker  1 FTE/500 MDT 
meetings 
165 1 
Dietician  1 FTE/1-500 
MDT meetings* 
163 1 
Data collection and registry 
Data manager  1 FTE/1000 
MDT meetings 
82 0.5 
Total   1 070 6.5 
* with ½ FTE /250 additional MDT meetings, and maximum 4 FTE per hospital 
  
oncologische basiszorg) and the oncology care programme (le programme 
de soins d’oncologie - het zorgpgrogramma voor oncologie). 
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2.1.3 Information flows between hospitals, the Belgian Cancer 
Registry and the sickness funds  
There are three main actors involved in the data collection of cancer 
incidence data and MDT meeting reports: the hospitals, the Belgian Cancer 
Registry (BCR) and the sickness funds. Different documents or registration 
forms are necessary (see list below).  
Hospitals have to register all new cancer diagnosesb, irrespective of the fact 
that the diagnosis is discussed during a MDT meeting, using the template of 
annex 55 (see appendix A). Paper registration ‘only’ by the hospitals is 
strongly discouraged (in 2014, only 2 hospitals still transfer their information 
on paper). Sending an electronic file with all data on a yearly basis, or direct 
registration via the online Web Based application for Cancer Registration 
(WBCR) are more straightforward.16 Cancer registration is typically done by 
data managers, who are financed by the Cancer Plan. Legally, the 
registration of cancer cases is one of the responsibilities of the coordinator 
in oncology (Note: there is one coordinator per oncological centre). 
Document Content Coverage Recipients 
Annex 55 Registration form for 
a new cancer case 
Mandatory for all 
patients 
BCR and 
sickness funds 
Annex 55 
(bis) 
List of participants 
attending the MDT 
meeting 
Mandatory to receive 
reimbursement of the 
MDT meeting 
Sickness 
funds 
Annex 55 
(ter)  
Registration form to 
declare a recurrence 
of a cancer (follow-
up) 
when patient discussed 
at MDT meeting 
BCR and 
sickness funds 
MDT 
meeting 
Report (no 
formal 
template) 
Written report of the 
MDT meeting  
Mandatory to receive 
reimbursement of the 
MDT meeting 
Sickness 
funds 
                                                     
b  The registration of new cases of cancer includes all malignant tumours (in situ 
and invasive), all haematological tumours (including myeloproliferative 
neoplasms and myelodysplastic syndroma), all tumours of the central 
If a patient is discussed during a MDT meeting in a hospital, 5 documents 
have to be sent (on paper) to the advisory doctor of the regional sickness 
fund of the patient:  
1. The MDT meeting request  
2. Annex 55 (the form to register a new cancer case)  
3. The MDT meeting report (which is different from annex 55, and should 
contain more detailed information 
4. The list of attending participants and their signature 
5. The billing request  
The regional sickness funds perform administrative controls. Basically they 
check if the MDT meeting was not already billed for this patient by another 
hospital; in that case it refuses the reimbursement of the MDT meeting in 
the second hospital. Sickness funds also transfer all documents to the 
national sickness funds, which then gather and transfer all required 
documents to the Belgian Cancer Registry. They are not electronically 
encoded, but are used as source of information if inconsistencies spotted in 
the data.  
The other source of information, in addition of the clinical network described 
above (hospitals sending cancer data directly to BCR) is the pathological 
network. 16 The pathology laboratories encode the received specimens 
following classification rules approved by the Consilium Pathological 
Belgicum. In Flanders most of the laboratories follow the Codap-2007 
classification. Various coding systems are used in the Walloon and Brussels 
Capital Region. Every (pre) malignant diagnosis is encoded and yearly 
transferred to the BCR, accompanied by the protocols as stated in the law. 
These data (clinical and pathological) are then linked by patient, and quality 
control and consistency checks are performed. In more complex cases, the 
data source is consulted to provide additional information.  
nervous system (benign, malignant, borderline), all urothelial tumours (low 
malignant potential, in situ et invasive), all ovarian tumours (borderline and 
malignant). 
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Figure 1 – Data flows between hospitals, sickness funds and the 
Belgian Cancer Registry 
 
2.1.4 Evolution in number of MDT meetings and costs 
Figure 2 and Table 3 present the evolution in use of MDT meetings between 
2003 and 2013 (2012 data are almost complete, and 2013 data are given 
for indication only).  
In 2012, 104 530 MDT meetings were reimbursed, of which 65% were first 
MDT meetings (N=68 142, which is more that the number of new cancers 
diagnosed in Belgium, 64 301 in 201117), 34% were follow-up MDT meetings 
(N=35 743), and less than 0.6% (N=645) were supplementary MDT 
meetings (Table 4).  
The charges for RIZIV-INAMI in 2012 amounted to € 16.6 million, thus on 
average € 160 reimbursed per MDT meeting per patient.  
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Figure 2 – Evolution of number of MDT meetings (2003-2013) 
 
Source: RIZIV-INAMI (DOC N, update August 2014, includes booking data 4Q2013), KCE calculation (year based on MDT meeting date), 
(2013)* data not yet complete 
 
 20  MDT meetings in oncology KCE Report 239 
 
Table 3 – Evolution over time of number of MDT meetings and costs for RIZIV-INAMI (2003 – 2012) 
Year # MDT meetings % increase in # of MDT 
meetings 
€ (total) € /MDT meeting/patient 
2003 28 350  3 875 029 136.7 
2004 47 783 68.5 6 567 018 137.4 
2005 54 548 14.2 7 420 868 136.0 
2006 58 291 6.9 8 096 502 138.9 
2007 60 744 4.2 8 603 825 141.6 
2008 72 248 18.9 10 352 560 143.3 
2009 83 980 16.2 12 563 093 149.6 
2010 93 241 11.0 14 181 072 152.1 
2011 101 171 8.5 15 761 252 155.8 
2012 104 530 3.3 16 578 724 158.6 
(2013*) 74 587 -28.6 11 949 968 160.2 
Year = year of the MDT meeting, #MDT MEETINGS based on number of first, follow up and supplementary MDT meetings, € total includes all reimbursed for MDT meetings 
(coordination, participation, additional fees) 
Source: RIZIV-INAMI (DOC N, update August 2014, includes booking data 4Q2013), KCE calculation (year based on MDT meeting date) 
(2013*) data not yet complete 
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Table 4 – Types of MDT meetings (first, follow-up, supplementary) 
Year First MDT 
meeting 
Follow-up MDT 
meeting 
Supplement
ary MDT 
meeting 
Total  
 N % N % N % 100%
2011 67 397 66.6 33 221 32.8 553 0.5 101 171
2012 68 142 65.2 35 743 34.2 645 0.6 104 530
(2013*) 47 907 64.2 26 372 35.4 308 0.4 74 587
Year = year of the MDT meeting 
*Data for 2012/2013 not complete yet 
Source: INAMI-RIZIV (DOC N, update August 2014, includes booking data 
4Q2013), KCE calculation (year based on MDT meeting date) 
(2013*) data not yet complete 
2.2 The international context – what we learn from the 
literature 
2.2.1 Variable MDT practice around the globe 
The use of multidisciplinary teams (MDTs) in cancer care is endorsed 
internationally, but its uptake varies considerably. MDT practice is well 
established in the United Kingdom (UK), Europe, Australia and Canada, as 
well as in parts of the United States (US); however, it is a less common 
model of care in Asia.18 A survey among 152 investigators in breast cancer 
from 39 countries revealed that 65% of the eastern European respondents, 
63% of the western European, 35% of the Asian and 25% of the South 
American respondents declared that MDTs were a mandatory part of breast 
cancer care in their country.19 The majority (90%) of European respondents 
reported that their MDTs met weekly, compared with only half of the 
respondents from Asia.19 
In Australia multidisciplinary meetings are a central focus of multidisciplinary 
care.20 National guidelines suggest the treatment plan should include all 
therapeutic options discussed and, ultimately, a preferred treatment 
strategy. The plan is then discussed with the patient and modified according 
to individual preferences. This approach should result in evidence-based 
practice that is individualized for the particular patient. It also incorporates 
shared decision making, which is preferred by patients and is a component 
of quality cancer care.20 
In France, certain quality criteria for multidisciplinary cancer meetings (e.g. 
at least three specialists, at least two meetings per month, regular evaluation 
of the multidisciplinary meetings) have been described precisely in the 
cancer plan and in legal documents (‘circulaires’).21 
Canada has state-defined guidelines for the use of multidisciplinary teams 
in cancer care.18 Cancer Care Ontario for instance published 
multidisciplinary cancer conference (MCC) standards in 2006 to guide the 
development of MCC, taking into account the different circumstances in 
regional centres and in community hospitals of various sizes 
(http://www.cancercare.on.ca). In 2007, Wright et al. reported that in Ontario 
very few hospitals had developed cancer conferences or forums for the 
prospective discussion of patient cancer care.22 
In the England and Wales the impetus for the widespread introduction of 
multidisciplinary cancer care began with the 1995 Calman-Hine report.23 The 
report recommended major organisational changes, including more team 
working among those providing treatment and care; multidisciplinary 
consultation and management were judged as essential.23, 24 Nowadays, all 
multidisciplinary teams submit self-assessments to a national database and 
a sample is validated by an external peer review team (clinicians, users, 
commissioners, and managers), who may also visit the teams.25 
2.2.2 Benefits of multidisciplinary meetings/settings 
Intuitively multidisciplinary care should be associated with better patient 
related outcomes. A Scottish study for instance linked a significant survival 
benefit in breast cancer survival to multidisciplinary care, over and above 
improvements expected to occur in the absence of multidisciplinary care.26 
Improved survival thanks to the multidisciplinary setting has also been 
illustrated for e.g. colorectal cancer (thanks to a significant increase in 
patients undergoing adjuvant postoperative chemotherapy27), inoperable 
non-small cell lung cancer, 28 prostate cancer,2 head & neck cancers29 and 
ovarian cancer;30 others failed to see any significant impact on clinical 
outcomes.31, 32, 33, 34 According to Lamb et al. it is not surprising that some 
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studies failed to show improved clinical outcomes as a direct result of the 
introduction of MDT meetings; it may have several reasons: clinical 
outcomes for cancer patients are multifactorial and MDTs are only one part 
of a complex care process.35, 36 Also, the quality of MDTs can be variable37 
as well as the team decision-making process and the ability of the team 
members to work together to reach the best treatment schemes for the 
patient.35, 36 In addition, traditional health professional hierarchies with e.g. 
nursing personnel not having the opportunity to participate actively in the 
discussions may lead to decisions where patient’s choices and psychosocial 
issues are hardly incorporated.38, 39 Lack of information (availability of proper 
imaging, histopathological information) may also add to suboptimal 
functioning of the MDTs.40  
Nevertheless, there is an abundance of literature that documents that MDTs 
may be beneficial for several aspects of cancer care: 
 Clinical decision making: increased likelihood that individual patients 
are offered the most appropriate treatment for their condition, because 
management plans are based on a broad range of expert knowledge 
from the start, and all aspects that influence treatment options are 
considered;24, 41, 42 revision of cancer diagnoses and of treatment plans 
in new cancer cases;43, 44 improved staging accuracy and treatment 
selection;45, 46 MDT discussion as an independent predictor of receiving 
radiotherapy, chemotherapy and referral to palliative care;34 better 
adherence to evidence-based guidelines;47-49 supporting evidence 
based decision making;50 sparing patients from unnecessary surgery;50 
 Clinical outcomes: improved survival for several cancer types (cfr. 
supra); reduced variation in survival among hospitals for breast 
cancer;26 significantly reduced rate of positive surgical margins after 
MDT discussion of staging with magnetic resonance imaging and 
subsequent preoperative treatment recommendations;51  
 Coordination and continuity of care: decreased time from diagnosis or 
presentation to initiation of treatment;52, 53 simplification of referral 
processes between health professionals, and avoidance of the 
duplication of examinations and investigations;54 better awareness 
among team members of efficient ways of treatment planning;54 
ensuring appropriately timed surgery;50  
 Communication: assist in communication and information sharing 
between healthcare professionals, particularly between hospital-based 
specialists and primary care providers, which enhances referral and 
continuing care pathways;24 
 Clinical trial recruitment: increased recruitment into clinical trials;55, 56  
 Staff wellbeing: excellent opportunity for training doctors and nurses;20 
the mutually supportive environment experienced as beneficial, 
especially in complex cases 57; improved education and collegiality for 
members of the MDT;58  
 Patient wellbeing: increased patient satisfaction by encouraging 
involvement of patients’ families and friends and by helping patients 
make treatment decisions;59 dissemination of information about support 
groups;43 more consistent information for the patient, as each team 
member is aware of their own and other team members' roles when 
they provide information to patients.24 
After having reviewed the literature, Patkar and colleagues (2011) 
concluded that the paucity of good-quality evidence to support the use of the 
MDT meetings in different tumour contexts should not be interpreted as 
evidence of ineﬀectiveness.60 One of the main reasons for the paucity of the 
data is the practical difficulties in setting up conventional randomised 
controlled trials for complex interventions like MDT meetings, while 
simultaneously other organizational changes (e.g. centralization, increased 
caseload, streamlining of clinical pathways, and appointment of new 
specialists) are being instituted. Moreover, since cancer MDT meetings have 
already been established as a standard of care in many healthcare systems, 
new RCTs are very unlikely.60 
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2.2.3 Barriers and obstacles for efficient multidisciplinary 
meetings/settings 
As multidisciplinary team meetings have been installed in several countries, 
quite some attention has been paid in the international literature to the 
potential barriers. The following are described: 
 Workload: participants spend an enormous amount of time in meetings 
and preparing for the meetings;61 
 Attendance: poor attendance by key staff;24 inconsistent participant 
interest and attendance62; lack of protected time;36 staff shortages;63 
allied health professionals not invited as the main focus is nursing and 
medical care;50 
 Logistics and organisational aspects: difficulty in coordinating the 
availability of material for review;61 the exchange of patient materials 
with outside institutions is a cause for concern when full data are not 
made available in a timely fashion;61 insufficient administrative 
support;24, 50 deficient record keeping;24 lack of availability of a 
consistent venue;62 no fixed sessional time;62  
 Team work and communication: hierarchical boundaries;24 
disagreement;64 communication amongst subgroups (e.g. surgeons) 
during the meeting; unequal participation in decision making e.g. nurses 
reporting that they were marginalised and their contribution of patient-
centred information ignored;64 lack of a dedicated clerk or MDT 
coordinator;62 not having a chair who is experienced, inclusive, 
respectful and efficient;50 lacking good leadership, which is necessary 
to foster inclusive case discussions;64 
 Information: lack of information at meetings to support decision 
making;24 lack of personal knowledge of the patient;64 lack of 
information on co-morbidities.64 
In general, participants of MDT meetings acknowledge the merits of these 
meetings and view them positively. Yet several aspects can improve the 
meetings’ efficiency and efficacy and ultimately enhance patient care. 
2.2.4 Core pillars of an effective MDT meeting 
In 2014 the European Partnership for Action Against Cancer (EPAAC), 
published a policy document in which signatories identify MDTs as the core 
component in cancer care organisation and set down the key elements to 
guide changes across all European health systems.1 According to EPAAC 
the core pillars of an eﬀective MDT include the following: 
 Clear care objectives that have the agreement of MDT diagnostic and 
therapeutic members and patients, covering issues around diagnosis, 
treatment and survivorship;  
 Organisation of the MDT that establishes operative leadership and 
coordination, designates a point of contact for patients, includes 
benchmarking exercises that integrate emerging scientific 
breakthroughs and reserves specific time and resources for physicians 
and healthcare professionals to participate on tumour boards; 
 Information databases that record clinical decisions, outcomes and 
indicators, facilitating the assessment of progress and the identification 
of areas to further improve; 
 Patient-centred approach, with available and comprehensible 
information on clinical and psychosocial aspects of the care process, 
clear communication channels between the care team and the patient 
and the promotion of participation and choice; 
 Policy support from national and regional health authorities, scientific 
societies and patients’ organisations, with special attention to including 
mechanisms to establish and sustain MDTs through national cancer 
control plans. 
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2.3 Key messages 
 A MDT meeting is a scheduled meeting where physicians from 
different specialities gather physically to discuss together the 
diagnosis and treatment plan of cancer patients. The meeting can 
be hold to discuss either the first occurrence of the cancer, either 
a change in the treatment plan, or at relapse. Attending specialists 
include typically a medical oncologist, a surgeon and a specialist 
from the organ affected. Other potential participants are medical 
imaging specialists, pathologist and specialists in radiotherapy. 
Several patients are discussed during the meeting. 
 The MDT meetings are reimbursed since 2003. In 2010 a distinction 
was made in the billing codes between the first MDT meeting (at 
first occurrence of the cancer), the follow-up MDT meeting (at 
relapse or to discuss change of treatment plan, with lower 
reimbursement than the first MDT meeting) and the supplementary 
MDT meeting (when the patient is referred to another hospital for 
second opinion). 
 The reimbursement rules foresee one coordinator, who is 
responsible for the written report of the discussion (the MDT 
meeting report) and the participation of three other specialists 
from the hospital staff, plus one extra physician (either the treating 
specialist or the patient GP). 
 Discussing every new cancer patient at MDT meeting is not a legal 
obligation, except for patients with a breast cancer treated in a 
recognized breast clinic. Yet, the registration and transfer to the 
Belgian Cancer Registry of every new cancer case, discussed 
during a MDT meeting or not, is mandatory. 
 Since 2003, the number of MDT meetings has continuously 
increased, to reach +/- 67 000 first MDT meetings in 2011. Follow-
up MDT meetings were billed more than 33 000 times, and 
supplementary MDT meetings are virtually not billed (553 cases in 
2011). 
 The cost for the RIZIV-INAMI budget amounted to € 17 millions in 
2011. 
3 ANALYSIS OF BELGIAN CANCER 
REGISTRY AND BILLING DATA FOR 7 
CANCER TYPES 
3.1 Introduction 
The purpose of the chapter is to analyse the evolution of the MDT meetings 
over the years from 2004 until the most recent available data (cancer 
incidences of 2011). More specifically, we will report the evolution regarding 
the coverage of patients who were discussed during MDT meetings, the 
characteristics of the MDT meetings themselves (number of attending 
specialists, time to the first MDT meeting after cancer incidence date, 
specialty of physicians involved) and the impact of changes introduced by 
the new reimbursement rules in 2010 (see Chapter 2 for more details on 
legal rules). First, a general analysis on all cancer patients was performed 
to have an overview on the coverage of MDT meetings. Secondly, it was 
decided to focalize on 7 different cancer types, ranging from low to high 
incidence rates and treated by different specialists. The 7 cancer types 
selected for this purpose are: 
 Female breast cancer  
 Prostate cancer 
 Lung cancer 
 Rectal cancer 
 Malignant melanoma 
 Acute leukaemia  
 Soft tissue sarcoma 
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3.2 Methods 
3.2.1 General methodology 
Used databases 
The databases used for this project were the database of the Belgian Cancer 
Registry (BCR), and the database of the Intermutualistic Agency (IMA/AIM).  
The BCR is population-based and includes data on all newly diagnosed 
malignant and in situ cases (as well as some benign lesions and lesions with 
uncertain or unknown behaviour) since 2004. At the date of beginning this 
project, the most recently available cancer incidence data cover the year 
2011. Since 2009, the BCR is authorized to link data from the BCR database 
with data on cancer-related diagnostic and therapeutic procedures and 
pharmaceuticals,65 which are obtained from all seven Belgian health 
insurance companies (HIC) via the Intermutualistic Agency (IMA/AIM). Via 
this linkage procedure, the Cancer Registry receives for each registered 
patient, health insurance data starting from January 1 of the year preceding 
the incidence year, until December 31 of the third year after the incidence 
year (further mentioned as HIC data). For this project, HIC data were 
delivered to the BCR in April 2014.  
Tumour Selection 
The study population as selected from the BCR database included patients 
diagnosed with a specific cancer type diagnosed between 2004 and 2011.  
Tumours were selected based on the International Classification of Disease-
10th edition (ICD-10),66 except for acute leukaemia for which the selection 
was based on a combination of topography and morphology codes 
according to the International Classification of Diseases for Oncology-3rd 
edition (ICD-O-3).67 
In a concrete manner, the following inclusion criteria were applied: 
 Female breast cancer (ICD-10: C50.0-C50.9) 
 Prostate cancer (ICD-10: C61) 
                                                     
c  The methodology used for the volume analyses is described in detail in 
Section 3.2.2 
 Lung cancer (ICD-10: C34.0-C34.9) 
 Rectal cancer (ICD-10: C20.0-C20.9) 
 Malignant melanoma (ICD-10: C43.0-C43.9) 
 Acute leukaemia (topography: C42.0-C42.9, morphology: 9840, 9861, 
9867, 9870, 9872, 9873, 9874, 9891, 9910, 9930, 9866, 9871, 9896, 
9897, 9895, 9984, 9931, 9920, 9987, 9728, 9836, 9729, 9837, 9727, 
9835, invasive behaviour) 
 Soft tissue sarcoma (ICD-10: C47.0-C47.9, C49.0-C49.9) 
The following patients were excluded from the analyses: 
 Patients without an official Belgian residence. 
 Patients without a known identification number for social security 
(INSS). 
 Patients who could not be linked to the health insurance data. 
The aim of the project was to focus on the multidisciplinary team (MDT) 
meetings during which the management of patients with 
suspected/confirmed cancers was discussed. Besides MDT meetings for 
the initial diagnosis, follow-up MDT meetings and additional MDT meetings 
were also considered. In order to exclude MDT meetings that were 
potentially charged for other lesions in the same patient, the following 
additional exclusion criteria were applied for all analyses except for the 
volume analysesc: 
 Patients with more than one invasive tumour (reported to the BCR, with 
incidences till the end of 2011) were excluded. 
 Patients with benign lesions, lesions with uncertain or unknown 
behaviour or in situ lesions diagnosed between one year before the 
incidence date of the invasive tumour and the end of 2011 were 
excluded. 
Detailed flowcharts including the selection criteria for each tumour type, as 
well as the number of excluded patients, were created (see appendix B). 
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Selection of nomenclature codes 
All nomenclature codes related to MDT meetings performed in the 
observation period were selected (see appendix B). Based on this list, all 
medical acts charged with one of these codes were retrieved from the 
IMA/AIM database for the patients included in the BCR selection. 
MDT meetings were taken into account within a time frame of 3 months 
before the date of incidence till the end of the observation period, defined as 
December 31st of the 3rd year after the year of incidence, with a maximum of 
December 31st 2012. As an exception to this rule, analyses on the time 
interval between the incidence date and the date of first registered MDT 
meeting did not consider MDT meeting charged before the date of incidence. 
Data cleaning based on patients for whom MDT meetings were charged 
more than 3 months before the date of incidence, led to the following 
additional decisions: 
 For prostate cancer, MDT meetings were considered from 6 months 
before the date of incidence onwards, as suspect prostate cancer 
lesions are potentially followed by biochemical measures (PSA 
sampling) prior to taking a biopsy. Similarly, MDT meetings for lung 
cancer were considered from 9 months before the date of incidence 
onwards. Especially slow growing cancers such as neuro-endocrine 
tumours may be followed by imaging prior to the definitive diagnosis of 
malignancy. 
 Patients for whom errors in either the date of incidence or date of MDT 
meeting were strongly suspected, were excluded from the analyses. 
All analyses mentioning “any MDT meeting” were based on the 6 main 
codes for MDT meeting coordination (350372-350383; 350276-350280; 
350291-350302). Codes referring to participation, additional fees and long 
consultation were not taken into account for these analyses. As an 
exception, additional fees for coordination of MDT meeting (350453-
350464) were considered for “any MDT meeting” when no other MDT 
meeting coordination code was charged. Every MDT meeting code within 
the “any MDT meeting” group that took place at a different date was 
considered to represent a different MDT meeting. Detailed analyses on first, 
follow-up and additional MDT meetings were provided for incidence years 
2010 and 2011. For these analyses, codes 350372-350383 were designated 
as “first” MDT meeting, 350276-350280 as “follow-up” MDT meeting and 
350291-350302 as “additional” MDT meeting. In the absence of any of these 
codes, additional fees for coordination of MDT meeting (350453-350464) 
were considered for “first” MDT meeting. 
For the analyses on the number of attending physicians, the nomenclature 
codes describing MDT meeting coordination and MDT meeting attendance 
were considered (350372-350383; 350276-350280; 350291-350302; 
350453-350464; 350416-350420; 350394-350405; 350475-350486). For 
each studied tumour type, the presence of the specialism which was 
assumed to be most involved in the treatment of the concerned tumour type, 
was included in a separate analysis. For each charged MDT meeting, the 
health insurance databases mention the competence code of the attesting 
physician. These codes were used to examine the presence of specific 
specialists or specialisms. The specialisms were classified into several 
categories, including surgery, internal or organ-specific medicine, 
radiotherapy, pathology, imaging or nuclear medicine, clinical biology or 
other. A detailed list of the categories and the corresponding competence 
codes is provided in appendix B. The analyses on the attending types of 
specialisms were performed for coordinators and participants together 
(350372-350383; 350276-350280; 350291-350302; 350453-350464; 
350416-350420; 350394-350405; 350475-350486). 
Analyses were presented by incidence year, year of MDT meeting, age 
group and stage, or a combination of these, as described within each table 
or figure. Unless otherwise specified, stage referred to the combined stage, 
being the pathological stage if available, and the clinical stage in the 
absence of pathological stage availability. As an exception to this rule, cases 
with clinical metastases (cM=1) were always considered as combined stage 
IV. For acute leukaemia and soft tissue sarcoma, no analyses by stage were 
provided as staging information was missing for acute leukaemia and 
frequently missing for soft tissue sarcoma. For malignant melanoma, no 
analyses by clinical stage were provided as the tumour category cannot be 
judged by clinical examination. 
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3.2.2 Specific methodology for volume analyses 
3.2.2.1 Tumour selection 
For the analyses concerning the number of cases discussed by MDT 
meeting per centre, all patients with a newly diagnosed cancer in 2009 or 
2010 and a discussion at a MDT meeting in the year 2010 were selected. 
No cases were excluded because of other invasive or non-invasive cancers.  
3.2.2.2 Selection of nomenclature codes 
All analyses mentioning “any MDT meeting” were based on the 6 main 
codes for MDT meeting coordination (350372-350383; 350276-350280; 
350291-350302). Codes referring to participation, additional fees and long 
consultation were not taken into account for these analyses. As an 
exception, additional fees for coordination of MDT meeting (350453-
350464) were considered for “any MDT meeting” when no other MDT 
meeting coordination code was charged.  
For the volume analyses, any MDT meeting charged within a period of 3 
months before and 6 months after the date of incidence was taken into 
account. In line with the other analyses, MDT meetings until 6 months before 
the date of incidence for prostate and until 9 months before the date of 
incidence for lung were taken into account. In case more than one MDT 
meeting was charged within this period, the MDT meeting closest to the 
incidence date was kept for further analyses. Patients were assigned to the 
centre which charged this MDT meeting. 
3.2.2.3 Availability of information on clinical or pathological stage 
by centre 
For each patient discussed at a MDT meeting in a specific centre, the 
information on the clinical stage or pathological stage of the concerned 
patient that was delivered to the BCR by that specific centre was examined. 
Only tumours that could be staged according to the 6th edition (incidence 
year 2009)68 or 7th edition (incidence year 2010) of the TNM staging 
classification69 were taken into account. For acute leukaemia and soft tissue 
sarcoma, no analyses on availability of clinical or pathological stage were 
provided as staging information was missing for acute leukaemia and 
frequently missing for soft tissue sarcoma. For malignant melanoma, no 
analyses by clinical stage were provided as the tumour category cannot be 
judged by clinical examination. 
To minimize influence of additional information coming from the pathology 
network, only information delivered by the clinical care program was 
considered. Due to switching fusions between centres, not all tumours 
discussed at a MDT meeting could be uniformly linked to a corresponding 
centre in the database of the BCR. Concretely, in case a centre defused into 
several smaller centres during the year 2010, patients for whom a MDT 
meeting was charged before this demerger could not be assigned to one of 
the smaller centres created after demerger.  
The analyses describing the availability of staging information by centre for 
patients discussed at a MDT meeting only included patients for whom the 
clinical care program of the centre that charged the MDT meeting could be 
identified in the BCR data as a data source. In addition, the included tumours 
needed to be “stageable“(i.e. no “not applicable (NA)”’ cases). 
3.3 Data limitations 
Working with administrative databases yields to some limitations in 
interpretation of the results. The following limitations were encountered in 
this project: 
 IMA database contains only the reimbursed data which implies that only 
registered and reimbursed MDT meetings are considered for analyses. 
Before 2010, only 1 MDT meeting per calendar year was allowed which 
implies that other possible MDT meetings were not registered at 
RIZIV/INAMI level. 
 Legal financial rules of RIZIV/INAMI allow only 4 (before 11/2010) to 5 
(after 11/2010) specialists to be mentioned on the RIZIV/INAMI’s form 
for MDT meeting (+ eventually an additional external specialist). This 
implies that other participants are not included in the analyses even if 
present at the consultation. 
 There is no rule on how hospitals should organize the MDT meetings. 
They are free to plan a MDT meeting by cancer type or to discuss all 
cancer patients in one MDT meeting whatever the cancer type. This 
might influence the results on the presence of some specialists in the 
MDT meeting and on the timing of the MDT meeting. 
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 The length of the observational period is 3 years after incidence date 
except for cancers diagnosed in 2010 and 2011 for which it is 
respectively 2 and 1 years. This might have an impact on the results for 
the last 2 years.  
 Selection of data: as mentioned in the methodology section, only 
patients with one invasive tumour were selected. Therefore, results do 
not include all patients with cancer. 
3.4 Results 
3.4.1 General results over all cancers 
Overall, the percentage of patients diagnosed with cancer (with or without 
multiple lesions) and discussed during a MDT meeting within a timeframe of 
1 month before and 6 months after the incidence date increases for each 
region between 2004 and 2011 to reach, at the country level, a coverage of 
82% of patients with a cancer diagnosed in 2011 (81% in Brussels, 85% in 
Flanders and 77% in Wallonia).  
Figure 3 – Percentage of patients diagnosed with an invasive cancer 
and discussed at a MDT meeting by year of incidence 
 
3.4.2 Percentage of MDT meetings performed per cancer 
The number of patients diagnosed with one invasive tumour and no other 
lesions increases slightly between 2004 and 2011 but varies across selected 
cancer types: between 6 000 and 9 000 patients per year for breast, prostate 
and lung cancer, around 2 000 patients per year for rectal cancer and 
malignant melanoma, and finally, below 500 patients per year for acute 
leukaemia and soft tissue sarcoma (see appendix B).  
The percentage of patients with one invasive tumour and discussed at least 
in one MDT meeting within the timeframe of 3 months before and 3 years 
after diagnosis (for more details on the patient selection and used time 
frames, see methodological section) increased over the years for all cancers 
selected (see Figure 4). Overall, for all cancers diagnosed during 2011, the 
coverage rate of cancers by a MDT meeting is above 70% except for 
malignant melanoma (69%). Even for cancers which were less 
systematically discussed at a MDT meeting in 2004, the observed increases 
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in coverage between 2004 and 2011 were noticeable (for rectum (28%), soft 
tissue sarcoma (28%), malignant melanoma (34%) and prostate (39%). 
Figure 4 – Percentage of patients diagnosed with one invasive tumour 
and discussed during a MDT meeting within the 3-month before and 3-
year after diagnosis 
 
Source: BCR-IMA data 
For all cancer types, the increase over time in coverage by MDT meeting 
was observed in each of the combined stages (see appendix B). Moreover, 
existing differences between combined stages observed in 2004 tend to 
disappear in 2011 reaching for each cancer type and each “stageable” 
combined stage (combined stage I to IV), a coverage rate of approximately 
90% (except for malignant melanoma). For malignant melanoma, this 
percentage increased with the stage: 66% for patients with combined stage 
I to 98% for combined stage III patients – see Figure 5. The low percentage 
of MDT meeting coverage for patients with malignant melanoma with low 
stage might be due to the fact that patients with small melanomas are not 
referred automatically to a hospital and do not enter the oncological care 
program. However, patients with malignant melanoma at higher stages are 
more frequently discussed during a MDT meeting. Overall, for any cancer 
type, the patients with higher combined stage are likely to be discussed 
during MDT meeting (around or more than 90% for combined stage IV). 
Figure 6 illustrates that the coverage rate decreased with the age of the 
patient. 
Figure 5 – Percentage of patients discussed in a MDT meeting per 
combined Stage - Incidence year 2011 
 
Source: BCR-IMA data 
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Figure 6 – Percentage of patients discussed in a MDT meeting per age 
category - Incidence year 2011 
 
Source: BCR-IMA data 
3.4.3 Missing cancer stage for patients discussed during a MDT 
meeting 
Surprisingly, we observed (Figure 7) that for almost all selected and 
stageable cancer types (i.e. excluding acute leukaemia, malignant 
melanoma and sarcoma), the clinical stage was missing in about 25% of the 
cases (in 32% of the cases for breast cancer). As the pathological stage 
could also be provided to the BCR by the pathology network outside of MDT 
meeting, the availability of the combined stage was higher in the BCR data 
than the clinical stage.  
Figure 7 – Percentage of patients having been discussed at a MDT 
meeting with missing stage (clinical and/or combined) – Incidence year 
2011 
 
Source: BCR-IMA data 
3.4.4 Timing and number of MDT meetings 
As shown in Table 5, for acute leukaemia and lung cancer, the MDT meeting 
was performed within 2 to 3 weeks after the incidence date for 50% of the 
patients (within 5 weeks for 75% of the patients), whereas for breast cancer, 
rectum and soft tissue sarcoma this delay was within 4 weeks after incidence 
for 50% patients (within 6 to 9 weeks for 75% patients). For malignant 
melanoma and prostate cancer, the first MDT meeting was performed within 
6 weeks for 50% of patients and within 12 weeks after incidence for 75% of 
patients. For patients with malignant melanoma, this longer period might be 
due to the referral period of patients with melanoma initially treated by the 
private dermatologist to the hospital. 
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Table 5 – Time to first MDT meeting after incidence date (in weeks) 
 N 25th 
Pctl
50th 
Pctl
75th 
Pctl
Acute leukaemia 2 606 1 2 5
Lung 34 077 1 2 5
Breast 57 479 2 4  6 
Rectum 11 529 2 4 7
Soft tissue sarcoma 1 210 2 4 9
Malignant melanoma 5 886 4 6 12
Prostate 36 624 3 6 12
Source: BCR-IMA data 
For none of the selected tumour types, large differences were noted in the 
time to first MDT meeting between the different stages (presented by 
separate analyses: see methodology and results displayed in appendix B).  
For the majority of patients discussed during a MDT meeting, there was only 
1 MDT meeting registered and linked to the cancer, but the number of MDT 
meetings performed per patient increased with the combined stage of the 
disease. In 2011, 20% of patients with combined stage I breast cancer were 
discussed during more than one MDT meeting compared to 35% of patients 
with combined stage IV. This phenomenon was observed for all cancers with 
the exception of lung cancer where the number of MDT meetings per patient 
was higher in combined stages II and III (more than 30%) than for combined 
stages I and IV (around 20%) - see appendix B. 
The number of MDT meetings per patient tended to increase over time for 
all cancer types except for prostate cancer (stable over incidence year) and 
malignant melanoma (decrease of the percentage of patients with more than 
one MDT meeting from 30% in 2004 to 20% in 2009- see appendix B).  
The time between the first and second MDT meeting was strongly influenced 
by the financial rule stipulating that a MDT meeting is reimbursed maximally 
once per calendar year. This rule changed on 1/11/2010 but we could not 
see the impact yet in the administrative data available for this report given 
that we only have 1 year follow-up data for patients with cancer incidence in 
2011. Before 2011, the delay between first and second MDT meeting was 
around 12 months for half of the cancer patients (for any of the 7 types of 
cancer considered in this report). 
3.4.5 MDT meeting participants: Specialists 
Parallel to the other analyses, the composition of the MDT meeting was 
analysed through the administrative data, limiting the analyses to registered 
and reimbursed data. Before 2010, a maximum of 4 specialists (including 
the coordinator) could be recorded in the database for reimbursement 
purposes according to the AR/KB (date: 27 September 2010; publication 
date: 24 October 2010). An additional external specialist could also attend 
the MDT meeting when needed, and be registered as such in the database. 
After 2010, this rule was extended to a maximum of 5 specialists (including 
the coordinator, with an optional external specialist in addition). There is no 
way to estimate the actual number of specialists present at the MDT meeting 
except through the web survey (see Chapter V). As shown in Figure 8, the 
composition of the MDT meetings (based on register only) followed the legal 
rules. The majority of the MDT meetings were composed of 4 specialists 
(including coordinator) until 2010 (more than 70% of the time) and we clearly 
see the change in 2011, with 5 specialists registered in around 60% of the 
cases for all cancer types except for malignant melanoma (53%) and 
prostate cancer (47%). In 2012, around 70% of MDT meetings were 
composed of 5 specialists (except malignant melanoma 63% and prostate 
cancer 59%). 
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Figure 8 – Percentage of MDT meetings by number of specialists registered – Year of MDT meeting 2010 to 2012 
 
Source: BCR-IMA data 
For female breast cancer, surgeons were registered and reimbursed for 
attending a MDT meeting in around 9 out of 10 MDT meetings (Figure 9). 
The participation rate of the internists/organ-specific specialists was also 
quite high (around 80 to 90% of the MDT meetings). However, there was a 
clear increase from 2010 onwards in the participation rate for radiologists, 
pathologists and specialists in imaging/nuclear medicine. For breast cancer, 
the gynaecologists (included in the surgeon category) were registered in 
74% of the MDT meetings in 2011. The participation rates for the other 
cancer types are displayed in appendix B.
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Figure 9 – Participation rate per specialism – Breast Cancer  
 
Source: BCR-IMA data 
A summary for all cancers having a MDT meeting in 2011 is displayed in 
Figure 10. The participation rate of internists/organ-specific specialists was 
above 90% for all cancers, followed by the surgeons (more than 80% of the 
time) for all cancers except for acute leukaemia and lung cancer. The 
participation rate of specialists in imaging, pathology and radiotherapy was 
more variable amongst the different cancer types. And as expected, 
specialists in clinical biology were mainly present at MDT meetings 
concerning acute leukaemia patients. 
Competence codes for some specialists (in gastroenterology and clinical 
haematology) have been introduced or modified. Therefore, the increase in 
the participation rate for those specific specialisms might be induced by 
introduction of those new “specific” codes. For example, there was a AR/KB 
(18.12.2009, publication date 28.01.2010) introducing new nomenclature 
codes for consultations with a specialist in clinical haematology. From 2010 
onwards, a new competence code for specialists in clinical haematology was 
introduced in the INAMI/RIZIV database. Those specialists were included in 
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the group of internists without distinction. For specialists in gastroenterology, 
new competence codes were introduced in 2007.
 
Figure 10 – Participation rate– All cancers (Year of MDT meeting 2011) 
 
Source: BCR-IMA data 
When needed “external” specialists can attend a MDT meeting; this is 
registered in the RIZIV/INAMI’s reimbursement form. In 2011, external 
expertise was requested more often for lung cancer (19%), prostate and 
breast (18%) cancer than for malignant melanoma (16%), rectal cancer 
(15%) and finally acute leukaemia and soft tissue sarcoma (8%) (Figure 11).
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Figure 11 – Percentage of MDT meetings with registered external specialist – MDT meeting year 2004-2011 
 
Source: BCR-IMA data 
3.4.6 MDT meeting participants: General Practitioners 
The participation of the general practitioner (GP) at the MDT meeting (as 
registered in the RIZIV/INAMI’s form) was very low for all cancers (around 
3% in breast, prostate, soft tissue sarcoma, melanoma to around 4% in lung 
and rectal cancer and 0% in acute leukaemia)(see appendix B). Again, as 
these analyses are based on administrative data, they do not necessarily 
reflect the true presence of GPs at MDT meetings. The GP participation is 
discussed in more details in Chapter VI, in which the results of the GPs’ 
interviews are presented. 
3.4.7 MDT meeting types 
From the end of 2010 onwards, changes in nomenclature codes were made 
in order to differentiate the first MDT meeting from the follow-up and 
additional MDT meetings. Figure 12 illustrates that for around 20% of 
patients diagnosed in 2011, a follow-up MDT meeting was performed and in 
less than 1% of the cases (except for acute leukaemia 4%) an additional 
MDT meeting was done.
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Figure 12 – Percentage of patients discussed in a MDT meeting by MDT meeting type - Incidence year 2011 
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3.4.8 Variability per centre and volume of patients discussed at a 
MDT meeting 
In this section, the analyses were performed on patients with a specific 
invasive tumour, regardless of other invasive or non-invasive lesions (as 
explained in methodology section 3.2.2). Only patients for which a MDT 
meeting was charged were taken into account. 
Breast cancer 
In 2007, the Belgian legislation on the recognition of breast clinics was 
published (AR/KB 26th April 2007), specifying the many quantitative norms 
that a hospital has to meet in order to be recognized as a breast clinic. A 
transition period was foreseen so that hospitals could reorganize their 
services: during the first two years, a minimal volume of 100 newly 
diagnosed patients per year was required. After the end of the transition 
period, the volume norm increased up to 150 patients per year (i.e. the EU 
recommendation). At the end of 2013 (AR/KB 23 December 2013), the 
recognition norms were modified again, and introduced the concept of a 
“breast clinic with a role of coordination” (for which a minimal volume of 125 
patients per year applies) and the concept of “satellite breast clinic” (which 
has an agreement with the coordination breast clinic, and for which a 
minimal volume of 60 patients per year applies). 
Figure 13 illustrates the situation in 2010, thus during the transition period. 
It shows a very large dispersion in the volume of breast cancer discussed at 
MDT meetings, with approximately half of the hospitals with a volume 
around (or lower than 50 cases per year), and with some strange cases of 
breast clinics with very low volumes.  
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Figure 13 – Number of patients discussed during a MDT meeting – Invasive breast cancer (Incidence year 2009 – 2010 and MDT meeting year 2010) 
 
Source: BCR-IMA data 
 
As shown in Figure 14 for breast cancer, the percentage of clinical stage (cstage) not reported to the BCR by the oncological care programs of the centres 
charging a MDT meeting was quite high for a lot of sites; in addition, there was a high inter-centre variability.  
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Figure 14 – Percentage of clinical stage not reported to Belgian Cancer Registry – Invasive breast cancer 
 
Source: BCR-IMA data 
Summary for all cancers 
Table 6 shows the centre distribution of the number of patients discussed 
during a MDT meeting and registered in the BCR database. There was a 
large dispersion of care for patients with soft tissue sarcoma or acute 
leukaemia: many centres discussed only a few number of patients at MDT 
                                                     
d  Recommendations for the management of rare cancers were discussed in 
KCE report 219. 
meeting a year. For soft tissue sarcoma, 75% of centres reported a 
maximum of 4 cases discussed at MDT meetings whereas for acute 
leukaemia, this number was set at 9 patients.d  
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There is also a high variability between centres with regard to the 
percentage of patients discussed in a MDT meeting for whom the clinical 
stage was missing/unknown (Table 7). Half of the centres did not report the 
clinical stage to the BCR for about 30% or even more of their breast cancer 
patients. (Figures by cancer types with the number of stageable tumours 
and the proportion of unreported clinical stage per centre are displayed in 
appendix B).
 
Table 6 – Number of patients discussed during a MDT meeting and reported to BCR 
 Breast Leukaemia Lung Melanoma Prostate Rectum Sarcoma
N (centres) 100 65 102 85 99 100 68 
Median 58 3 50 8 49 17 2 
Q1-Q3 38 - 130 1 - 9 27 - 90 4 - 18 28 - 79 10 - 29 1 - 4 
Min-max 2 - 531 1 - 52 2 - 217 1 - 127 1 - 269 3 - 97 1 - 19 
Table 7 – Percentage of missing clinical stage per centre – stageable patients discussed during a MDT meeting (excluding NA stage) 
 Breast Leukaemia Lung Melanoma Prostate Rectum Sarcoma
N (centres)* 99 NA 99 NA 96 97 NA 
Median 27%  11%  19% 21%  
Q1-Q3 6% - 67%  4% - 21%  5% - 41% 7% - 37%  
Min-max 0% - 100%  0% - 97%  0% - 100% 0% - 83%  
*Centres with stageable patients discussed at a MDT meeting (excluding NA stage) 
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3.5 Conclusion – Discussion 
From 2004 onwards, there was a continuous increase in the coverage rate 
of the cancers by a multidisciplinary oncological consultation, for all 7 
cancers under study. Differences between cancer types remained, yet they 
decreased over time: in 2011 more than 9 out of 10 breast cancer patients 
were discussed during a MDT meeting, compared to only 7 out of 10 
malignant melanoma cases. The low percentage of MDT meeting coverage 
for patients with malignant melanoma at low stage might be due to the fact 
that patients with small melanomas are not referred automatically to a 
hospital and do not enter the oncological care program. However, patients 
with a higher stage (for any of the cancer types) are generally well discussed 
during MDT meetings (around or more than 90% of the cases for stage IV). 
The reasons for the low percentage of MDT meeting coverage in patients 
with soft tissue sarcoma might be explained, according to the experts, by 
the fact that soft tissue sarcomas are less frequent than other cancer types 
included in this project and therefore it takes probably more time to have 
enough cases to set up a MDT meeting. Nonetheless, despite the high 
financial incentives the target set in the cancer plan (i.e. most cancer 
patients being discussed during a MDT meeting) is not yet achieved. 
The way the MDT meeting is organised (i.e. either through a general MDT 
meeting or through cancer-specific MDT meetings) could not be derived 
from the administrative data. This aspect is further elaborated in Chapter 5.  
Another limitation of the data is that they are limited to what has been 
registered and charged. Therefore, for example, the number of specialists 
present at the MDT meeting as reported in this chapter was limited to the 
legal maximum number of specialists for whom reimbursement can be 
requested. Nevertheless, the data showed that MDT meetings were 
performed within a short period after incidence date (within 1 to 2 months 
depending on the cancer) regardless of the stage of the disease (except for 
malignant melanoma) and include in most of the cases, at least the 
maximum number of specialists that might be registered on the 
reimbursement form. The MDT meetings included most of the time the 
                                                     
e  Management of rare cancer patients in Reference Centres is discussed and 
recommended in recent reports, including KCE reports 219 (rare cancers) 
and 229 (hospital financing). 
internists/organ specific specialists, surgeons, pathologists, radiologists and 
other imaging specialists. The increase of the participation rate of 
pathologists, radiologists and imaging specialists from 2011 onwards 
undoubtedly followed the change in legal rules allowing to add one specialist 
on the reimbursement form. They joined probably the MDT meetings before 
2011 but were not automatically registered on the form due to the limitation 
of specialists to 4 (including the coordinator). 
Participation rate of GPs (reported on the RIZIV/INAMI’s form) was very low 
for all cancer types considered in this report. These results should be put in 
perspective with the web survey results described in Chapter 5. 
In view of the fact that MDT meetings are highly recommended for all breast 
cancer patients and that breast clinics have to reach minimum volume 
criteria (i.e. initially 100 new cases per year and nowadays 150), it was 
surprising that some breast cancer clinics reported less than 100 new cases 
per year being discussed in a MDT meeting. In addition, there is evidence 
of very low levels of activity for the centres which do not have the recognition 
of breast clinic, as physicians working in those hospitals are still allowed to 
treat breast cancer patients.  
For all cancers under study the volume of patients treated by centre is highly 
variable and for some specific cancers, like soft tissue sarcoma and acute 
leukaemia, there is even a larger dispersion of care.e  
Cancer stage reporting is one of the legal obligations of the responsible 
physician of the MDT meeting in order to keep the accreditation as 
oncological care program. Despite this legal requirement, the reporting of 
clinical stage to the BCR is not yet optimal; there is also a high variability 
between centres. To improve stage reporting, linking the reimbursement of 
the MDT meeting discussion and the financing of data managers to the 
registration of the cancer stage could be a targeted intervention. 
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3.6 Key Messages 
 Since 2004, there is a clear increase in the proportion of cancer 
patients discussed in MDT meetings. 82% of the cases diagnosed 
in 2011 were discussed during a MDT meeting within a timeframe 
of 1 month before and 6 months after the incidence date.  
 However, for some specific cancer types (e.g. malignant 
melanoma, soft tissue sarcoma, prostate) there is still some 
“underuse” of the MDT meeting. Specificity of the cancer type 
plays an important role in the need fo a MDT meeting (e.g. small 
melanoma might not request to have a MDT meeting in contrast to 
higher stages). 
 There is room for improvement with regard to the report of the 
clinical stage of patients discussed during a MDT meeting: the 
clinical stage was missing for 32% of female breast cancer cases 
and for 20% to 25% of other (stageable) cancers under study. 
 For most cancer types, the first MDT meeting was held within a 
month after cancer incidence date, yet there are differences 
between cancer types (2 or 3 weeks in 50% of patients with acute 
leukaemia and lung cancer, within 4 weeks for breast cancer, 
rectal cancer and soft tissue sarcoma; and within 6 weeks for 
patients with prostate cancer and acute leukaemia). When the 
stage of the disease was considered, the variability in time to the 
first MDT meeting was small fo all cancer types under study. 
 Since the creation of the MDT meeting in 2002, there were several 
legal changes that had an impact on the reimbursement and 
financing rules of the hospital. The administrative data showed 
clearly the impact of the 2010 rule that extended the maximum 
number of specialists registered and reimbursed (including the 
coordinator) from 4 to 5. Before 2010, nearly 70% of the MDT 
meeting reports registered 4 specialists whereas in 2012 70% 
registered 5 specialists. The additional registrations related above 
all to specialists in imaging (radiologists) and pathologists. Yet, 
due to the legal limitation of the number of MDT meeting 
participants that are reimbursed (and hence registered in the 
administrative database), the actual number of MDT meeting 
participants cannot be derived from administrative data.  
 Due to the same limitation, the actual GP participation in the MDT 
meetings cannot be evaluated in a reliable way based on 
administrative data. Approximative estimates however show very 
low presence rate of GPs at MDT meetings. 
 It was apparent that some breast cancer clinics reported less than 
100 new cases a year being discussed during a MDT meeting while 
there is a volume norm (initially set at 100 and then increased to 
150) and while there is consensus that MDT meeting discussions 
are valuable in all breast cancers.  
 For all cancer types under study dispersion of care was observed, 
based on the volume of patients discussed during a MDT meeting 
per centre. 
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4 WHAT DO BILLING DATA TELL US 
ABOUT MDT MEETINGS IN BELGIUM?  
4.1 Introduction 
In this chapter we analyse the billing data as such, with no reference to other 
data sources.  
The first section refers to the accounting process. It was found, by chance, 
during the analyses that some services were entered into the sickness fund 
accounts a very long time after they were provided. Although this is purely 
an administrative point, it was decided to study this unusual phenomenon in 
more detail, given its consequences for the data analysis in general.  
These billing data do not in themselves contain a great deal of medical 
information, the nomenclature codes relating to MDT meetings are not very 
specific. Nevertheless, they have the advantage of being reliable, given the 
checking procedures used by the sickness funds, and relatively recent whilst 
it would take time to link them to other data sources to enrich them. In the 
second and third sections we will attempt to generate information with 
statistical tools which can be of use in assessing whether these services are 
being properly used. In part two, we evaluate differences in the number of 
MDT meetings between hospitals, and in part 3 we examine the qualification 
of the medical doctors, and how these vary between hospitals. 
4.2 Methods 
4.2.1 Time taken to book the MDT meetings 
The analysis is based on the so-called ‘P documents’ of the National Institute 
for Health and Disability Insurance (NIHDI, RIZIV-INAMI). These billing data 
are recurrently/periodically transmitted to the national institute by the 
sickness funds. Data were used of the accounting period 01/01/2011 to 
30/06/2013. The identity of the hospital is registered in the zone ‘place of 
service’ in case of an intramural service, which is the case for MDT 
meetings. When this zone did not contain usable information, which was 
rarely the case, the identity of the hospital was detected by other 
parameters. 
For every hospital we subsequently calculated the number of ‘primary’ MDT 
meetings (nomenclature codes 350372/-383, coordination fees for the first 
MDT meeting) carried out during 2011. We then checked how many of these 
services were recorded by the sickness funds during 2011. This number is 
expressed as a percentage of the number of these fees provided in 2011. If 
the percentage is found to be, for example, 90%, this means that 90% of the 
MDT meetings carried out in 2011 were recorded by the sickness funds in 
2011, with 10% being recorded in 2012 or even, possibly, 2013.  
We carried out the same calculation for all medical services (articles 1-26 
and 32-34 of the nomenclature) to give us a reference frame.  
4.2.2 Benchmarking of MDT meeting activities 
As before we calculated for every hospital the number of primary MDT 
meetings carried out in 2011. Taking into account the slow booking process 
for some hospitals these are the most recent complete data available. Given 
the differences in size between hospitals, we weighted this figure using a 
parameter which reflects as accurately as possible the oncological activity 
in each hospital, and which is easily available from NIHDI (RIZIV-INAMI) 
data. We chose to use for this purpose the number of one-day 
chemotherapy patients during the same period. This figure is available in the 
so-called ‘ADH documents’, namely the ‘maxiforfait’ 761353/761095. These 
‘ADH documents’ are, as the P documents, supplied by the sickness funds 
This lump sum is reimbursed for nursing care in case of an intravascular, 
intracavitar or intravesical administration of a product of ATC class L01, 
V03AF or L03AX03 (chemotherapeutic agents). This parameter does not 
cover all cancer patients, and excludes, for example, those who undergo an 
operation or radiotherapy without chemotherapy. Nevertheless, this proxy 
has the advantage of being accurate and immediately available in the data.  
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4.2.3 Studying the qualification of MDT meeting medical 
specialists 
The P documents provide information, using a ‘qualification code’, on the 
discipline of the medical specialist charging for MDT meeting services. An 
analysis of these qualifications and comparisons between hospitals can give 
an insight into how MDT meetings are organised and to what extent 
particular disciplines are represented.  
The analysis is divided into four parts: 
 analysis of the coordinator’ specialty (codes 350372, 350383, 350276, 
350280, 350291); 
 analysis of the participant’ qualification (code 350394, 350405, 350416, 
350420); 
 analysis of the qualification of the MDT meeting coordinator or 
participant in general; 
 analysis of the qualification of the physician providing information to the 
patient after the MDT meeting (code 350232, 350254, 350265). 
Once again, the analysis is based on services provided in 2011 for an 
accounting period up to 30/06/2013. In the case of additional qualifications 
which are not directly relevant to the assessment of MDT meeting-services 
(for example an urologist with a further health professional qualification in 
emergency healthcare), we group the qualification codes together according 
to the basic specialty (in this case urology).  
The analysis was performed at national level and hospital level; in some 
cases the analysis was performed by type of hospital (general/university). 
Hospitals with an atypical profile were analysed in detail. 
4.3 Results 
4.3.1 Time taken to book the MDT meetings 
Figure 15 shows, per hospital, the percentage of primary MDT meetings 
carried out in 2011 and entered in the sickness funds accounts in the same 
year. A high value means that the services have been quickly invoiced and 
recorded by the hospitals and sickness funds; a low value implies the 
opposite. The national average is 68.5%, which is lower than the general 
percentage for medical fees (see data in appendix C). This means that the 
invoicing process for MDT meetings is slower than the general invoicing 
process. Some hospitals have a very low value, such as 20%, which means 
that most of the MDT meetings carried out in 2011 were only recorded in the 
sickness funds books the following year, or even later.  
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Figure 15 – Primary MDT meetings realized in 2011: percentage booked in the same year – analysis per hospital 
 
Note: code 350372/-383, coordinator honorarium  – 100% = rapid booking, all MDT meetings realised in 2011 are also booked in 2011 
Data source: RIZIV-INAMI doc P – booking period 01/2011 – 06/2013 
 
4.3.2 Benchmarking of MDT meeting activities 
Figure 16 presents the number of primary MDT meetings carried out per 
hospital in 2011, in descending order; together with follow-up MDT meetings 
and second opinion MDT meetings. It shows large inter-hospital variation in 
follow-up MDT meetings, with large numbers in some hospitals, sometimes 
exceeding the number of primary MDT meetings. Second opinion MDT 
meetings are rare and occur particularly in large hospitals. 
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Figure 16 – Number of MDT meetings per acute hospital (primary, follow-up, second opinion) realised in 2011 
 
 
4.3.3 Studying the qualification of MDT meeting medical 
specialists  
4.3.3.1 Qualification of coordinators 
In this section we map the specialties of coordinators, firstly by type of 
hospital (general/university), and then by individual hospital. 
Figure 17 shows the number of coordination fees, divided according to the 
specialty of the physician. There were 100 144 coordination acts in 2011; 
specialties with less than 300 coordination acts were excluded from the 
results. We carried out three analyses, looking at hospitals in general, then 
the subgroup of ‘general hospitals’, and finally the subgroup of ‘university 
hospitals’. We added relative frequency, based on the total number of 
coordination fees.  
If we look at the figures for all hospitals (general and university together), we 
can see that most frequently medical specialists specialised in oncology (i.e. 
qualification code 660) coordinate MDT meetings (52.8%). Other specialties 
each account for less than 10% of cases; in descending order they are: 
internist-haematologists (9.9%), urologists (6.8%), gastroenterologists 
(6.6%), pulmonologists (6.3%), gynaecologists (5%), radiotherapists (4.7%) 
and general surgeons (3.3%).  
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When we examine the results by hospital type, then we see that oncologists 
are less frequently responsible for coordination in university hospitals than 
they are in general hospitals (38.5%, as opposed to 56.%), but are still the 
group which most frequently take on this role. We also found that in 
university hospitals, general surgeons are much more likely to act as 
coordinators (9.6%, as opposed to 1.7%); gynaecologist coordinators are 
also more frequent in university hospitals (9.6%, as opposed to 3.8%). 
‘Smaller’ specialties such as ENT, neurosurgery, paediatrics and 
dermatology also provide coordinators in university hospitals (percentages 
between 3 and 1%), while this is far rarer in general hospitals.
 
 
Figure 17 – Specialty of MDT meeting coordinator by type of hospital - 2011 
 
Datasource: RIZIV-INAMI doc P booked ≤ 30/06/2013 
 
As already stated, in general oncologists most frequently take on the role of 
coordinators, in, on average, 52.8% of cases. Figure 18 shows the 
distribution of this parameter per hospital. It shows that situations still differ 
greatly. In some hospitals, all the MDT meetings are coordinated by the 
oncologist (100%), whilst in others, these specialists never take on this role.  
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Figure 18 – Percentage of MDT meetings coordinated by oncologist – per hospital - 2011 
 
Data source: doc P booked ≤ 30/06/2013; Note: code 660; base = total N of number of MDT meetings with coordination fees 
 
Specific analyses presented in the appendices show some examples of 
hospitals with an atypical qualification profile compared to the average of all 
hospitals. In the first four hospitals, the MDT meeting is coordinated 
exclusively by a surgeon, radiotherapist, pneumologist or gastroenterologist. 
In other hospitals MDT meetings are coordinated exclusively by urologists 
and gynaecologists, or exclusively by pneumologists, gynaecologists and 
ENTs, or exclusively by an internist-haematologist. 
4.3.3.2 Qualification of participants (not taking into account the 
coordinator of the MDT meeting) 
Table 8 shows the qualification of the participants for general and university 
hospitals as a whole. In total, there were 379 917 participations in 2011. The 
table includes the disciplines with at least 3000 participations. The 
disciplines are listed in descending order of the number of cases. 
Radiotherapists and pathologists are the most frequent participants, 
representing respectively 18.9% and 16.8% of the total number of 
participations. The next most frequent participants are oncologists (11.1%), 
radiologists (11.1%), general surgeons (9.7%), gynaecologists (4.8%) and 
urologists (4.4%). General practitioners represent 0.8% of participations.
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Table 8 – Qualification of MDT meeting participants - 2011  
 
Data source: doc P booked ≤ 30/06/2013 
Figure 19 shows the distribution for general practitioners; they also only take 
on the role of participant. In approximately half of the hospitals, there is never 
a GP attending the MDT meetings. The maximum frequency of GP 
participation is 7%. 
.
 50  MDT meetings in oncology KCE Report 239 
 
Figure 19 – Percentage GP participation per hospital - 2011 
 
Datasource: doc P booked ≤ 30/06/2013; Note. code 003 + 004; base = tot N of participants
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4.3.3.3 Qualification of MDT meeting medical specialists in 
general 
Table 9 shows at national level the qualification of medical specialists who 
are present at a MDT meeting, irrespective of their role, either as coordinator 
or participant. In total, in 480 061 times the participation of medical 
specialists was recorded at a MDT meeting; the table contains the 
disciplines with at least 3 000 cases. The disciplines are listed in descending 
order of the number of cases. Oncologists are most often involved in MDT 
meetings; 19.8% of the medical specialists who are present at a MDT 
meeting are oncologists. They are followed by radiotherapists (15.9%), 
pathologists (13.3%), radiologists (8.8%) and general surgeons (8.4%). 
These are followed by urologists (4.9%), gynaecologists (4.8%), 
gastroenterologists (4.8%), haematologists (4%) and pneumologists (3.3%). 
  
Table 9 – Qualification of physicians attending MDT meetings, regardless of their role (coordinator or participant) - 2011 
 
Data source: doc P booked ≤ 30/06/2013 
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Oncologists (Figure 20) represent in some hospitals more than 35% of the 
presences at a MDT meeting, but less than 5% in others. Other figures are 
presented in the appendices, and show the distribution for some organ 
specific specialties as urology, gynaecology, gastroenterology and 
pulmonology; again we see a large variation. 
 
Figure 20 – Percentage oncologist as coordinator or participant per hospital attending a MDT meeting - 2011 
 
Data source: doc P booked ≤ 30/06/2013; Note: code 660; base = total N of physicians attending a MDT meeting, coordinator or participant 
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From Table 10, we can deduce at a national level the extent by which a 
particular discipline takes on the role of ‘coordinator’ more often than that of 
‘participant’. We can therefore see that oncologists, the group that is most 
frequently involved in MDT meetings, are coordinators in 56% of cases and 
vice versa participants in 44% of cases. Radiotherapists are primarily 
present as participants (94%); pathologists and radiologists act only as 
participants (100%). These are followed by the surgical specialties, with 
general surgeons being predominantly present at MDT meetings as 
participants (92%); the MDT meetings in which they appear as coordinators 
are primarily in university hospitals, as shown earlier. Gynaecologists and, 
in particular, urologists, take on the role of coordinator somewhat more 
frequently (21% and 29% respectively). We also note that haematologists 
and pneumologists regularly take on a coordination role (51% and 41% 
respectively).
 
Table 10 – Physicians attending MDT meetings, function (coordinator or participant) per qualification - 2011 
 
Data source: doc P booked ≤ 30/06/2013 
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4.3.3.4 Qualification of “the informer” 
A physician who informs the patient about the outcome of the MDT meeting, 
hereafter referred to as the ‘informer’, can charge a fee for this. This service, 
hereafter referred to as a ‘debriefing’, can only be charged after a primary 
MDT meeting (codes 350372 and 350383), not after a ‘follow-up’ or a 
‘second opinion’ MDT meeting. The qualification of this informer will be 
analysed further in this section. The number of debriefings is, as shown 
earlier in the national data, relatively limited in relation to the number of 
primary MDT meetings, i.e. 16 583 as compared with 66 379 (i.e. 25%).  
Table 11 shows that urologists and gynaecologists are the most frequent 
informers (registered), as they carry out 21.6% and 18.6% of the total 
number of debriefings. They are followed by pneumologists, oncologists and 
gastroenterologists, who carry out 11%, 10.3% and 9.4% of debriefings 
respectively. General practitioners carry out only 3% of debriefings. An 
analysis by hospital showed that there is a large variation per hospital: some 
hospitals apparently organise these debriefings systematically (ratio around 
1), other rarely or never (figure in appendix C). 
Table 11 – Qualification of physician who debriefs patient after MDT 
meeting - 2011 
 
Data source: doc P booked ≤ 30/06/2013 
Note: MDT meeting: code 350232, 350254, 350265  
 
 
4.4 Conclusion – discussion 
4.4.1 Time taken to book the MDT meetings 
The MDT meetings carried out in certain hospitals are booked very late by 
the sickness funds, which indicates that the billing process there goes very 
slowly. In some hospitals, the MDT meetings carried out in 2011 were, for 
the most part, booked in 2012 or even later. This slow billing process 
compromises the data analysis, surely at hospital level, because a reliable 
analysis assumes that a complete sample is used and this is only available 
after a few years. If, for example, the billing and booking information up to 
2013 is available, this only gives a complete picture of the MDT meetings 
that took place in 2011. If these data are linked to other information, the 
delay becomes even longer.  
The reasons for this slow billing/booking process are unclear, but the 
following hypotheses may be put forward: 
 The MDT meeting is an atypical service, since this is carried out without 
the patient being present. A report is one of the conditions, according to 
the nomenclature. It is possible that there may be a long wait for this 
report, which may still need to be approved by the various participants.  
 There may also be a delay in billing the MDT meeting within the hospital 
because various healthcare providers are involved in this, and some 
billing and accumulation rules in the nomenclature need to be checked.  
 There may also be a delay in the MDT meeting being booked by the 
sickness funds. The nomenclature specifies, for example, that the 
sickness funds advising physician should also receive the report. The 
possibility cannot be ruled out that validation of the report at this level 
may be a delaying factor.  
4.4.2 Benchmarking of MDT meeting activities 
By relating the number of MDT meetings to the number of chemotherapy 
patients, we get a rough idea of how these services are used in hospitals. 
We find that this varies considerably and that the frequency of MDT 
meetings varies in hospitals that have the same level of oncological activity, 
measured by the number of chemo patients. This raises the question as to 
whether MDT meetings in some hospitals are organised for situations where 
this does not really add value, for example for tumours for which the 
treatment is fully standardised and not open to discussion. Conversely, one 
may ask whether ‘too few’ MDT meetings are perhaps carried out in some 
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hospitals and invasive treatments are started for tumours for which different 
therapeutic options exist and prior multidisciplinary consultation is useful.  
The analyses further show a large inter-hospital variation in number of 
follow-up MDT meetings. In some hospitals the number of follow-up MDT 
meetings exceeds the number of primary MDT meetings.  
4.4.3 Studying the qualification of MDT meeting medical 
specialists 
4.4.3.1 Qualification of the coordinator 
The coordinator plays an important role in the MDT meeting since he/she, 
according to the nomenclature, draws up the report of the meeting, which 
includes the diagnosis, prognosis and the proposed treatment. This 
coordinator therefore receives a different, far higher fee than the participants 
(K80, as opposed to K17). This coordinator, therefore, should presumably 
have sufficient expertise to carry out this task. 
Generally, medical specialists in oncology, a relatively new discipline, most 
often take on the role of coordinator (in 52.8% of cases). They are followed 
by internist-haematologists, urologists, gastroenterologists, pneumologists, 
gynaecologists, radiotherapists and general surgeons (percentages from 
9.9% to 3.3%). In university hospitals, oncologists take on the coordination 
role somewhat less frequently, but surgeons and gynaecologists are more 
frequently involved as coordinators. Other specialties are also mentioned in 
university hospitals (ENT, neurosurgery, paediatrics, dermatology…). 
If we compare this situation with that of a few years before, we find that, in 
2008, internists most frequently coordinated MDT meetings, whereas they 
hardly appear in the current analysis of 2011. These medical specialists 
have presumably re-qualified as oncologists and also as internist-
haematologists, specialties that in 2008 were inexistent and in 2011 reach 
52.8% resp. 9.9% of MDT meeting coordinatorship. 
Some hospitals have a rather atypical coordinator profile, compared to the 
national average. In some hospitals, MDT meetings are exclusively 
coordinated by one or a few organ-specific specialties (for example, surgery, 
gastroenterology, urology, gynaecology); the question arises as to whether 
these medical specialists have received sufficient multidisciplinary training 
to cover oncology as a whole.  
4.4.3.2 Qualification of the MDT meeting participants 
The maximum number of refundable participation fees is four; in case of 
participation of an extramural physician it is five. When interpreting these 
results we should take into account that in some cases this maximum can 
be reached and not all physicians present at MDT meetings are registered 
in billing data. 
Radiologists and pathologists are only present at MDT meetings as 
participants, and almost never as coordinators. At a national level, they 
make up a significant proportion of the participations, 17% and 11% 
respectively. They can give interesting information on the stage of the 
tumour based on medical imaging and laboratory examination of tissue. If 
we look at the distribution at hospital level, we find considerable differences; 
in some hospitals these medical specialists participate regularly to MDT 
meetings (to 30%), in others much less. We should take into account that 
not all hospitals have an own laboratory for pathology and that participation 
of an external pathologist can be more difficult to organise. 
General practitioners also only attend MDT meetings as participants; they 
make up a small proportion of the total number of participations, notably 
0.8%. There are presumably organisational reasons for the limited 
participation of this health professional group. GP’s, however, can provide 
useful information about the general condition of the patient, his 
comorbidities, his psychological capacity and social situation, which are 
factors that can be useful when taking a decision as to whether to carry out 
possible invasive treatments.  
4.4.3.3 Qualification of MDT meeting attending medical 
specialists in general 
If we look in general at which disciplines are present at MDT meetings, 
irrespective of their role (as coordinator or participant), then we find that 
oncologists form the largest group, representing 19.8% of the total. They are 
followed by radiotherapists, pathologists, radiologists and general surgeons 
(percentages from 15.9% to 8.4%). These are followed by urologists, 
gynaecologists, gastroenterologists, haematologists and pneumologists 
(percentages from 4.9% to 3.3%). 
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The same calculation was carried out at hospital level for the most common 
disciplines. Oncologists can play an important role in MDT meetings and 
their presence, as coordinator or participant, can be expected in a 
considerable part of them. Yet we see an underrepresentation in some 
hospitals. In view of the fact that oncology is a new specialty, it is possible 
that not every hospital already has a dedicated oncologist. It can be useful 
to re-evaluate this item on more recent data in a few years.  
For organ-specific disciplines (e.g. urologists, gynaecologists, 
gastroenterologists and pulmonologists) we also see a large inter-hospital 
variation. However, it is not excluded that in some hospitals a MDT meeting 
is requested by some specialists but these specialists themselves actually 
do not attend the MDT meeting.  
4.4.3.4 Qualification of the informer 
A physician who informs the patient about the outcome of the MDT meeting 
can charge a fee for this debriefing (in the case of a primary MDT meeting). 
The national data show that, on average, only one in four primary MDT 
meetings is followed by such a debriefing. This service was introduced into 
the nomenclature at the end of 2010 and it is possible that the frequency will 
be higher in more recent data (the current analysis covers 2011).  
Urologists and gynaecologists most frequently take on the role of informer 
(21.6% and 18.6% of the total, respectively). They are followed by 
pneumologists, oncologists and gastroenterologists (percentages from 
11.0% to 9.4%). General practitioners represent just 3% of cases.  
Analysis at hospital level shows – in contrast with rather low national 
average – that some hospitals organise these debriefings systematically 
(and other seldom).  
 
4.5 Key messages 
Time taken to book the MDT meetings  
 The billing/booking process for MDT meetings takes much more 
time than the general billing/booking process. In some hospitals, 
an extreme delay is noted. This slow billing process compromises 
the evaluation of MDT meeting activity, surely at hospital level, 
because a complete sample is not available until many years later 
and there is thus a time-lag. 
Benchmarking of MDT meeting activity 
 It is not easy to assess whether MDT meetings are being used 
appropriately by looking at the billing data alone, given that the 
nomenclature codes are not very specific. If we compare the 
number of primary MDT meetings with the level of oncological 
activity, estimated by the number of chemo patients, then we still 
observe a considerable variation between hospitals. This raises 
the question as to whether MDT meetings in some hospitals are 
organised for cases where this does not have any clear added 
value, and vice versa. Based on the present billing data, no 
conclusive answer can be given about this. 
 There is an important interhospital variation in number of follow 
up MDT meetings. In some hospitals the number of follow-up MDT 
meetings exceeds the number of primary MDT meetings. 
Studying the qualification of MDT meeting physicians 
 According to the nomenclature, the coordinator has an important 
function within the MDT meeting; the size of his fee is also in line 
with this. In 2011, oncologists were the most important 
coordinators; in 2008, it was the internists, but they have 
presumably re-qualified as oncologists and also as internist-
hematologists. If we analyse this by hospital, then we find that 
oncologists do not appear in the data in a significant number of 
hospitals, not as coordinator and even not as participant. This may 
look different in more recent data, since oncology is a new 
specialty and it is possible that not every hospital already has a 
dedicated oncologist. In some hospitals, MDT meetings are 
coordinated by one or a few organ-specific disciplines, which 
raises the question as to whether they have sufficient 
multidisciplinary knowledge to cover the full range of tumors.  
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 Radiologists and pathologists attend MDT meetings regularly as 
participants; at hospital level, we find that this varies significantly 
and in some hospitals these specialists participate relatively 
seldom. For pathologists there can be practical reasons (external 
pathology laboratory).  
 The participation of general practitioners in MDT meetings is, 
generally speaking, very limited, presumably for organisational 
reasons. Interpreting these results we should take into account 
that in some cases the maximum number of refundable fees can 
be reached (4 to 5) and not all present participants are registered 
in the billing data. This remark also applies for following results. 
 For organ-specific disciplines (e.g. urology, gynaecology, 
gastroenterology, pneumology) we also see a large inter-hospital 
variation in their presence at MDT meeting. It is not excluded that 
in some hospitals MDT meetings are requested without the 
presence of these specialists at the discussion, which could 
explain lower values. 
 Finally, we note that only one in four primary MDT meetings is 
followed by the debriefing service that is allowed for in the 
nomenclature. The code in question was only introduced at the 
end of 2010; the frequency of this may be higher in more recent 
data.  
Nevertheless if we carry out the analysis at hospital level we see 
that some hospitals systematically organise these debriefings and 
other almost never. 
5 MDT MEETINGS IN BELGIUM - 
EXPERIENCES AND PERCEPTIONS OF 
ITS PARTICIPANTS  
5.1 Introduction and objectives 
We conducted an online survey to give an overview of the current practice 
of multidisciplinary team (MDT) meetings in Belgium and more precisely to 
answer the following research questions: 
 Today, how are MDT meetings organized in the Belgian hospitals?  
 Who attends the MDT meetings (including the GP and paramedical 
staff)?  
 How is the transfer of information organized between the hospitals, 
sickness funds and Belgian Cancer Registry?  
 What are the barriers and opportunities for a more efficient organization 
of the MDT meetings? 
5.2 Methodology 
5.2.1 Data collection 
The survey was conducted online (web-based) using Lime Survey©. Lime 
Survey, an open Source Survey Software, is a web-based interface for the 
creation and administration of online surveys. It offers good support for 
research surveys. 
5.2.2 Population, sampling and recruitment 
The web-survey was carried out at the national level, dedicated to all 
hospitals registered with a program in oncology. 
All hospital coordinators (administrative contact persons) identified by the 
Belgian Cancer Registry (BCR) received an e-mail describing the aim of the 
survey and inviting them to transmit to the KCE the email addresses of every 
participant of the MDT meeting(s) organized in their hospital, whatever their 
competency or their role in the MDT meetings.  
In total, 153 coordinators from 112 centres with a program in oncology were 
contacted per e-mail. We also searched for email addresses on the websites 
of those hospitals that could not be reached. Hospitals for which no 
coordinator’s email address were received, were invited by email to send an 
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email to the members of their MDT meeting(s) in order to invite them to 
register themselves directly to the KCE. 
On the basis of the whole list of potential participants, the KCE sent a 
personal email with the invitation to complete the websurvey; it included a 
unique code to access the online survey and the procedure to follow. 
Between May 22nd and June 15th 2014, 4 203 people received a personal e-
mail from KCE. It is very well possible that MDT meeting participants who 
work in more than 1 hospital, have received more than 1 email. Duplicates 
were unfortunately undetectable if the participant had more than one email 
address. 
Two reminders were sent to non-responders, each time a week after the 
previous mailing, as recommended in several methodological reference 
documents.70, 71 
The invitation can be found in appendix D. 
5.2.3 Questionnaire development process 
Themes and questions of the questionnaire were inspired from an Australian 
survey on MDT meetings, 50 and from the results of the literature review 
presented in chapter 2. In addition, the authors attended several MDT 
meetings to get an idea of the practical process of MDT meetings. 
The whole questionnaire consisted mainly of closed-ended questions with 
some open-ended questions when additional information could have an 
added value. The majority of the questions were mandatory. 
The questionnaire was first developed in French. The definitive version was 
then translated in Dutch. The usefulness and the formulation of each 
question was discussed within the research team involving medical, 
paramedical, statistical, juridical and social science expertise. A draft version 
was also sent to several experts in the field for comments and suggestions. 
Several rounds of revision were executed before pre-testing in both 
languages was performed. The objective of the pre-test was to verify the 
formulation of the questions (clarity, comprehension), the completeness of 
the questionnaire and the technical aspect of the survey. There was also 
space for free comments. The pre-test was performed by 6 coordinators in 
oncology, i.e. 3 Dutch-speaking and 3 French-speaking. It led to light 
modifications of the questionnaire. 
The pre-final online version was finally tested for technical aspects by the 
members of the research team. 
5.2.4 Anonymity 
The survey was not performed anonymously because the software required 
an identification by email, allowing participants to complete their 
questionnaire in several times. Nevertheless, the analyses were performed 
ensuring confidentiality of the responses.  
5.2.5 Survey process and structure 
When respondents entered the link to the web-survey mentioned in their 
invitation or reminder letter, they arrived at a welcome page, where they had 
to enter their personal code and choice of language to be able to continue. 
The welcome page also allowed for signing out of the survey.  
The survey contained: 
 a set of ‘identification’ questions (such as age, gender, professional 
activity, the field of medical specialization for the physicians, and which 
proportion of their activities was related to oncology; non-physicians 
were asked about their involvement in coordination of care); 
 a set of questions on the hospital (size, university hospital and non-
university hospital, type of program of care in oncology); 
 a set of questions on the participation in the MDT meetings; 
 a set of questions on the last MDT meeting attended: 
o organizational aspects; 
o theme/cancer(s) discussed; 
o the coordination role (or not) of the respondent; 
o the (non) participants (number, profession, field of activities); 
o patients who were discussed (number, time per patient, definition 
of the clinical stage defined, criteria used to define the treatment, 
definition of pathological stage); 
o follow-up of the MDT meeting; 
o the use of the guidelines: systematic for every patient or not (and if 
not, why?), types of clinical recommendations followed; 
o technical resources used (information, medical file, imaging, 
pathological results); 
o reporting of discussions and decisions in the medical file of the 
patient. 
 KCE Report 239 MDT meetings in oncology 59 
 
 a set of questions on the perceptions of the respondents: 
o on the MDT meeting about invasive cancers: patients discussed, 
cancer types not discussed, and the reason for not discussing 
them; 
o on the content of the MDT meeting: opinion on the timing of the 
MDT meeting in the clinical path, aspects discussed, missing 
aspects,… 
 a set of questions on the perceived advantages and weaknesses of the 
MDT meetings (and their importance); 
 a set of questions on administrative aspects (only for coordinators of 
care, coordinators of MDT meetings and data managers): billing, 
transfer of the data to the Belgian Cancer Registry, reason(s) for not 
billing some patients, delay to write and sign the MDT meeting report, 
types of MDT meetings in the hospital, check of the adherence to the 
manual of oncology and reasons for the non-transmission of the 
diagnosis to the Belgian Cancer Registry. 
 a set of questions on the implication of the general practitioners (GPs) 
in the MDT meetings: (systematic) invitation of the GPs, when, how long 
before the meeting, how they are invited, the frequency of their 
participation, their contribution to the decisions, the information of the 
GPs on the discussions, the way that the GP is informed of the decision; 
 a question on the information of the patient on the decisions of the MDT 
meeting; 
 an open-ended question allowing comments or suggestions about the 
MDT meetings in general. 
The full questionnaire, in Dutch and French, can be found in appendix D. 
5.2.6 Data analysis  
All analysis were conducted in SAS Entreprise Guide 6.1. 
5.2.7 Discussion of the results with respondents  
At the end of the survey, respondents were asked whether they were 
interested in participation in a group discussion to further elucidate and 
comment on the results of the web survey.  
Candidates were invited to follow a link to the KCE website where they could 
register. In that way, there was no direct link between the answers to the 
survey and the coordinates of the candidates for the discussion groups. The 
group discussions (one in French, one in Dutch) took place in September 
2014. 
5.3 Results 
5.3.1 Response rate 
We sent the invitation to participate to the questionnaire to 4 203 email 
addresses. In total, 1 142 persons participated in the survey giving a 
response rate of 27.2%. Of those 1 142 respondents, 93 did not fill in the 
questionnaire completely. Another 35 respondents did not attend a MDT 
meeting during the preceding 6 months and hence were excluded from the 
rest of the survey (as it was believed that they could not inform us in a 
profound way). Finally data from 1 014 MDT meeting participants were 
available for analysis. 
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Figure 21 – Number of respondents to the web survey 
  
 
5.3.2 Sample characteristics 
The 1 014 respondents work in 74 different hospitals.f Table 12 describes 
their sociodemographic characteristics and Table 2 their professional 
activities. As expected, most of the participants of the survey are between 
30 and 60 year old (10% were elder), good balance between French and 
Dutch speaker, with a bit more male (55%) participants and specialized 
medical doctor as the majority (82%) of the panel. 
                                                     
f  In 2013, 106 hospitals were registered with a care programme for basic 
oncological care and/or an oncology care programme.  
Table 12 – Sociodemographic characteristics of the respondents (N = 
1 014) 
 n % 
 
Age 
<30 year-old  43 4.2 
31-40 year-old 270 26.6 
41-50 year-old 325 32.1 
51-60 year-old 272 26.8 
60+  year-old 104 10.3 
Gender 
Male 557 54.9 
Female 457 45.1 
Language of the questionnaire  
French 512 50.5 
Dutch 502 49.5 
Table 13 – Professional characteristics of the respondents (N = 1 014) 
 n % 
Professional activity   
Specialized medical doctor 834 82.2 
Nurse 72 7.1 
Psychologist 40 3.9 
Data manager 25 2.5 
Dietician 13 1.3 
Administrative personnel 8 0.8 
1142 respondents
1014 questionnaires 
available for analysis
In‐complete 
questionnaires (n=93)
No MOC participation 
during preceding 6 
months (n=35) 
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 n % 
Social worker 5 0.5
Physician (in speciality training) 5 0.5
Other 4 0.4 
General practitioner 3 0.3 
Speech therapist 2 0.2 
Physiotherapist 2 0.2 
Technician (e.g. medical imaging, lab 
analytics) 
1 0.1 
Dentist 0 0.0 
Specialist physician (including in training)   
Yes 839 82.7 
Other 175 17.3 
Frequency of MDT meeting participation    
More than once per week 278 27.4 
About once per week 492 48.5 
About once per fortnight 133 13.1 
Less than once per fortnight 111 10.9 
Mobility   
Move from a hospital or a site to another to 
participate in MDT meeting 
548 54.4 
 n % 
 
Surgeons (N= 202) 84 41.6 
Oncologists (N=106) 63 59.4 
Medical imaging specialists (N=117) 44 37.6 
Pathologists (N=70) 38 54.3 
Radiotherapists (N=63) 53 84.1 
Other medical specialists (N=320) 138 43.1 
In our sample, 61 nurse respondents were Coordinators of care in oncology 
(CSO/onco-coachg). They represented 79% of the nurses of the sample. 
Additionally, 3 CSO/onco-coaches were dieticians, and 1 was speech 
therapist. 
More than 50% of respondents moved from a hospital/site to another. This 
is unsuspectedly high proportion was explained by the participants of the 
discussion meetings as a result of the fact that physicians who work in 
multisite hospitals answered positively to the question, while they actually 
do not move uniquely to attend MDT meetings. Nevertheless, and 
confirming partly this hypothesis, results clearly illustrated that 
radiotherapists are moving much more than other specialists and that 
specialists in medical imaging are not often moving. 
Table 14 illustrates that there are a lot of “small” hospitals (i.e. less than 400 
beds) represented in the web survey sample with a mean of 6 respondents 
per hospital. The majority of the respondents (48%) came from hospitals 
with more than 800 beds (with, in average, 27 respondents per hospital).  
 
                                                     
g  The function of coordinator of care in oncology has no devoted title. The 
respondents of the survey reported more than 15 different names for the 
function. 
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Table 14 – Number of respondents per hospital and size of hospital 
Number of beds per 
hospital 
Number of hospitals Percent Number of respondents Percent Mean number of 
respondents per 
hospital 
Missing** 0 0.0 4 0.4 . 
under 400 beds 34 45.9 199 19.6 6 
401-600 beds 16 21.6 168 16.6 10 
601-800 beds 7 9.5 157 15.5 22 
above 800 beds 17 23.0 486 47.9 27 
TOTAL 74 100.0 1 014 100.0  
Note: hospital = not by site  ** Identification of the hospital was not possible 
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Table 15 – Respondents by type of hospital 
 Number of 
respondents
% 
(N = 1 014) 
Type of hospital   
General hospital 567 55.9 
University hospital* 439 43.3 
Missing  8 0.8 
* including general hospital with university beds 
University hospitals as well as non-university hospitals are represented. 
Among university hospitals, 73% reported that the number of beds were 
higher than 800, compared to 30% in the general hospital. There is a direct 
link between the size of the hospital and the type of hospital. Therefore, we 
choose to present only data according to hospital size, and not by hospital 
type. 
Table 16 shows more specific results for specialists. Amongst specialists 
(N=839), 1 out of 4 specialists had surgery in his/her domain of activity and 
almost 3 out of 10 have, in addition or not, another medical specialties (e.g. 
pneumology, gastro-enterology, gynaecology,…) in his/her domain of 
activity. All results mentioning specialists also include in training specialists. 
Almost 50% of the specialists claimed to have more than 50% of their activity 
in oncology and 29% had exclusively or partly coordinated the last MDT 
meeting he/she attended.  
Table 16 – Specialties of the medical specialist  
 n % 
(N = 839) 
Domain of activity   
Surgery 202 24.1 
Digestive surgery (abdominal) 75 8.9 
General surgery        49 5.8 
Breast surgery       47 5.6 
Thoracic surgery (pulmonary) 28 3.3 
Head and neck surgery     28 3.3 
Digestive surgery (thoracic) 22 2.6 
Neurosurgery 21 2.5 
Plastic and reconstructive surgery     13 1.5 
Maxillo-facial surgery 12 1.4 
Medical oncology 106 12.6 
Medical imaging 116 11.4 
Radiology 76 9.1 
Nuclear medicine 40 4.8 
Pathology    70 8.3 
Radiotherapy       62 7.4 
Other medical specialties 318 31.4 
Pneumology        65 7.7 
Gastro-enterology       58 6.9 
Gynaecology        54 6.5 
Urology        48 5.7 
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 n % 
(N = 839) 
Haematology        47 5.6 
Ear, nose and throat (ORL-NKO)    30 3.6 
Hepatology (incl. pancreatology. biliary tract)   21 2.5 
Endocrinology       20 2.4 
Clinical Biology      16 1.9 
Internal Medicine      12 1.4 
Dermatology        11 1.3 
Paediatrics       11 1.3 
Palliative care       11 1.3 
Neurology       8 0.9 
Activity in oncology   
Less than 25 181 21.6 
Between 25 and 50 237 28.2 
Between 50 and 75 166 19.8 
More than 75 238 28.4 
Don’t know 17 2.0 
Role in the last MDT meeting   
Participant 595 71.0 
Both roles. depending on patients discussed 142 16.9 
Coordinator of the MDT meeting 101 12.1 
Note. several answers possible 
5.3.3 Functioning of the last MDT meeting attended by the 
respondents 
For the following questions, the respondents were asked to focus only to the 
last MDT meeting they had attended; this was done in order to minimize 
recall bias. 
5.3.3.1 General vs. specific MDT meeting 
In general MDT meetings, patients with different types of cancer are 
discussed in the same meeting while in specific MDT meetings only patients 
suffering from a certain type of cancer (e.g. breast cancer MDT meeting, 
colorectal MDT meeting, etc.) are discussed. 
Nearly 80% of the respondents refer to a specific MDT meeting as the last 
MDT meeting they had attended. As Figure 22 shows, there are differences 
in the proportion of specific or general MDT meetings in function of the 
hospital size. These differences are statistically significant (p<0.001). These 
differences can be explained by the need to have a sufficient number of 
patients with a cancer type to organize specific MDT meetings.  
According to the participants we met in the discussion meetings after the 
web survey, general MDT meetings are sometimes organized in such a way 
that cases are grouped by cancer type and the different specialists are 
coming and leaving in function of the cancer type.  
The next figure shows the cancer groups of the last specific MDT meeting 
respondents had attended. The distribution corresponds roughly to the 
cancer incidences, more common cancer types being more frequently 
discussed in specific MDT meetings. 
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Figure 22 – General and specific MDT meetings by size of the hospital 
 
* 4 non identified hospitals 
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Figure 23 – Specific last MDT meeting by cancer type (N=797) 
 
5.3.3.2 The participants 
Number of participants (not including students) 
Nearly 1 out of 2 respondents estimated that the number of attendants to 
the MDT meeting ranged between 6 and 10. There were slight, but 
statistically significant differences according to the hospital size (p = 0.028). 
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Table 17 – Number of participants of the last MDT meeting by hospital size 
   ≤ 400 beds 
(N=197) 
401-600 beds 
(N=168) 
601-800 beds 
(N=157) 
> 800 beds 
(N=483) 
Total 
(N=1 005) 
n % n % n % n % n % 
≤ 5 10 5.1 5 3.0 8 5.0 23 4.8 46 4.6
6-10 94 47.7 103 61.3 84 53.5 205 42.2 486 48.3
11-15 75 38.1 43 25.6 47 29.9 177 36.6 342 34.0
> 15 18 9.1 17 10.1 18 11.5 78 16.1 131 13.0
There is no difference in the number of attendants of the last MDT meeting according to the type of MDT meeting (General vs. specific). 
Professional profile of participants 
All expected professional profiles (according to the aim of a MDT meeting) attend MDT meetings but not every meeting (Figure 24).  
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Figure 24 – Professional profile of the participants of the last MDT meeting (internal to the hospital/site and external) (N=1 014) 
 
The more represented specialties are medical oncology, surgery and 
radiotherapy. According to the respondents there was in less than 80% of 
the last MDT meetings they attended a specialist in medical imaging and 
pathology present.  
The attendance of data managers and nurses was also mentioned by 55%-
65% of the respondents. Nevertheless, this figure is probably slightly 
overestimated because the denomination ‘data manager’ could also 
encompass clinical research managers or onco-coaches. 
More than 20% of the respondents cited the presence of a GP during the 
last MDT meeting they attended; this proportion was also judged as 
surprisingly high by the participants of the discussion meetings. They 
suspected a confusion between the GP of the patient and the GPs working 
in the hospitals (e.g. in geriatrics). Nevertheless, GP’s participation differs 
according to the hospital size. They are more present in COM meetings 
organized in small hospitals than in big hospitals (see data in appendix D). 
This difference is statistically significant (p<0.001). It is therefore logical that 
GPs are also more often represented in general MDT meetings than in 
specific ones (40.3% vs. 18.9%; p< 0.001).  
Missing participants in the last MDT meeting 
Among the respondents, 123 (12.1%) participants deplore the absence of 
one or more actors during the MDT meetings. It concerns mainly medical 
specialists (80.1%), GPs (14.6%) and social workers (7.3%). Other reported 
missing key actors are psychologists, physiotherapists, data managers, 
technicians and specialists in training (less than 5% each). 
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5.3.3.3 Organization of the last MDT meeting  
Table 18 gives an overview of the practical organizational aspects of the last 
MDT meeting respondents had attended. 
Table 18 – Last MDT meeting: organizational features 
 n % 
Frequency (N=1 012) 
Twice per week, or more 28 2.8 
Once per week 798 78.9 
Once per fortnight but less than once 
per week 
128 12.6 
Once per month but less than once per 
fortnight 
50 4.9 
Between once every 2 months and 
once every 6 months 
6 0.6 
Once every 6 months or less 2 0.2 
Length (N=1 006) 
Less than 60 minutes 363 36.1 
60- <90 minutes 463 46.0 
90-120 minutes 141 14.0 
More than 2 hours 39 3.9 
Timing (N=1 012)   
During lunch break 401 39.6 
During regular working hours 383 37.8 
Before or after working hours 228 22.5 
 n % 
Number of patients discussed (N=1 000) 
<5 patients 29 2.9 
5-10 patients 285 28.5 
11-15 patients 345 34.5 
16-20 patients 211 21.1 
21-25 patients 69 6.9 
>25 patients 61 6.1 
Time spent per patient (N=1001) 
<5 minutes 151 15.1 
5-10 minutes 746 74.5 
11-30 minutes 101 10.1 
31-50 minutes 2 0.2 
>50 minutes 1 0.1 
 
More than 80% of participants had a MDT meeting once a week or more. 
Eighty two percent of the participants estimated to have participate to MDT 
meeting lasting maximum 90 minutes whose 36% estimated this time to less 
than 60 minutes. Only 38% of participants have been enrolled in MDT 
meeting during working hours. 
In 65% of the MDT meetings, not more than 15 patients are discussed during 
the meeting. There is no difference in the number of patients discussed in 
specific MDT meetings and in general MDT meetings, nor regarding the size 
of the hospital. 
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According to about three quarters of the respondents, each patient is 
discussed between 5 and 10 minutes on average (Table 18). According to 
15% of the respondents the discussion lasted less than 5 minutes per 
patient. There is no difference according to the hospital size or the type of 
MDT meeting (specific or general). It should be noted however that the 
length of a discussion cannot be considered a valuable quality indicator. 
A large majority of respondents (92.7%) reported that in their opinion, most 
patients with an invasive cancer are discussed in a MDT meeting.  
5.3.3.4 Clinical information available for the treatment 
About 81% of the respondents reported that during the last MDT meeting 
they attended the clinical stage was clearly defined for each patient using a 
recognized classification (e.g. TNM, FIGO) (Figure 25). When the clinical 
stage was not defined, they justified it by the fact that the assessment of the 
patient was still ongoing (36.4%) or because the clinical stage was not 
applicable (20.3%). Other reasons counting for less than 10% of the cases 
related to the incompleteness of the medical file, because it was a follow-up 
MDT meeting, a relapse or progression of the cancer, because the clinical 
stage was implicit in the discussion or still has to be discussed. Poor 
functioning of the MDT meeting, perceived uselessness of the clinical 
staging as well as clinicians’ lack of tradition to determine a clinical stage 
before initiating a treatment were also mentioned. According to the 
respondents, the clinical stage was sometimes simply impossible to classify. 
Figure 25 – Clinical stage defined (N=975) 
 
When the clinical stage was missing, discussion on the treatment was either 
postponed (31.7%) or was based on other criteria: clinical and prognostic 
(i.e. general status of the patient, comorbidities, surgery results) (21.8%), or 
on the pathological stage (21.1%). In less than 10% of the cases, treatment 
has been based on recommendations (oncological handbook or guidelines), 
physicians’ opinion or on another international classification.  
About 91% of the respondents reported that the pathological stage was 
defined for each patient discussed during the last MDT meeting they 
attended (Figure 26). 
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Figure 26 – Pathological stage defined (N=978) 
 
When the pathological stage was not available (i.e. in 9% of the cases – see 
Figure 6) this was explained by the respondents because the assessment 
was still ongoing (37.0%), because the MDT meeting did not function well 
(22.2%), because a pathological stage was not applicable (16.7%). In some 
cases, it was reported that it was because the patients were discussed in 
the context of their follow-up MDT meeting, because pathological staging 
was considered unusual practice or because it was not reported in the 
medical file of the patient.  
5.3.3.5 Topics addressed during the last MDT meeting 
The discussions in the MDT meeting covered several aspects. The 
discussion of the purely medical issues evidently occurred in 100% of the 
cases, but additionally the psycho-social situation of the patient was often 
debated. Dietary aspects were least frequently addressed (Table 19). 
 
                                                     
h  National recommendation might be based on international guidelines 
Table 19 – Issues discussed during the last MDT meeting  
 n     % 
(N=1014) 
Medical topics (diagnosis, therapeutic strategies) 1014 100.0 
Psychological situation       807 79.6 
Social situation       706 69.6 
Patients’ personal wishes       700 69.0 
Financial situation       204 20.1 
Dietary aspects         124 12.2 
Other 16 1.6 
Note. Several answers possible 
5.3.3.6 The use of guidelines 
A MDT meeting implies the use of guidelines to support the clinical decision. 
As shown in Figure 27, international guidelines were used in the MDT 
meetings attended by the majority of the respondents (71.1%); in about 40% 
of the cases, national recommendations and/or hospital’s oncological 
handbook were also used to guide the management of the patienth.  
 72  MDT meetings in oncology KCE Report 239 
 
Figure 27 – Recommendations used to guide the treatment strategy 
during the last MDT meeting (N=1 014) 
 
Note. More than 1 answer possible 
Figure 28 – The utility of the guidelines during the last MDT meeting 
according to physicians (N=839) 
 
Regarding the usefulness of the guidelines to orientate a treatment, 86% of 
the respondents reported that they were supportive (at least for some 
patients – possibly for every patient) for the discussions in the last MDT 
meeting they attended. When it was not so, around 50% of the participants 
to the survey justified it by the uncommon patient situation that does not 
answer to general recommendations, and 1 out of 4 participants considered 
the guidelines whether not recent enough whether not present for the 
particular case (Table 20). 
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Table 20 – Why were guidelines not useful for some patients during 
last MDT meeting - according to physicians 
 n % 
(N=171) 
The patient is a particular case, out of mean, complex  80 46.8 
No recent recommendation or no recommendation at all 
for this cancer           
37 21.6 
The oncologist is specialist in his/her field and does not 
require guidelines. He/she knows what are the most 
appropriate treatments 
20 11.7 
Particular comorbidities not covered by the guidelines     17 9.9 
Decisions are taken in the MDT meeting             8 4.7 
Patient refusal to follow the recommended treatment / 
side effects         
4 2.3 
Opportunity to include the patient in a clinical study, out 
of recommendations       
2 1.2 
International recommendations do not suited to 
reimbursement rules in Belgium       
2 1.2 
Negative pathology               1 <0.1 
 
Only a minority of the 25 data managers who participated in the survey 
reported that they check systematically if the treatment decisions followed 
the oncological handbook recommendations; a task which they officially 
have to fulfil. This is mainly due to the high administrative workload they 
experience.  
Figure 29 – Check of the adherence of the decision to the oncological 
handbook (N=25) 
 
 
5.3.3.7 Support during last MDT meeting  
Almost three-quarters of the respondents reported that the necessary 
“resources” (information on the patient, technological support, expertise 
support) were available for each patient at the MDT meeting. 
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Figure 30 – Support during last MDT meeting (N=1 014) 
 
The next table describes the way information was made available to the 
MDT meeting participants during the last MDT meeting they attended. 
Table 21 – Availability of medical information during the last MDT 
meeting  
 n % 
(N=1014) 
Medical file 
Electronically available for someone in the room. and 
projected for the participants           
693 68.3 
Electronically available for everyone in the room           204 20.1 
On paper                    195 19.2 
Electronically available for someone in the room           82 8.1 
Other                    15 1.5 
Don't know                    5 0.5 
Medical imaging 
On a big screen so that everyone can see it  949 93.6 
No medical imaging was shown during the meeting       34 3.4 
On computer screen 34 3.4 
Don’t know           4 0.4 
Pathological results 
The written report was presented (orally or projected)   766 75.5 
The written report was available                    299 29.5 
The slices were projected             149 14.7 
Virtual pathology images were accessed and 
projected         
58 5.7 
Other                    23 2.3 
Don't know                    6 0.6 
No results of pathology were discussed                    2 0.2 
Note. Several answers possible 
In terms of technical resources, the medical file was made available for the 
paticipants as shown in Table 21, i.e. mainly by projection on a big screen. 
The medical imaging files were also most of the times projected. Finally, 
pathological results were directly communicated during the meeting 
(presented or projected). 
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Digital decision support tools (e.g. MATE, OncoDoc2, Adjuvant!) are barely 
(5%) used by the respondents; only few of them used it during their last MDT 
meeting. Besides, videoconferencing was a little more frequently used: 
12.6% used it in their last MDT meeting, mainly to correspond with another 
hospital (9.2%) or with a GP (3.5%). 
5.3.3.8 Turning MDT meeting decisions into action 
Clinical pathways and responsibilities 
For 97.5% of the respondents, the next steps in the clinical pathway were 
clear for all discussed patients. Moreover, 46.8% of the respondents 
confirmed that the name(s) of those responsible for the next step in the 
clinical pathway was (were) noted in the medical file of each patient, while 
21.6% confirmed it was not. 
Information to the patient 
According to the CSO/onco-coaches and coordinators of MDT meeting, 
patients are in most cases (89%) informed by their treating specialist about 
the MDT meeting’s results. Less frequently, the information is transmitted by 
the CSO/onco-coach or the GP (Table 22), rarely by the MDT meeting 
coordinator, the data manager or a secretary. Patients may also receive the 
information by letter or by a copy of the MDT meeting report. 
Table 22 – Who informed the patient of the MDT meeting decisions - 
according to CSO/onco-coaches and coordinators of MDT meeting 
(N=304)  
 N % 
The treating specialist   270 88.8 
The CSO / onco-coach       49 16.1 
The GP 22 7.2 
Don't know      5 16.1 
Other 8 2.6 
Note. Several answers possible 
5.3.4 Perceptions on the MDT meetings’ functioning 
5.3.4.1 Perceptions about the quality of the discussion 
Several aspects of the discussion could be used as indicators of the quality 
of the MDT meeting. MDT meetings aim to discuss a patient as soon as 
possible in order to develop a treatment plan in a multidisciplinary way. From 
Figure 31, we see that the majority of the respondents agreed that the MDT 
meeting occurs early enough in the clinical pathway of the patients (88.8%), 
that non-medical aspects are also discussed during the MDT meeting 
(75.6%) and that all aspects seem to be covered during the MDT meeting 
(72.7%). In case of delay in discussing a patient during the MDT meeting, 
this was mostly due to the choice of the treating specialist, who preferred to 
discuss the patient after the first curative treatment (i.e. when their treatment 
is already launched or when they already have been operated) or due to the 
low frequency the MDT meetings are organised in certain hospitals.  
Figure 31 – Perception of several quality aspects of the discussion in 
MDT meetings (N=1 014) 
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As presented in section 1.3.3.5, several aspects related to the patient 
(medical, psychological, social, financial...) or to the treatment are discussed 
in the MDT meeting. Nevertheless, as shown in Figure 31, 13.8% of the 
respondents think that non-medical aspects are not sufficiently addressed 
during the discussions and 15% believe that some aspects are still missing, 
i.e. psychosocial and/or socio-economic issues, images, GP or paramedic’s 
advices and patients’ desires. Respondents attribute this ‘gap’ mainly to the 
absence of key actors, shortness in time or the lack of a real discussion 
during the MDT meeting. 
5.3.4.2 Advantages of the MDT meeting 
Many advantages were recognized by the respondents (Figure 32); they 
relate to quality of decision making, quality of care but also social contacts 
between healthcare providers and positive impact on the training process, 
positive impact on the diagnostic and staging process. Nearly 90% of the 
respondents agreed that the MDT meetings ensure joint decision, improve 
coordination between healthcare providers and improve also the quality of 
care offered to the patient. These advantages were also ranked as 3 first in 
terms of importance (see data in appendix D). 
Figure 32 – Perceived advantages of MDT meetings (N=1 014) 
 
Note. Several answers possible 
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5.3.4.3 Barriers to an efficient organization of the MDT meetings 
The reported barriers are mainly organizational: chaotic meetings, timing (of 
the MDT meeting during the day), number of patients discussed, absence of 
key actors, etc. Nevertheless, 6% of the respondents identified no barriers 
to an efficient MDT meeting and 10% did not know. The 3 most frequently 
reported barriers were also ranked first in terms of importance (see data in 
appendix D). 
Figure 33 – Barriers to an efficient MDT meeting (N=1 014) 
  
Note. Several answers possible
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5.3.4.4 Time to prepare MDT meetings 
Figure 33 shows that 26% of the respondents consider a lack of time to 
prepare the MDT meeting as a barrier to an efficient MDT meeting. Yet, 
Figure 34 illustrates that one fifth of the respondents (22%) never or rarely 
have sufficient time to prepare the MDT meeting; 56% reported that they 
have most of the time sufficient time to be well prepared. 
Figure 34 – Sufficient preparation time (N=832) 
 
Note : N = 823, only for participants who have to prepare MDT meeting 
5.3.5 GP’s implication in MDT meetings  
5.3.5.1 Invitation of the GPs 
In order to increase the reliability of the information, we only consider the 
answers given by the onco-coaches/CSO’s and MDT meeting coordinators 
as they are the ones involved in the organisational aspects of the MDT 
meetings. According to 46% of them, GPs are systematically invited to the 
MDT meeting where one of their patients is discussed. However, 13% does 
not know if the GP is systematically invited and another 22% reported that 
this is never the case (Figure 35). 
Figure 35 – Invitation of the GP to the MDT meeting (according to MDT 
meeting coordinators and CSO) (N=304) 
 
 
Table 23 shows that if the GP is not systematically invited, he is on his/her 
demand. The invitation is generally made by phone or by e-mail. 
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Table 23 – Practical aspect of the GP’s invitation according to 
CSO’s/onco-coaches and MDT meeting coordinators (N=304) 
 n % 
If the GP is not systematically invited, when exactly is he still 
invited? (N=51) 
If the GP asks for it 20 39.2 
Depending on the patient (complex, age, psycho-
social aspects, etc.) 
14 27.5 
Depending on the specific MDT meeting 4 7.8 
If the patient asks for it 1 2.0 
Other 12 23.5 
How the GP is in general invited? (N=297)* 
Telephone call 99 33.3 
E-mail 81 27.3 
Letter 74 24.9 
Information in the patient’s electronic file 
accessible by GP 
37 12.5 
SMS 2 0.7 
*Several answers possible 
On average, GPs are invited 4 days prior to the meeting, with a median of 3 
days. 
5.3.5.2 Participation of the GP 
According to 23% of the respondents, a GP was present during (parts of) 
the last MDT meeting they attended (see Figure 24). More than 50% of the 
respondents reported that the GP is seldom or never present at the MDT 
meeting (Figure 36). 
Figure 36 – Frequency of the GP's presence in MDT meetings (N=1 014) 
 
5.3.5.3 Perceived contribution of the GPs in MDT meetings 
Table 24 focuses on the respondents who met a GP in the last MDT meeting 
they attended. There is no consensus on the added value of GPs’ presence 
in the MDT meeting and this is not related to the professional profile of the 
respondents. 
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Table 24 – Does the GP contribute to the discussion? 
 n %
(N=777)
Systematically  21 2.7
Mostly   80 10.3
Sometimes  209 26.9
Rarely   55 7.1
Never  329 42.3
Don't know  83 10.7
 
5.3.5.4 Information of the result of the MDT meeting  
In the large majority of the cases (Figure 37), the GP is systematically 
informed of the results of the MDT meeting, obviously if the patient has an 
entitled GP. Yet, this is not the case according to 13% of the respondents 
and another 8% do not know.  
Figure 37 – Information of the GP of MDT meeting results according to 
onco-coaches/CSO’s and coordinators of MDT meeting (N=304) 
 
 
The GP is mainly informed of the results of the MDT meeting by a letter, and 
in a smaller percentage of cases by email and/or phone call. Some MDT 
meetings use electronic secured flows as Medibridge or the medical 
electronic file. 
  
 KCE Report 239 MDT meetings in oncology 81 
 
Table 25 – How is the GP informed of the result of the MDT meeting 
according to CSO/onco-coach and coordinators 
n %
(N=304)
Letter       249 81.9 
Electronically 12 3.9 
E-mail       54 17.8 
Don't know      2 <0.1 
Telephone call        37 12.2 
Note. Several answers possible 
5.3.6 Administrative aspects of the MDT meetings 
Questions on administrative issues were only presented to data managers, 
CSO’s/onco-coaches and MDT meeting coordinators. Among them 
(N=329), 86 (26%) are involved in the billing to the sickness funds and 113 
(34%) in the data transfer to the Belgian Cancer Registry. 
Not every patient is billed to the sickness funds; the reasons for not doing 
so are, in descending order: (1) the patient was already billed for a previous 
MDT meeting occurring in the same or in another hospital, (2) the decision 
on treatment was postponed due to the need of additional exams, (3) non 
Belgian resident or no affiliation to a sickness fund, (4) the hospital is not the 
reference hospital mentioned in the MDT meeting report. Sometimes, a 
patient is discussed but after all no malignity was diagnosed and hence the 
MDT meeting could not be billed. 
It happens that data transmitted to the BCR are incomplete. This is mainly 
because data are missing in the MDT meeting report itself, but other reasons 
are also reported: sometimes some criteria are not applicable, the 
administrative overload, technical problems or a lack of training in encoding 
the data. 
According to 36% of the CSO/onco-coaches and MDT meeting coordinators, 
the MDT meeting report is signed directly after the meeting. In the other 
cases, it is done within 2 weeks (median) following the MDT meeting. 
5.3.7 General comments on the MDT meetings 
The free comments reported by the respondents were summarized in three 
categories: positive comments, critics and suggestions. Even if a comment 
was only given once, it is reported, in order to give a complete view of the 
respondents’ opinions. 
5.3.7.1 Positive comments on MDT meetings 
Many people underlined their satisfaction with MDT meetings for: 
 Quality of care 
o they are needed for a good practice in oncology, 
o increase the safety for the patient, 
o real progress in the treatment of the patient, 
o increase quality of care for the patient, e.g. by collecting information 
for the diagnosis, discussing complex cases, thoroughness in the 
management of the patients. 
 Work process 
o increase multidisciplinarity, 
o allow multidisciplinary decisions, 
o improve the quality of the relationship between healthcare 
providers, 
o allow that all healthcare providers provide the patient with the same 
information, 
o are time saving for the participants. 
 Personal 
o are enriching. 
 Societal 
o allow savings in healthcare expenditures (avoiding unnecessary 
exams and treatments). 
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5.3.7.2 Negative comments on MDT meetings 
Respondents gave also their negative feelings they experienced on the MDT 
meetings. 
About the MDT meeting in general: 
 The MDT meeting reports are not adapted to hematological 
malignancies. 
 Several MDT meeting participants could discuss the patient case 
directly with the treating physician, outside the MDT meeting and 
therefore should not have to attend the meeting (e.g. dieticians, social 
workers, etc.). 
 MDT meetings do not bring added value in the treatment. 
 Nutritional aspects are not systematically discussed. 
About financial aspects: 
 MDT meeting participants are not paid in proportion to the workload 
(preparation and attendance time). 
 The billing by the 1st hospital hampers the remuneration of the 
contribution of the “expertise/university hospitals” consulted afterwards. 
 MDT meetings are a way to finance oncologists. 
 Discrepancies between remuneration of oncologists and surgeons are 
unfair. 
 The reimbursement by the sickness funds are often delayed; 
sometimes up to 2 years after the billing. 
 Currently no budget for material (screens, video-conference, etc.) is 
provided  
Critics on the meetings: 
 Absence of key actors in the meetings. 
 Presence in the meetings of specialists without know-how in oncology 
or in some pathologies. 
 The information and the discussion are not always of high quality. 
 Lack of respect between physicians. 
 Discussions are virtual, merely based on the patient’s file when 
participants have not seen the patient. 
About overload: 
 MDT meeting participation takes a lof of time: preparation, transport, 
outside working hours, many participants with only limited 
contributions…. It is more and more difficult to conciliate clinical practice 
and administrative tasks. 
 Administrative overload of the MDT meeting. 
 Too many cases discussed in too short time. 
 Lack of recognition of the coordinator’s workload by his/her chief as the 
MDT meeting coordination is not considered a clinical activity. 
 Organized outside working hours 
5.3.7.3 Suggestions made by the respondents 
MDT meeting in general: 
 Make MDT meeting mandatory for each new cancer. 
 Abolish MDT meetings in small hospitals as there is no sufficient 
expertise and/or the frequency is too low for an efficient organisation of 
the treatment. 
Organization: 
 Every MDT meeting should be attended by at least 1 oncologist, 1 
radiologist, 1 pathologist, 1 nuclear medicine specialist, 1 surgeon, 1 
radiotherapist and 1 data manager 
 Consultation with paramedics and social workers should happen 
outside the MDT meeting to limit the number of attendees. During a 
mandatory contact of the patient with the social service before the 
treatment starts, the psycho-socio-economic information can be 
collected while it saves the social worker the time of attending the MDT 
meeting. Patient’s cases should be presented in the MDT meeting by 
the treating specialist. 
 Depending on the case discussed, key actors (e.g. the geriatric liaison 
nurse) should attend the MDT meeting.  
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 MDT meetings should follow a mandatory discussion scenario so that 
all aspects (e.g. also psychosocial) are discussed. 
 Videoconferencing has to be encouraged for GPs and (external) (sub) 
specialists. 
 In order to compensate the GP’s difficulty of attending the meetings, a 
discussion between the GP and the treating specialist based on the 
MDT meeting proposal could be held afterwards.  
 Discuss patients during a ‘follow-up MDT meeting’ where the results of 
the treatment (including death) can be discussed. 
 Redefine the role of the data managers. 
Financing: 
Financing of the MDT meeting should be increased and/or reviewed in order 
to make it more adequate: 
 Remunerate administrative work. 
 Financing of the hospitals should be based on more recent activities. 
 Increase the number of reimbursed disciplines: 3 treatment pillars 
(surgery, radiotherapy and systemic therapy) + 3 diagnostic disciplines 
(radiology, pathology and nuclear medicine) + for hematology, 
physician with cytogenetic and molecular competences. 
 Remunerate videoconference. 
 Revise and clarify the rules of the follow-up MDT meetings. 
 Improve the inspection of what is done with the funds received within 
the frame of the cancer plan. 
 Reimburse the review of scintigraphic data (including PET/CT). 
 Reimburse the discussion of benign tumours. 
 Separate sickness funds billing and data for Cancer Registry. 
MDT meeting report: 
 Create an online registration system with a standardized report so that 
the transfert of data to BCR and sickness funds can be improved. 
 Adapt the questionnaire for each pathology, and in particular for 
hematology. 
 Improve the form for the follow-up MDT meetings. 
 Register the reason why the MDT meeting’s decision was not applied. 
 Control the MDT meeting report by the MDT meeting coordinator. 
 Select the data that have to be registered in a better way. 
 Make data available for benchmarking purposes. 
 Belgian cancer registry should give feedback.  
Technological support: 
 Improve technological support (computer screens, videoconference, 
meeting rooms,…). 
 Integrate pathologies’ images. 
5.4 Discussion 
5.4.1 Context and limitations 
The results of the online survey complement the administrative data on the 
organization of the MDT meetings which are described in the other chapters. 
Yet, they are descriptive and, generally speaking, do not necessarily appeal 
to very detailed comments or further reflection. 
The response to the online survey can be called a success. In part, this can 
be explained by the health professionals’ enthusiasm about the MDT 
meetings but also by the ease of access to the survey. The possibility to fill 
in the questionnaire in several steps, and the mandatory aspect of questions 
favoured the availability of a huge number of complete questionnaires. 
Nevertheless, it should be realised that not every hospital has participated, 
and within any hospital not every MDT meeting attendee. Also, the length of 
the questionnaire - targeted to health professionals who already have a very 
busy schedule - may have impaired a higher participation rate.  
Questions were inspired by other, yet not validated, surveys published in the 
literature. The present questionnaire was not validated either, still it was 
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pretested by a small number of coordinators of care in oncology (CSO/onco-
coaches). In addition, during two meetings (one in Dutch and one in French) 
the results were thoroughly discussed and some peculiar results were 
elucidated by the experts of the field. The fact that more than 80% of the 
respondents had at least one MDT meeting a week definitely adds to the 
reliability of the results. 
In the next paragraphs, the following themes are discussed: organizational 
aspects of the MDT meeting, the MDT meeting as a place for training, billing 
of administrative aspects, the function of the data manager and the place of 
the GP. We will also discuss privacy issues and the possibility to use 
videoconference.  
5.4.2 Organizational aspects of the MDT meetings 
5.4.2.1 The General and the specific MDT meeting 
MDT meetings are organised in two different settings: either as general 
meetings where all types of cancer are discussed, either as specific 
meetings where a specific cancer type is discussed. The first are organized 
in hospitals with low numbers of new cancer cases. The order the patients 
are discussed is such that specialists only attend those cases in which they 
are/will be involved/they have experience.  
Sometimes it is very hard to find an expert with sufficient subspecialty for 
certain cancer types. In these cases videoconferencing could improve the 
attendance of those subspecialists. 
5.4.2.2 Attendance to the MDT meeting 
Among the ‘missing specialties’, radiologists are highly ranked. 
Nevertheless, their presence is crucial to assist in the interpretation of the 
imaging, certainly when there are discrepancies between the imaging and 
clinical data. Pathologists are also often missing, which is not surprising 
giving the lack of physicians specialized in this field and the fact that their 
presence is highly desirable in most MDT meetings (whereas e.g. a 
gynaecologist will only be invited for dedicated MDT meetings). In daily 
practice, pathologists often have to move for MDT meetings to another 
                                                     
i  The “Walloon Health Network” allows a secured exchange of computerized 
medical documentation (test results, medical reports, letters, etc.) between 
the doctors treating a same patient. 
hospital (site), which is also a waste in time. In some hospitals, they try to 
organize the MDT meetings in the pathology service in order to increase the 
attendance of pathologists. Here also, videoconferencing could offer a 
partial solution to this problem. 
The following “minimal composition” for a MDT meeting was suggested: 1 
specialist in imaging (subspecialized), 1 radiotherapist, 1 oncologist, 1 
specialized surgeon and 1 pathologist. It is imperative that the referring or a 
treating specialist of the patient also attends the MDT meeting. This would, 
according to respondents, guarantee the quality of the MDT meeting 
discussion and decisions. 
Other professionals 
Whether social workers (and by extension also other para-medical 
specialties) should attend MDT meetings was a matter of debate. Some 
argued that they should not waste their time in MDT meetings and can be 
informed through other means, while other argued that if psychosocial 
aspects are taken in consideration, the treatment plan may look different. 
In the meantime, the presence of psychologists is considered of added 
value, surely in case of mutilating interventions.  
5.4.2.3 Practical organization of the MDT meetings 
The results demonstrated that in many hospitals MDT meetings are 
organized outside regular working hours. As so many different disciplines 
are involved in the MDT meetings it may be impossible to find time that fits 
perfectly in everybody’s schedule. In addition, though the web survey as well 
as during the discussions afterwards, it was well brought to our attention that 
the preparatory efforts for an efficient MDT meeting should not be 
minimized. Yet, if attendees do not want to waste their (and others) valuable 
time it is extremely important that the meeting is well prepared, for instance 
that colleagues know well in advance which cases will be discussed, that 
imaged that were generated in another hospital(site) can be retrieved and 
interpreted in advance. A national or at least regional registry, like “Réseau 
Santé Walloni” may be very helpful in these cases.  
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5.4.3 The MDT meeting as a fruitful place for training 
There was clear consensus on the training dimension of the MDT meetings, 
certainly not only for physicians in training and assistants but also for all 
other attendees, including practicing specialists. This aspect could be further 
improved when every case is also presented during follow-up. 
5.4.4 Billing problems 
Several problems related to the billing of MDT meetings were raised during 
the discussions. Firstly, the rules for billing follow-up MDT meetings are not 
clear at all. Moreover, they would like to be able to bill a systematic 
presentation of the patients after surgical resection to discuss the following 
steps of the treatment plan. Thirdly, it causes a lot of problems that, in order 
for the “second hospital” to receive reimbursement, the name of this hospital 
has to be mentioned in the MDT meeting report of the “first hospital”. Some 
patients who ask a second opinion do not inform the first hospital where they 
were diagnosed, hence nothing is stated on the MDT meeting report and the 
second opinion MDT meeting cannot be reimbursed. In other cases, even 
when a hospital wants to refer patients for a second opinion, they may do so 
without naming directly the hospital in their report, as there is no direct 
interest for them to do so. Also, some “smaller” hospitals have arrangements 
with bigger hospitals and refer the patient systematically to the latter, without 
giving the patients the possibility of being referred to the hospital of their 
choice. 
Last, if it is decided in the MDT meeting not to treat the patient, no MDT 
meeting can be billed, while much time and efforts may have been spent to 
come to that conclusion. The same applies when a patient has 
simultaneously 2 tumours: for the second tumour, the MDT meeting cannot 
be billed. 
In addition to these financial issues, the quality of the sickness funds’ 
process in all these was virulently deplored: lost documents, high number of 
refusals, length of the process, engender a lot of extra administrative 
workload. An electronic flow was claimed for. 
Finally, it was questioned why the physical presence of someone is 
mandated in order to get reimbursement while a videoconference of good 
quality gives the same result. In some hospitals this has led to virtual 
“administrative MDT meetings” in order to get reimbursement for those 
colleagues who can only attend the “real” MDT meetings through 
videoconferencing. 
5.4.5 The function of data manager  
According to the law, a lot of administrative and even qualitative tasks have 
been transferred to the data managers. In reality, however, the data 
managers have far too much work to realize what is written in the law. In 
daily practice they (are asked to) focus on the administrative tasks, certainly 
because it has a major financial impact for the hospital (and the financing of 
their own job). Hence, the function of the data manager has to be redefined 
thoroughly. 
Due to the enormous administrative workload and the high number of MDT 
meetings, the physical presence of the data manager in every MDT meeting 
is impossible.  
The data manager has to have at least a master degree. Nevertheless, not 
every task, in particular the administrative part, needs to be done by 
someone with a university degree. 
5.4.6 GP at the MDT meetings 
In general, GP’s rarely attend MDT meetings; when they do, they go to MDT 
meetings organised in smaller hospitals close by. A couple of reasons were 
put forward for their low level of attendance: lack of invitation/information, 
too much time lost in relation to the length of the case discussion. Here, 
videoconferencing could also offer a solution. A pilot project to implement 
Telemoc with GPs, which was financed by the INAMI/RIZIV, was carried out 
from 2009 to October 2010.72 Videoconference resulted in an increased 
participation of GPs, both in terms of the number of GPs attending the MDT 
meeting and the frequency of their participation. Users (GPs and MDT 
meeting participants) were very satisfied and it was noted that the 
implementation of Telemoc could be realized with negligible costs. 
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However, the presence of a GP in the MDT meeting is not considered 
valuable by all. The proponents explained that the GP brings another point 
of view on the patient, knowing him or her better than healthcare workers 
from the hospital, that he/she can forward the wishes of the patient and/or 
his family. The opponents argued that although a good GP – specialist 
relationship is important for the treatment, a GP is not necessarily present 
in the MDT meeting. Also, a GP’s presence may be time consuming for the 
meeting: MDT meeting coordinator has first to explain the history, listen to 
the GP, and explain the proposed treatment… 
5.4.7 Privacy 
While medical secrecy links the medical staff members of the hospital and 
the professional secrecy for the others, patients are not necessarily aware 
of the high number of people (and their qualification) who hear the 
discussion of their case. It may be good to inform him/her properly on the 
way such a meeting is organized. And, to increase the liability of the MDT 
meeting participants/spectators, a list of attendance could be signed.  
5.4.8 Utility of the handbook 
In nearly 80% of the last MDT meeting the respondents attended, 
international recommendations were followed. Apparently, the hospital 
oncology handbook is very important; it has a powerful unifying role. It allows 
the identification of strengths and weaknesses of the hospital in the 
treatment of cancers (could recommendations be followed in the hospital: 
do they have the expertise inside the institution?) and ensures a better 
homogeneity in the practices. 
Once the (lack of) resources and weaknesses of the hospital are identified 
solutions could be explored, like developing collaboration with other 
reference centres or referring the patient, if the expertise is not present in 
the hospital. 
5.4.9 Videoconference 
As it was already mentioned several times, videoconference solves the 
problem of mobility between sites or between hospitals or for the GP. It 
allows to mobilize better expertise (for example in subspecialties or by 
consulting another MDT meeting), should reduce the shortage of 
participation of disciplines in penury (i.e. pathologists) and could favour the 
organization of more specific meetings.  
Nevertheless, to be efficient, videoconference needs good technology 
support (including for the GP) and therefore a good financial support. 
Results from the pilot project ‘Telemoc with GPs’ could be useful to pursue 
reflection on such implementation. 
Billing rules have to be reviewed if videoconference will be encouraged in 
order to increase attendance in MDT meeting. 
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6 WHAT IS THE CURRENT PERCEIVED 
ROLE OF GPS AT THE MDT MEETINGS? 
WHAT ARE THE GPS' EXPECTATIONS 
AND BARRIERS FOR THEIR 
ATTENDANCE AT THE MDT MEETINGS? 
6.1 Introduction 
Multidisciplinary team (MDT) meeting allow specialists from different 
disciplines to form the best possible team capable of achieving a shared 
goal of optimal care for a cancer patient. The purpose of the MDT meeting 
is to discuss the overall care of an individual within a planned meeting and 
to develop a strategic plan of diagnosis, treatment and follow-up. 
With a 5-year cancer prevalence in the Belgian population of 1.7% (Belgian 
Cancer Registry, 2014) and the average size of a GP’s practice population 
of 1 003 patients,73 a GP may face an actual average amount of 17 cancer 
patients undergoing actual treatment or needing close monitoring in his/her 
daily practice. 
At different moments of the disease trajectory, a MDT meeting is organized 
either at the hospital where the patient is treated, or at the hospital’s 
reference centre. The MDT meeting’s organizers can invite the GP, along 
with other medical specialists who can add value to the treatment discussion 
(e.g. an oncologist, radiotherapist, anatomo-pathologist, radiologist, 
surgeon, etc.). Numerous cases are often discussed within the same 
meeting. Participation requires physical attendance at the hospital, although 
videoconferencing also allows virtual GP attendance from within his/her own 
practice. 
The legal framework of MDT meetings (Royal Decree 21/03/2003 & 
18/08/2010) recognizes the importance of GP’s participation with other 
specific medical specialties, although his/her participation is not compulsory. 
Participation is rewarded by financial incentives. 
However, the participation of GPs in MDT meetings, according to the GP’s 
nomenclature code for participation at MDT meetings, is currently minimal 
(around 3% for breast cancer patients in 2010, see chapter 3). 
The legal framework of MDT meetings does not provide any task description 
for the GP during the MDT meeting or any stringent requirements for the 
MDT meeting’s organisation and coordination in hospitals. 
Along with the low attendance rate, the lack of legal task description may 
question the necessity of the GP’s presence and of his/her role during the 
MDT meeting. However, based on the general description of the MDT 
meeting’s content in the Royal Decree of August 2010, one could deduce 
parts of the role of a GP, as it is stated that psychological and social items 
have to be taken into account when discussing treatment plans. Variations 
in the GP’s attendance rate by hospital (see chapter 4) suggest that 
contextual factors are important. 
This research aims to answer 3 questions: 
1. What are the current experiences and the perceived roles of GPs 
towards the MDT meeting? 
2. What are the barriers perceived by GPs towards their participation to 
the MDT meeting? 
3. What are the preferences and expectations towards effective 
contribution during the MDT meeting? 
6.2 Methods 
To answer the research questions, a qualitative research methodology was 
chosen. Qualitative research aims to understand the lived experiences of 
people and can add meaning to numbers resulting from quantitative 
research. 
To elicit participants’ personal experiences and preferences, semi-
structured interviews are an appropriate method. Interviews may be 
preferred over focus group discussions when personal or sensitive issues 
are at stake. Exploring personal barriers may best be done by interviews. 
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6.2.1 Sample 
6.2.1.1 Criteria of inclusion 
Aiming to explore the GPs’ MDT meeting experiences, we selected GPs who 
had already participated in MDT meeting. Including GPs who had never 
participated in a MDT meeting might give additional information on barriers 
for attendance. However, they would not be able to respond to research 
question 1 and 2, therefore we chose only to include GPs with MDT meeting 
experience. A separate interview-study investigating the views of GPs 
without MDT meeting experience might complement this study. 
According to the philosophy of a qualitative approach, we built a sample with 
maximum diversity, not aiming at statistical representativeness of GPs. 
Diversity was based on: 
 Language: 
French- and Dutch-speaking: In order to achieve an equally 
compounded sample of interviewees, half of the GPs were recruited in 
the Dutch speaking part of Belgium and half in the French speaking part 
of Belgium. 
 Regions and density of hospitals organising MDT meetings: 
Based on the FPS webpage “Care institutions”/Hospitals,j 4 areas in 
different provinces in each part of the country were chosen according 
to: 
o High-density areas: Gent, Roeselare, Liège, Charleroi 
o Low-density areas: Lier, Tienen, Libramont, Chimay 
GPs in high-density areas may have experience in different hospitals 
and are therefore able to compare the different experience. GPs in low-
density areas only have experience in one hospital and may formulate 
their lived experience in a different way. 
 Age (no strict categorisation has been used but younger and older GPs 
are included), gender and practice organisation (solo/duo/group 
practice). GPs working in group practices may have different 
                                                     
j 
 http://health.belgium.be/eportal/Healthcare/Healthcarefacilities/#.U43RBW
e_nGg 
opportunities for MDT meeting participation and may also have different 
experiences in discussing shared patients than solo working GPs. 
6.2.1.2 Sampling procedure 
GP’s were recruited in the vicinity of hospitals offering an oncological care 
program. Within the eight areas selected, representatives of the local GP 
circles and of GLEM/LOKs (French/Dutch: Groupes Locaux d'Evaluation 
Médicale/Lokale kwaliteitskringen) were contacted by telephone, asked 
about their MDT meeting experience during the last 5 years and their 
willingness to be interviewed. Through these contacts, snowball sampling of 
other GPs was done. For each of the eight areas, 2 GPs were selected 
according to the inclusion criteria. 
Initially 16 interviews were planned but further sampling would have been 
organised when data saturation during analysis had not been reached. 
6.2.2 Ethical approval 
Ethical approval was obtained from the Comité d’Ethique Hospitalo-
Facultaire Universitaire of Liège and the central ethical committee of the 
University Hospital Ghent (No. B670201421076). 
6.2.3 Data collection tool 
The basis for the interview guide was delivered by the KCE in French, 
translated into Dutch and adapted by the subcontracting research teams 
(UGent and ULg) after discussion. 
The main themes comprise: GPs’ experience with MDT meetings; their 
perceived role towards the MDT meeting; and their perceived barriers and 
facilitators to participating. Each research team performed a pilot test of the 
interview guide in their native language by interviewing one participant. After 
this, the interview guide was adapted and finalised for use. 
The interview guide is presented in appendix E. 
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6.2.4 Data collection process 
The interviews were conducted at the interviewee’s location of choice (in all 
cases this was the GP’s practice). Informed consent was obtained before 
starting the interview. All interviews were audio-recorded and transcribed 
verbatim. 
6.2.5 Analysis 
Analysis was done using Nvivo 10 software. A first thematic scheme was 
built based on the interview guide and the discussion of the first interviews’ 
analysis by both research teams. Subsequently every interview was coded 
by two researchers independently and discussed two by two (within the 
same research team). Refining of the code book was done during further 
analysis and regular discussions between both research teams. To cross-
check the coding results Skype discussions were held between researchers 
of both research teams. Additionally, the main findings and results were 
discussed during meetings between both research teams. 
6.3 Findings 
6.3.1 Sample description 
Sixteen GPs were interviewed, of whom 6 are female. The mean age is 
48.75 years (range 29–67 years old). 5 GPs are working solo and 4 as a 
duo. The remaining 7 GPs work in group practices; 3 of them work in a 
mono-disciplinary and 4 in a multi-disciplinary practice. Three of these multi-
disciplinary group practices have a capitated payment system. 
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Table 26 – Participants of the interview study 
Participant Language M/F Age Practice  Payment model: 
Capitation/Fee-for-
service (FFS) 
N hospitals where GP 
participated in MDT 
meeting 
GP 1 Dutch  F 55 Group – mono disciplinary FFS 3 
GP 2 Dutch M 42 Group – multi-disciplinary FFS 3 
GP 3 Dutch F 29 Duo FFS 3 
GP 4 Dutch M 38 Solo FFS 4 
GP 5 Dutch F 61 Duo FFS 1 
GP 6 Dutch  M 58 Solo FFS 1 
GP 7 Dutch M 63 Solo FFS 1 
GP 8  Dutch M 47 Group – mono disciplinary FFS 1 
GP 9 French  F 56 Duo FFS 4 
GP 10 French F 38 Solo FFS 1 
GP 11 French M 37 Group – multi-disciplinary Capitation 2 
GP 12 French M 39 Solo FFS 3 
GP 13 French M 67 Group – multi-disciplinary Capitation 2 
GP 14 French F 48 Duo FFS 1 
GP 15 French M 62 Group – mono disciplinary FFS 3 
GP 16 French M 40 Group – multi-disciplinary Capitation 4 
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6.3.2 Results 
6.3.2.1 How do the GPs perceive their role in the MDT meeting? 
The GPs have 3 perspectives when talking about their role: 
 GP’s own view on his/her tasks; 
 GP’s perception of patients’ expectations towards him/her; 
 GP’s perception of specialists’ expectations. 
In general, the GP’s perception of others’ expectations of him/her serve to 
build his/her own task and role description. As such, the results will be 
presented from the GP’s standpoint towards his/her role in the MDT 
meeting. Where his/her perceived expectations from others differ from 
his/her personal view, these will be highlighted. 
GPs in our study have a clear opinion about their role in the MDT meeting, 
based upon their position and role in health care in general. However, 
performing according to this opinion is dependent on multiple factors which 
will be described as barriers and facilitators. 
GPs have a unique position in healthcare  
Patients and GPs share a history of longitudinal care resulting in a repertoire 
of knowledge managed by the GP. This repertoire contains medical facts 
(e.g. previous diseases, medication regimens), social facts (e.g. a family’s 
cohesion, the home care situation), as well as personal facts (e.g. a patient’s 
way of coping with misfortune, a patient’s wishes and values towards life). 
‘Donc il peut y avoir des éléments nouveaux entretemps qui peuvent 
intervenir, et là je me rends compte dans les réunions pluridisciplinaires, 
ils n’ont pas toujours toutes ces informations-là que nous on a en 
longitudinal puisqu’on voit les gens depuis longtemps, et puis il y a aussi 
notre connaissance des éléments non médicaux qui peuvent parfois 
être intéressants.’ 
(GP 15: M, 62y) 
As a result, GPs declare to be the caregiver par excellence because of their 
access to this kind of relevant information which may have an impact on 
treatment option choice. 
‘Ah mais je trouve ça important parce qu’il y a des éléments qu’ils ne 
connaissent pas, parce que, quand on doit adhérer à un traitement 
aussi lourd que des rayons ou une opération qui peut être délabrante, 
je crois que, vraiment bien connaître son patient et le suivre depuis 
longtemps, c’est quelque chose qui peut vous faire sentir si le patient 
va adhérer ou pas.’  
(GP 14: F 48y) 
Most of the information uniquely known by the GP concerns non-medical 
information such as: specific demands; attitudes towards futile medical care; 
specific home care conditions; presence of informal caregivers; financial 
aspects; and family and patient concerns. These are aspects which may 
alter the decision process during the MDT meeting. 
‘(…) surtout si c’est un traitement qui va être lourd pour quelqu’un dont 
l’état et/ou l’âge peuvent causer problème, donc pour voir aussi quelle 
est un peu l’attente de la personne par rapport à ça, et ce que nous on 
en connaît, voir s’il y a d’autres indications, d’autres éléments que nous 
on ne connaît pas, et alors quand même les éléments non médicaux 
c’est quand même pas si rare que ça, ou les conditions de vie. Bon y a 
des personnes pour lesquelles il vaut mieux les garder à l’hôpital pour 
certains types de soins ou de traitements parce qu’à la maison ça n’est 
pas gérable, ou si c’est pour les ramener à la maison et ils n’ont pas 
des conditions de vie, il y a pas moyen de mettre un lit convenable ou…’  
(GP 15: M, 62y) 
The way GPs take all the available (medical and non-medical) information 
into account during a patient’s assessment is a feature of holistic care. 
According to our study participants, this attitude towards holistic care is 
characteristic of GPs. Therefore their presence during the MDT meeting is 
desirable. 
The patient’s and family’s personal preferences are often implicitly deduced 
from the shared history by the GP if there is no official declaration or written 
statement from the patient. 
‘de context, de sociale context, de familiale context, de individuele 
context van de patiënt, de levensgeschiedenis dat ge meegemaakt hebt 
met die patiënt. Ook hoe de thuisomgeving is, heeft die veel 
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mantelzorg, heeft hij niet veel mantelzorg? Heeft hij veel familie, heeft 
hij niet veel familie? De context van de familie – want dat is vaak ook 
een belangrijk punt. Soms wil de familie dat er niets meer gedaan wordt 
wat de patiënt wil of omgekeerd . allee. Er is zo een hele boel zaken die 
ge niet direct op papier hebt maar die gij wel kent door de geschiedenis 
van de patiënt te kennen en de omgeving van de patiënt te kennen.’ 
(GP 6: M, 58y) 
Consequently, GPs describe themselves as representatives, spokesmen, 
confidants or defenders of the patient. 
‘dat betekent voor mij een moment waarop dat ik de specialisten kan 
zien die een patiënt een kort of lange tijd zien gaan opvolgen en waar 
ik vind dat ik op dat moment als huisarts misschien ook de stem van de 
patiënt kan vertegenwoordigen, in zaken van: ik wil wel of niet een 
bepaald beleid mee volgen, ik wil niet of wel chemo ondergaan, mijn 
houding, ik heb een euthanasieverklaring vroeger al, gelieve daar 
rekening mee te houden. Ik vind dat dat het moment is waarop dat je 
als huisarts een inbreng kunt hebben.’ 
(GP 1: F, 55y) 
‘Alors c’est peut-être pas très objectif, ni très scientifique, mais je pense 
le contact privilégié que le patient nous donne. Donc, certains sont fort 
dépendants et ont vraiment besoin que vous les portiez jusqu’au bout 
et d’autres vraiment ne vous donnent pas ce rôle d’acteur.’ 
(GP 10: F, 38y) 
During the curative phase of a cancer patient’s disease, however, some 
patients may have more frequent contact with the specialist than with the 
GP. Consequently, specialists often have abundant actual and up-to-date 
information on the patient’s clinical situation as well as on the patient’s view 
towards the disease and its treatment. Specialists therefore can have a 
broader view of the patient’s situation than just the specific focus of their 
specialty. Nevertheless, this will never match the GP’s holistic view resulting 
from a longstanding relationship with the patient. 
‘ja, vertegenwoordiging van de patiënt en zijn omgeving, omdat ge als 
huisarts toch wel dichter bij de thuissituatie staat. Omdat ge ze meestal 
toch goed kent, maar in mijn geval is dat ook maar beperkt he. Mijn 
collega kent ze dikwijls al van bij de geboorte, dat is nog anders dan 
van mij he? Maar ja, zo een beetje de thuissituatie, naar haalbaarheid 
thuis, wat willen ze, wat willen ze niet? De spreekbuis zijn van de 
patiënt. 
I: de spreekbuis zijn van de patiënt. 
L:   de specialisten, en zeker na verloop van tijd ook heel goed contact 
he met de patiënt. Maar er is toch wel een verschil als ge de thuissituatie 
kent gewoon bij iemand ne keer in de living gaan zitten en ne keer 
kijken: er is al een heel ander beeld dan dat hij voor u zit op consultatie.’ 
(GP 3: F, 29y) 
Something that is distinctive for the intense personal relationship between 
the GP and the patient is the fact that, according to our study participants, 
the patient considers the GP’s participation in the MDT meeting as a 
reassurance of good care (and sometimes makes an explicit demand to 
participate towards the GP). This results in a sense of moral responsibility 
for the GP to participate. 
‘Het euhm, ja, patiënten hebben ook wel graag, (lacht), da ge daar zijt. 
Als ze weten da ge daar geweest zijt, dat geeft hen, ja, “mijne huisdokter 
was daar ook”, eh, eh, als ge kunt zeggen we hebben met z’n allen 
samen gezeten en we hebben het besproken, en, dat is iets dat wel 
euh, denk ik dat patiënten graag hebben. Geeft vertrouwen.’  
(GP 8: M, 47y) 
To guarantee continuity of care, which is a main task for GPs, GPs need 
detailed and timely information (which is not the case when GPs wait for the 
written MDT meeting report) to ensure the adequate and comprehensive 
organisation of care at home: technical aspects about treatments (e.g. 
stoma care, perfusion); practical aspects to respond to patient disabilities 
(e.g. home care nurses, administrative aspects concerning palliative care); 
and finally some treatment side effects which can be prevented, recognised, 
and better managed if known beforehand. The written MDT meeting report 
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does not provide the detailed and timely information required to organise 
good care, and therefore GPs are urged to attend the MDT meeting. 
‘Moi je suis là pour m’informer de l’ordre des choses et des délais et 
voir quelles sont les infos que je peux donner au patient pour le soutenir, 
pour assurer sa prise en charge entre le domicile et l’hôpital et puis 
après l’hôpital le retour à la maison. Dans quel état va-t-il rentrer, aura-
t-il besoin de soins ? Kinés, infirmiers, psychologue, assistant social, 
des repas ou pas ? Donc voilà.’ 
(GP 11: M, 37y) 
‘‘k Ben beter geïnformeerd. Alhoewel dat wij, ge kunt natuurlijk uzelf 
informeren. Ge krijgt dan wel nen brief maar ge krijgt ook natuurlijk de 
radiologies van het ziekenhuis waar da ge dan ook al wel is ziet, en zo, 
maar toch wel euh ja, dat vind ik wel, da ge daar toch wel wat meer. Ge 
volgt uw patiënt beter op |- Ja <I> -| en ge kunt euh, ja, in de opvolging 
achteraf ook beter, volgen, als ge daar bij participeert, ja. Naar, vooral 
naar het praktische toe. Naar diagnose, planning, euh ja, dat vind ik 
wel.’ 
(GP 7: M, 63y) 
 
Influencing factors for the GPs’ roles and unique position in the MDT 
meeting process 
The GPs’ tasks and roles in the MDT meeting process are not predefined – 
rather they are variable and changing, depending on many different 
influencing factors. 
The complexity of the patient’s case 
GPs mention a varying personal need to participate in the MDT meeting 
according to the complexity of the patient’s case. 
Complex medical situations (e.g. multi-morbidity and extensive medical 
history, but also the complexity of the current disease status, treatment 
failure or deteriorating functional status) and complex home care situations 
(e.g. absence of family support, problematic financial status) prompt the GP 
to attend the MDT meeting and to participate in the deliberation process. 
The main reason for this effect is the direct and practical impact of the MDT 
meeting conclusions on the GP’s work and practice, such as preparing the 
organisation of home care for the patient (in the case of home care 
complexity) or acquiring new medical knowledge (in the case of medical 
complexity). 
‘Ik ga mij bv wel voor een MOC verplaatsen als ik ja, weet van: het is 
een complex probleem he. Een jonge vrouw met een borstkanker die 
kinderen heeft die weet ik veel wat, waarvan ik verwacht: er gaat hier, 
er gaan een hoop zaken op ons afkomen waarmee het belangrijk is dat 
de communicatie met de specialist goed afgelijnd is. Ja, dan doet ge 
dan wat extra moeite voor.’   
(GP 2: M, 42y) 
‘Alors là vous, … peut-être égoïstement, j’estime qu’il n y a pas de 
points d’interrogations, pas de zones d’ombres, qu’il n’a pas réellement 
besoin que j’intervienne, je n’y vais pas parce que je pense qu’il n’y a 
pas d’éléments à apporter. Et pour être juste un acteur présent 
physiquement mais n’apporter aucune information, ben, je ne vois pas 
la nécessité. Je ne vois pas la nécessité de ma présence. Voilà’  
(GP 10: F, 38y) 
The added value of discussion and reaching consensus during the MDT 
meeting compared with the one-way communication of referral letters 
equally promotes GPs’ participation. 
‘En dan zeggen: kijk, voilà dat zijn de resultaten van de anapat. Dat is 
die soort kanker. Voor die soort kankers zijn dat de mogelijke 
behandelingen. En dan zei die bv: het is voor een oude dame zoals 
jullie zien, goed in de 80 maar zeer kranig. Die willen we nog een kans 
geven. We zullen nog gaan voor de maximale behandeling. Zijn jullie 
daarmee akkoord? Ik was daarmee akkoord, ik had het ook met de 
familie besproken op voorhand die er geweest waren. Ik zeg: ja, oke, 
iedereen staat op dezelfde lijn, dus we gaan ervoor gaan. En dan is 
inderdaad die behandeling gestart, relatief snel. Dat is ook het voordeel, 
iedereen is daar op dat moment. De radiotherapeut kan zeggen: oke, ik 
zal de patiënt oppikken, ik zal de patiënt opbellen, ik ga zeggen 
wanneer dat gaat gebeuren. Die zegt dat dan aan mij wanneer dat gaat 
gebeuren. Ik kan dan met de familie communiceren. Ziet ge, dat gaat 
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allemaal op 10 minuten hebt ge al uw afspraken bijna gemaakt, dat is 
formidabel he. Anders duurt dat dagen, soms weken.’ 
(GP 6: M, 58y) 
‘On n’est plus dans l’aspect purement thérapeutique pur et dur, la 
chimio et tous ces trucs-là, on essaie vraiment d’englober des 
notions…on a aussi un cancer chez une personne, et comment est 
cette personne, notamment vu son âge, est-ce que c’est raisonnable de 
se lancer dans telle et telle chose. C’est des choses qui sont de plus en 
plus prises en compte.’ 
(GP 15: M, 62y) 
Other patient-related variables may determine the relevance of the GP’s 
input during the MDT meeting, but they do not alter the GP’s readiness to 
participate. 
Considering the diagnosis (cancer type), no distinction was made as to the 
GP’s interest in participating in the MDT meeting. 
 ‘ik ga er altijd naartoe. Zowiezo. 
I: als ge uitgenodigd wordt? 
L: ahjaja, als er een MOC. Ook al is het zo gemakkelijker, ge weet dat 
niet uiteindelijk he. Misschien zijn er problemen die zij zien dat gij niet 
ziet. Dat ge zegt: oh, daar had ik misschien niet aan gedacht. Maar nee, 
alle typen. Ik zeg niet direct voor één type zou ik niet gaan. Ik zou niet 
weten waarom ik niet zou gaan. Ik ga het zo zeggen.’  
(GP 6: M, 58y) 
Interaction with other MDT meeting participants 
The interaction with other MDT meeting participants during the meeting 
influences the GP’s perception of his/her tasks and role and thereby 
modifies his/her readiness and conviction to participate in the future. 
This interaction influences the quality of the interpersonal and 
interprofessional relationships. 
‘Mais donc là, effectivement, il y a eu une impression de collaboration, 
et d’ailleurs ça m’a marqué parce que j’ai ouvert le courrier ce matin, 
concernant cette dame-là qui malheureusement est décédée, et le 
spécialiste dans son rapport dit : « le médecin traitant est passé, ça a 
été discuté avec lui et autres », même dans le courrier transparait cette 
interaction qu’il y a eu avec moi. Je me dis qu’effectivement ça a dû les 
marquer.’  
(GP 16: M, 40y) 
Participating GPs feel welcomed at the MDT meeting by the other team 
members. Most of the time, they experience their participation being 
appreciated and their contribution being respected. The reciprocal 
interprofessional appreciation (GPs equally value the contribution of the 
specialists) creates a feeling of being part of a team. The sense of being part 
of a team facilitates an active involvement from the GP during the MDT 
meeting. If specialists take no account of their contribution during the 
decision process, however, GPs will feel disrespected. If GPs feel valued by 
the specialists for bringing in their expertise, it will improve their involvement. 
Nevertheless, there is a range of GPs: some don’t feel inhibited to contribute 
while others do not feel at ease during the MDT meeting and would rather 
prefer contact by telephone. 
‘Je hebt het gevoel dat er in de perifere ziekenhuizen dat je daar meer 
een deel van dat team zijt. Dat motiveert u om te gaan, het is een 
vicieuze cirkel. Daardoor kennen ze u ook beter, daardoor, terwijl in een 
groot Universitair Ziekenhuis geraakt ge daar niet voorbij voor bij die 
drempel. 
I: als ge zegt: ik heb meer het gevoel van een deel van een team te zijn, 
op welke manier is dat dan? 
B: ho, dat is op communicatievlak he. Daar wordt er gewoon allee , een 
deel van de informatie op huisarts niveau doorgespeeld naar ons en 
wordt daar ook een soort taakverdeling in toegewezen van ja, wie gaat 
welk stuk van de verzorging doen? Of van, terwijl in die grote centra, 
men organiseert daar alles. In feite, een oncologische patiënt die naar 
een Universitair centrum gaat, die heeft geen huisarts nodig he.’ 
(GP 2: M, 42y) 
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Considering interpersonal contacts, GPs from our study emphasise the 
importance of good relationships with their colleagues and stated that 
meeting specialists facilitates future contact (direct contact, or by phone or 
mail). Personally knowing your interlocutor helps to overcome some 
difficulties (e.g. traditional interprofessional hierarchy) between GPs and 
specialists that could otherwise impair the working relationships. 
‘De se sentir impliqué dans une équipe, de faire connaissance avec des 
spécialistes dont on ne voit jamais que la signature, oui c’est important. 
Et pour autant que la communication se passe bien, de pouvoir plus 
facilement après demander un complément par téléphone, ou… C’est 
important que le spécialiste me connaisse et que moi je connaisse le 
spécialiste.’ 
(GP 13: M, 67y) 
Task agreements between the GP and the medical specialists 
The agreements on sharing tasks, made during the MDT meeting, influence 
the uptake of the GP’s role. 
As described, GPs’ view of their role in the MDT meeting is largely based 
upon their specific relationship with the patient, their holistic view towards 
patient care and their perceived responsibility towards continuity of care. 
The opportunity and affordance to play this role, however, depend on task 
agreements between the GP and the medical specialists during the MDT 
meeting process. These agreements are not uniform, stable or ‘contractual’ 
agreements but are to be negotiated for every situation and for every patient 
individually. These negotiations depend on the concrete working procedures 
of the MDT meeting and lead to agreements on communicating decisions to 
the patient: 
 The concrete working procedures of the MDT meeting 
The concrete working procedures during the MDT meeting account for the 
level of involvement afforded to the GP. In general, the patient’s case is 
presented by the main specialist in charge of the patient. Thereafter, other 
disciplines, including the GP, bring in additional information and finally there 
is a discussion to deliberate treatment plans. Depending on the MDT 
meeting coordination, the level of GP involvement varies between GPs who 
simply receive the right to speak, through GPs who are asked specific 
questions, to GPs who play a full part in the discussion. 
‘Het is de behandelende specialist die overloopt wat het laatste verslag 
is. De beeldvorming wordt daar bij gehaald. Dan wordt de mening 
gevraagd van de andere collega’s die er zijn, de oncoloog, de 
radiotherapeut. Dat hangt ervan af. Maar het is altijd de eerste 
behandelende specialist die aan de hand van beeldvorming de casus 
een beetje schetst voor iedereen eigenlijk.’ 
(GP 3: F, 29y) 
‘Ils ne posent pas de questions. Ils me donnent la parole. Voilà. Est-ce 
que tu as quelque chose à apporter au dossier dont tu es au courant ? 
Tu vois comment ça va se passer ? Est-ce que tu veux intervenir ? Est-
ce que tu as quelque chose à exposer ? Et puis ben du coup, comme 
ils voient que je suis là, ben oui j’ai quelque chose à apporter. Ben oui, 
je leur ai mentionné tel ou tel problème.’  
(GP 10: F, 38y) 
On the one hand, GPs in our study mention that they have enough 
opportunities during the meeting to bring their input into the discussion. 
‘Ik heb het gevoel dat ze met u echt wel rekening houden maar dan 
moet je er zelf ook wel moeite voor doen. Ge moet er ten eerste 
aanwezig zijn en ge moet ook zorgen dat ge een beetje dossierkennis 
hebt over de patiënt waarover het gaat en dat je op sommige vlakken 
waar ik vind dat ze in het ziekenhuis niet altijd veel rekening mee 
houden, dat wij die ook moeten aankaarten. Maar ge moet dat natuurlijk 
ook wel doen.’ 
(GP 2: M, 42y) 
On the other hand, it has been stated that MDT meetings are rather speedy 
meetings and that there is ‘no time to waste’. Therefore it can be helpful for 
the GP to prepare his input and personal views in advance. 
‘Le précédent, ça, ça avait été un petit peu moins, je vais dire, un petit 
peu moins collaboratif, mais justement parce que je pense que cette 
réunion était un peu moins structurée. Car un des spécialistes qui était 
impliqué était vraiment très pressé, il est passé, il a dit ce qu’il avait dire, 
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ce qui fait que, bon. Ça n’a pas été inutile je pense, mais là je me suis 
senti un peu moins impliqué.’  
(GP 16: M, 40) 
The GP’s input is especially important during the later disease stages when 
a palliative care approach becomes a probability. In early stages of a 
disease, where deliberation and discussion is mostly about treatment 
schemes, GPs feel less competent to play a significant role. 
‘ja, als het om louter hun vakdomein is de beslissingen, daar kom ik niet 
veel in tussen, |- uhu <I> -| dan laat ik ze doen, ik bedoel en dat is ook 
zo, dat is ook zo zoals zij dat willen. Maar als dat bij voorbeeld, en dat 
is dan als het oudere patiënten zijn, ik bedoel maar die 85 zijn, die al 
hartfalen hebben, die al dit hebben en waar men nog iets bij ontdekt, 
zoals mijn tweede patiënte, die is 85 die man, die heeft al een keer 
lymfeklierkanker gehad, die (…) kanker met uitzaaiingen, de familie 
heeft zelf beslist, ook met de de de de kinderen en de vrouw, mevrouw 
was hier van de morgen, van pf we doen daar nu echt niks niet meer 
aan, we gaan het echt niet meer doen, dat heeft geen enkele zin om |- 
uhu <I> -| dat nog te gaan doen. Ja dat is dus de vertolking die ik doe, 
daarnaartoe ja. en dan zeggen zij ook: okee goed. En dan luisteren ze 
toch. Dan zeggen ze niet: we zouden toch nog wat dat of dat |- ja <I> -
| allez, dan ben je toch wel de belangrijke speler’ 
(GP 5: F, 61y) 
 Agreements on communicating MDT meeting decisions to the patient.  
A major self-perceived responsibility for the GP is to guarantee the continuity 
of care for the patient. To that extent, they consider the communication of 
the MDT meeting decisions an important responsibility. 
‘voor mij is dat een belangrijk luik van de MOC. Ik denk dat dat 
essentieel is in de MOC, dat wij als huisarts bewaken van: wat wordt er 
gecommuniceerd, aan wie wordt gecommuniceerd, en door wie gaat 
dat gecommuniceerd worden?’  
(GP 2: M, 42y) 
Participants from our study mention different reasons for taking up the role 
of communicator after the MDT meeting: providing answers to patient’s and 
his/her family’s questions by bringing back previously unknown information; 
enhancing treatment adherence by explaining and advocating the chosen 
treatment options; ensuring patient’s understanding of his/her disease and 
treatment by providing explanations in line with the level of the patient’s 
health literacy. This conversation is to be seen in continuity with previous 
conversations with the patient before the MDT meeting. 
‘D’abord un relais de l’information et donc un soutien par rapport aux 
décisions qu’ils vont prendre et donc une meilleure compréhension de 
la part du patient et donc une meilleure adhésion à son traitement. C’est 
comme cela que je le vois ; être vraiment le relais pour une meilleur 
compliance.’ 
(GP 9: F, 56y) 
‘Voilà, du moment que quelqu’un est porteur de la nouvelle et de la 
proposition thérapeutique, que ce soit le spécialiste ou le généraliste, 
je pense que vraiment c’est important qu’on puisse éventuellement le 
gérer mais ce n’est pas indispensable. Par contre, je pense que, par 
moment, c’est important que ce soit nous qui le fassions. Je trouve que 
c’est important, par exemple, pour des personnes plus âgées, ou pour 
des personnes plus psychologiquement fragiles, qu’on arrive chez eux, 
sans téléphone, sans être dérangé, on met son GSM en silencieux. 
Parfois les enfants sont là. On explique, c’est parfois plus facile. Donc 
qu’on ait ce choix éventuel qu’on puisse le faire nous-même mais il y a 
des gens qui sont à l’aise et il y a des gens qui sont pas à l’aise avec 
ça, hein. Oui, je pense que c’est bien !’ 
(GP 14: F, 48y) 
It is usually agreed upon during the MDT meeting who will take responsibility 
for discussing the decisions with the patient. According to participants of this 
study, coordinating the caregivers, which results in consistency of care, is 
an important aspect of the MDT meeting and enhances patient’s confidence 
in the professional team. 
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‘ik denk dat het belangrijkste is de samenwerking van de specialisten 
en specialismen die er bij betrokken zijn, dat de patiënt voelt dat er een 
eensgezindheid is tussen iedereen. Dat niet iemand zegt ik wil dat en 
de andere niet. Er wordt aan hetzelfde zeel getrokken. En ik denk op 
lange termijn dat dat voor veel patiënten hoe moet ik zeggen? 
Gemoedsrust geeft.’  
(GP 6: M, 58y) 
Agreements on communicating the decisions to the patient are sometimes 
depending on the patient’s whereabouts (e.g. when the patient is 
hospitalized, mostly the medical specialist will make a visit to communicate 
the treatment decisions). 
6.3.2.2 What are the GPs’ current experiences (barriers and 
facilitators) with the MDT meetings? 
Participants mention practical and interpersonal themes influencing the way 
they play their role in the MDT meeting. These themes contain barriers as 
well as facilitators: some influence the GPs’ preparedness to attend the MDT 
meeting, while others mainly influence the GPs’ role during the MDT 
meeting. 
1 – Practical factors influencing participation of GPs in MDT meetings 
Time aspects: 
 The timing of the MDT meeting during the day: GPs in our study find 
it difficult when they have to leave practice during consultation time to 
attend the MDT meeting. Having many patients waiting while they are 
caring for one patient by attending the MDT meeting is not always an 
easy decision as it may endanger the continuity of care for other 
patients. The prioritisation between different patients and their needs is 
not always easy to decide upon. 
‘À part les problèmes organisationnels, d’autres réunions, des patients 
à voir, parce que oui, il faut quand même voir les patients, c’est la base 
du boulot. Des visites. Ça c’est ce qui me freinerait dans le fait d’aller à 
une COM. Mais sinon dès que j’ai la possibilité…’ 
(GP 11 : M, 37y) 
For most GPs, noon seems to be the best time (no interference with 
daily practice schedules), especially when a small lunch (e.g. 
sandwiches) is provided so there is no loss of lunchtime. 
 The timing of the invitation: When GPs are informed at too short 
notice, it is difficult to organise their practice to participate (especially 
for single-handed practices). Group practices find it easier to arrange 
the practice and to have someone available to attend the MDT meeting. 
‘Moi je pense vraiment que c’est une question horaire. Je pense que si 
je participe plus que certains de mes confrères, c’est parce que j’ai la 
chance de travailler ici avec des copains, que je peux dire « demain, 
entre 10 et 11 je serai absent parce que je vais là-bas », et je peux 
parfaitement comprendre qu’un confrère qui est plus débordé que moi 
se dise que c’est quelque chose de moins prioritaire que d’aller voir 
certains patients. Je peux le comprendre et en même temps je pense 
que la participation à certaines COM est vraisemblablement aussi 
importante que…mais bon, voilà, ça c’est le contexte de travail, 
d’organisation de travail de la médecine générale.’  
(GP 16: M, 40) 
Both telephone and email notifications are acceptable (though not everyone 
checks his/her email constantly), provided they are delivered in a timely 
manner. 
‘En in het UZ loopt dat hopeloos fout, dat is afschuwelijk. Elke MOC, 
elke groep heeft daar een ander tijdstip, een andere MOC, een andere 
locatie. We worden verwittigd per mail de dag zelf. Nu, de post wordt 
hier binnen gehaald ’s morgens door het secretariaat om 8 uur, maar ik 
kijk niet om 9 uur al naar mijn post om te zien dat ik om 11 u 30 of om 
12 uur in het UZ moet zijn. Ik bedoel: ik denk dat ze in het UZ ook niet 
het belang inschatten dat je als huisarts hecht aan een MOC.’ 
(GP 1: F, 55y) 
GPs are sometimes simply not invited at the MDT meetings.  
‘En ik weet dat uit ons bestuur. Iemand die veel contact heeft met het 
ziekenhuis X, de MOC wordt daar voor zover ik weet tot nu toe de 
huisarts zelfs niet uitgenodigd. Dus die MOC werkt daar niet, allee, 
werkt daar niet zoals het zou moeten werken. De huisarts is daar, allee, 
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ik vind principieel eigenlijk allee, moét de huisarts uitgenodigd worden. 
Dat hij komt of niet, dat is een andere zaak. Maar die moét uitgenodigd 
worden. Als zijn patiënt besproken, ik kan mij niet voorstellen dat die 
niet uitgenodigd wordt, ik vind dat een aberratie. Maar ik weet dat dat 
dus niet goed gebeurt. De reden waarom dat weet ik ook niet. … En dat 
vind ik erg. ... Ik weet ook van collega’s dat die niet worden uitgenodigd.’ 
(GP 6: M, 58y) 
 The time management during the MDT meeting: GPs appreciate 
very much that the MDT meeting starts at the scheduled time and that 
discussions are efficient so that they mostly do not lose more than 15 
minutes per patient. They also much appreciate the flexible MDT 
meeting agenda, as a GP’s patient is discussed directly upon the GP’s 
arrival. As the ‘first come, first serve’ principle is used, some GPs try to 
arrive early. 
 ‘Het grote voordeel is ook, ze zijn daar heel correct in. Ge gaat daar 
naartoe, ze bespreken de patiënt verder dat ze bezig zijn en dan is het 
direct aan u. Ge zit daar max een kwartier, 20 minuten dat ge daar 
aanwezig zijt tijdens dewelke uw patiënt wordt besproken. Dan moogt 
ge weggaan, dan doen ze de andere he.’ 
(GP 6: M, 58y) 
‘Et bien chaque fois on a commencé par mon cas où ils ont terminé le 
cas en cours et ils ont fait en sorte que l’on parle de mon patient tout de 
suite après et …donc cela m’a pris un quart d’heure, un quart d’heure 
déplacement non compris…’ 
(GP 9: F, 56y) 
 
The geographic proximity of the hospital:  
Distance seems mostly to play a role because of the time spent travelling. 
When a hospital is too far away, MDT meetings are skipped and replaced 
by telephone calls. Distance as a single factor, however, may not be decisive 
as GPs do travel far e.g. to visit a patient in a palliative care unit. So the MDT 
meeting (‘just a 10-minute meeting’) might not be considered worthwhile 
travelling far for, especially since there are alternatives for information 
exchange (e.g. a telephone call). 
‘Nee, nee, ik ga nooit euh, ik ben nog nooit in een MOC in een ander 
ziekenhuis geweest. Nee. 
I: Omwille van, de de duur van de afstand?  
J: Ja. Ja. Niet om gebrek aan interesse euh, maar natuurlijk in Lier het 
gelijkvloers ge gaat daar binnen, euh, ‘k ga daar tegen acht uur naar 
toe, kwart na acht, twintig na acht zijt ge daar buiten. Ge kunt nog iets 
anders plannen, een huisbezoek. Ik ga niet euh naar Augustinus rijden 
op een morgen om acht uur, in de file, allez ik geraak daar niet eh. Nee, 
nee. Dat doe ik niet. Het ligt me… ‘k zal dan wel al es bellen en, ‘k hou 
mij wel op de hoogte van de patiënt zijn toestand en zo. Of, dat wel. 
Maar MOC nooit. Nee.’ 
(GP 7: M, 63y) 
‘Ik euh, ik ga alleen naar het ziekenhuis in Lier. Ik word al es ne keer 
gevraagd, ook soms in Duffel, of zelfs ne keer in Antwerpen, omdat ik 
nog ook wel patiënten heb in Vincentius Augustinus ziekenhuis. Heb ik 
af en toe patiënten, ga ik nooit. Ik euh, die inspanning, allez ja, kan ik 
nie, nie opbrengen. Als het echt patiënten zijn, die zo echt preterminaal 
zijn in een ziekenhuis in Antwerpen, probeer ik er ook wel op bezoek te 
gaan. Zelfs es in Leuven, ja ik, mensen waarmee ik echt een goede 
band heb opgebouwd en die zijn ge moet dan naar Leuven, of naar 
Antwerpen, en sterven daar, of probeer ik daar toch ook op bezoek te 
gaan. Vraagt wel wat inspanning, maar het loont. Veel.. Allez loont ook 
voor mezelf. Ik vind dat een deel van mijn werk.’ 
(GP 7: M, 63y) 
GPs’ more frequent attendance at MDT meetings in nearby hospitals may 
be explained by another argument, namely interpersonal relationships. 
Medical specialists and GPs know each other better when the hospital is 
nearby. A good interpersonal relationship enhances GPs readiness to attend 
the MDT meeting and vice versa, attending the MDT meeting and meeting 
each other in real life strengthens the relationship. 
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‘Comme vous l’avez compris ici sur Chimay, c’est quand même 
particulier. Il y a une proximité qui est quand même appréciable. Et à 
mon avis, voilà, qui ne doit pas se rencontrer partout. Voilà, des patients 
qui sont pris en charge sur des gros centres hospitaliers où je n’ai pas 
vraiment de contact, où je ne connais pas vraiment les médecins, je 
pense que l’accès est plus difficile. Voilà, parce qu’on ne sait pas où. 
C’est difficile de savoir comment, qui sont ces personnes ? Alors je 
pense que moi, je n’y vais pas spontanément dans ce genre d’endroits. 
Parce que, voilà, il y a aussi les kilomètres qui sont présents.’ 
(GP 10: F, 38y) 
‘La proximité, oui. Et alors voilà, vous avez des centres hospitaliers 
extrêmement spécialisé dans les pathologies, vous avez, je pense à 
une patiente qui s’est fait soigner à Bordet. Ca a été très compliqué 
pour moi, pour le suivi. Je n’ai pas eu accès. Fin, finalement j’ai quand 
même pris mon téléphone. C’était des médecins que je ne connaissais 
pas. Je ne pouvais pas me rendre évidemment sur place, pour ces 
COMs. Donc, on a discuté par téléphone. Voilà, je crois quand même 
que les centres hospitaliers spécialisés offrent beaucoup d’avantages 
thérapeutiques pour le patient, c’est évident. On est clairement sur une 
information qui est au top. On sait. Mais voilà, je trouve que les hôpitaux 
de proximité offrent un autre avantage, c’est les délais de réaction qui 
sont franchement…’ 
(GP 10: F, 38y) 
The remuneration for MDT meeting attendance: 
The remuneration is only mentioned by the interviewees after explicit 
questions on it. Participating GPs state that it’s normal to be paid as they 
make an effort, but on the other hand, MDT meeting participation is 
considered part of their job and a service to the patient so the remuneration 
is no priority and surely no barrier. 
‘Euh, ‘k vind, allez, ‘k vind dat wel correct dat je toch, als je moeite doet, 
dat je toch voor iets beloond wordt. ‘k Ga niet zeggen dat dat mijn 
primaire drijfveer is om het te doen, dat ook niet maar ‘k vind het niet 
slecht dat je er toch iets voor krijgt. ‘k Vind toch, allez ja als gij de moeite 
doet voor iets te doen voor uw patiënt, dat je daar toch mag voor 
beloond worden natuurlijk ja, als dat uw enige drijfveer is, dan is dat ook 
wel erg, maar ’t is aangenaam bijgekomen dat je geapprecieerd wordt 
daarvoor beetje.’  
(GP 4: M, 38y) 
‘(la rémunération) c’est un élément important ? Ho, non, ce n’est pas un 
élément important, mais c’est vrai aussi que ça prend pas mal de temps, 
en théorie on remplit un document…(…) Mais attention, moi je raisonne 
comme ça mais j’ai mon âge, mais je sais que les plus jeunes ne 
raisonnent plus comme ça (…) tout travail doit être rémunéré, et 
qu’effectivement comme c’est prévu… Quand je vois par exemple mes 
jeunes collègues si elles ont été à un truc et qu’elles n’ont pas été 
payées, elles vont retéléphoner pour dire « hé, quand est-ce qu’on sera 
payé de ça? » c’est normal elles ont raison.’  
(GP 15: M, 62y) 
The educational aspect of the MDT meeting: 
Participating GPs state the MDT meetings to be informative to them in 
regards to scientific knowledge (e.g. new chemotherapy regimens), 
although it does not replace continuing medical education. 
‘Wel, het is wel een manier om kennis bij te blijven he. Er is evolutie op 
oncologisch vlak waarbij dat ge vooral aan de hand van casuïstiek toch 
wat extra input en extra kennis kunt verwerven.’ 
(GP 2: M, 42y) 
The team composition of the MDT meeting: 
In some hospitals, the specialists attending the MDT meeting are not the 
same as the specialists treating the patient. This results in MDT meeting 
discussions and decision that are not always taken into account during the 
following treatment of the patient. Consequently, GPs doubt the benefits of 
attending these kinds of MDT meetings. 
‘Als gij naar een MOC gaat bij het begin van een behandelingsplan en 
ge zijt daar bij en ge spreekt over een aantal zaken, maar daar wordt er 
verder niet meer op terug gekomen, na, dan heb je het gevoel: wat ben 
ik daar gaan doen he. 
 100  MDT meetings in oncology KCE Report 239 
 
I: dat is ook een ervaring die je al gehad hebt? 
B: ja. 
I: en waar heeft dat dan mee te maken? 
B: dat heeft vaak te maken met de anonimiteit van de specialisten. 
Vooral in het UZ is dat een probleem omdat patiënten bij de diagnose 
door dokter x behandeld worden, in supervisie bij een assistent die dat 
dan volgt. Ge gaat naar de MOC en ge hebt eigenlijk wel wat interactie 
met die …, maar in het verder verhaal wordt dat dan een behandeling 
door een groep andere mensen gedaan.’  
(GP 2: M,42y ) 
The video-conference: 
Though GPs appreciate and welcome MDT meeting through 
videoconferencing, they also mention a practical barrier. The use of different 
technical systems for MDT meeting through videoconferencing used by 
different hospitals is very confusing to GPs and not very inviting. 
‘Ja, dat ergert mij mateloos in het UZ als dat niet vlot gaat. Dat we 
verwend zijn he, en ik denk altijd; alle, waarom doen jullie dat niet in de 
rest van de ziekenhuizen? Waarom moeten ze opnieuw het warm water 
uitvinden? Het gaat goed. Ze hebben de problemen gehad met fire 
walls en inloggen en hoe kan dat veilig, en beveiliging. Waarom moet 
een ander ziekenhuis tot hetzelfde komen? Blijkbaar gaat het minder 
goed. Allee.’ 
(GP 1: F,55y) 
2 – Interpersonal factors influencing participation of GPs in MDT 
meetings 
Although participants of our study express themselves in favour of the MDT 
meeting, they specify some aspects limiting GPs’ active participation during 
the meeting. These experiences are demotivating and may restrict GPs’ 
participation in the future. 
Interpersonal aspects during MDT meetings: 
A discouraging interpersonal theme is the feeling of not being valued (as a 
person or as a professional) and the feeling of not being part of the team 
leads to lesser efforts of the GP for future participation (as described earlier). 
Contrarily, participants also mention a better interpersonal relationship with 
some specialists emerging through MDT meeting participation. Equally, the 
GPs’ precise role description during the MDT meeting was mentioned as a 
benefit. These effects of the MDT meeting are welcomed and may act as a 
facilitator for future attendance. 
‘mijn doorverwijsgedrag denk ik. Ik denk dat ik zelfs mijn oncologische 
patiënten doorverwijs naar het ziekenhuis die die teleMOC aanbiedt 
omwille van het feit dat door die teleMOC, dat ge een betere 
verstandhouding hebt met de specialisten.  
I: dus het is ook iets dat een stuk vanuit uzelf gestuurd wordt? 
B: ja. Dat groeit ook he. Als ge een patiënt doorverwijst, en je weet : dat 
is mijn plaats in dat ziekenhuis of mijn plaats wordt daar gerespecteerd 
en gevalideerd, de communicatie verloopt beter, voor de patiënt geeft 
dat meer vertrouwen, dan stimuleert dat ook in de beide richtingen’ 
(GP 2: M, 42y) 
Interprofessional contact previous to the MDT meeting: 
When the result of the MDT meeting discussion is known in advance (e.g. 
through pre-MDT meeting contact between GP and specialist) or when the 
case in itself and the home care situation is not complex at all (e.g. breast 
cancer patient without comorbidities and straightforward therapeutic 
regimens), GPs in this study mention not being motivated to make efforts to 
participate in the MDT meeting. 
‘En we hebben dan een paar maanden later ook een MOC van iemand 
met een colonbehandeling, die ze ook zeiden van: hij had van de 
specialist gehoord dat hij palliatief ging zijn omdat ze eigenlijk niets 
meer gingen doen en een week later was het MOC. Dat mijn collega 
zegt: het is voor te zeggen dat ze niets meer gaan doen. Daar moet 
eigenlijk niemand naartoe gaan. Ah ja. Omdat ge daar ook tijd mee kwijt 
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zijt en als het inderdaad maar is voor dat te zeggen, allee, we leren er 
als huisarts niets bij.  
I: als het alleen maar is om dat te zeggen, hoe bedoel je dan? 
L: hewel, als het alleen maar is om te zeggen dat patiënt palliatief is, de 
behandeling wordt stopgezet, we gaan geen andere behandeling meer 
opstarten. Als je dat al weet als huisarts, dan is dat misschien dat de 
specialist dat efkes wil checken bij de andere collega’s. Dat gebeurt 
zelden hoor. Misschien bij 2 of 3 MOCs dat we niet geweest zijn omdat 
we wisten, en dan is dat meestal omdat we kort voordien al iemand 
gehoord hebben die zei: “dat zal de beslissing zijn”.’ 
(GP 3 : F, 29y)  
Professional confidentiality: 
Professional confidentiality has been named as a barrier since attending 
MDT meetings leads to overhearing other patients’ stories. 
‘Je ne me sentais pas à l’aise d’être au milieu des autres spécialistes et 
d’entendre discuter de patients qui ne me regardent pas et il y avait les 
noms et tout ça et je me disais que ce n’était pas tellement ma place’ 
(GP 12: M, 39y) 
Contrarily, to other participants of this study, the discussions about other 
patients act as a facilitator for attendance, as a means of learning more 
about cancer care. 
‘een gezamenlijk proces inderdaad. En dat duurt eigenlijk niet zo lang, 
ik verschiet er altijd van. Zo’n oncologisch consult, tien minuten, max 
een kwartier en meestal zijn dan de geesten in dezelfde richting gesteld. 
En dat, voor mij is dat ook heel boeiend want ik blijf soms zelf langer 
zitten als het mijn patiënten niet zijn, gewoon omdat ik vind dat boeiend 
van te zien hoe dat ze daar gewoon over praten.’ 
(GP 6: M, 58y) 
6.3.2.3 What are the GPs’ suggestions and expectations toward 
future effective participation in the MDT meeting? 
Based on their experiences as described above, study participants 
expressed their preferences towards future MDT meeting participation 
according to three different domains: GPs’ responsibility and continuity of 
care; the organisational aspects of the MDT meeting; and the meeting 
dynamics during the MDT meeting. 
The GPs’ responsibility and continuity of care:  
GPs consider their participation in the MDT meeting to be self-evident as a 
part of their job and are willing to invest time and energy in it. As they 
consider MDT meeting participation as one of their responsibilities, they 
prefer to attend whenever possible. GPs in this study position the MDT 
meeting as an element in the continuity of patient care and not as an isolated 
meeting between health professionals. A major prerequisite is mentioned in 
order to realise this continuity, namely information flow. A MDT meeting 
discussion must be based on all previously known relevant information (both 
physicians’ and patient’s information) and lead to conclusions which must 
be communicated to all relevant actors (again both physicians and 
patient/family members). Only when such information-transparency and 
information-coherence are realised, the MDT meetings have a rightful place 
in the GP’s task description concerning continuity of care. 
The organisational aspects of the MDT meeting: 
 The invitation:  
There was no general preference about the way the invitation was 
delivered (by email or by telephone) but there was consensus that it 
needed to be timely in order for the practice to be organised. 
Furthermore, this would offer the opportunity to the GP to prepare for 
the discussion and even to talk with the patient before the MDT meeting 
to clarify the patient’s view. If a timely invitation is difficult, then a 
telephone alert was preferred. 
‘Donc je pense qu’il faut les (les autres MG) inciter et je pense que une 
des façons, je pense qu’un contact personnel ça peut être efficace. Ici 
par exemple, moi, maintenant, je reçois aussi par mail, donc je peux 
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être informé sauf quand c’est décidé en dernière minute, mais je pense 
que par exemple si l’infirmier ou l’infirmière de coordination, puisque 
c’est son rôle dans le service d’oncologie, peut téléphoner au médecin 
en disant « ben voilà, il y aura la concertation de votre patient tel jour à 
telle heure, est-ce que vous venez ? ».’ 
(GP 15: M, 62y) 
 The timing of the MDT meeting:  
There were differing ideas, but organising the MDT meeting at noon 
seems preferable because this causes the least interference with daily 
practice. 
‘Ja, in feite is dat zouden ze bijna moeten maken dat dat altijd rond, 
tussen, op allez rond 12 of rond 1 is. Dat dat plaats vindt.’ 
(GP 4: M, 38y) 
‘Toujours à la même heure. Toujours sur l’heure de midi qui est l’heure 
la plus facilement …switchable…parce le matin consultation, l’après-
midi rendez-vous donc….’ 
(GP 14: F, 48y) 
 The MDT meeting through video-conferencing:  
This has been described by our study participants in a positive way, 
though not all of them had experience with it. The most positive attribute 
of video-MDT meeting is the limited impact it has on practice 
organisation and time loss. Participants expressed a preference 
towards expanding the implementation of video-MDT meeting. On the 
other hand, GPs mention the loss of personal contact during video-MDT 
meeting, which has previously been named as a strong benefit of a 
regular meeting. It is not clear if this loss is being outweighed by the 
practical benefits of video-MDT meeting. 
‘Ha: daar hebben we een tele-MOC. En dat gaat schitterend. Dat werkt 
perfect. Er kan altijd iemand uit de praktijk inloggen. We worden twee 
dagen tevoren meestal verwittigd, de vrijdag voor de maandag of de 
maandag voor de donderdag. Dat is over de middag bij hen; ge krijgt 
een uur om in te loggen en dat duurt maximum 10 minuten. Ge verliest 
daar geen tijd mee, we zijn hier toch op de praktijk, of ge komt terug en 
zijt ge een beetje te vroeg, ge kunt iets van post doen, ge kunt iets 
anders doen, een dossier bijwerken, ge kunt direct in uw dossier 
meekijken, mee invullen op de computer. Ge ziet ook de collega’s in de 
zaal, zij zien u. Ik vind dat schitterend.’ 
(GP 1: F, 55y) 
‘Et voilà, l’outil informatique est quelque chose que je maîtrise plus que 
moyennement. Donc voilà, je préfère toujours aller serrer la main au 
gens.’  
(GP 10: F, 38y) 
‘Le contact humain passe moins bien. Et puis, étant à dix minutes de 
l’hôpital, je ne gagnerais pas tellement de temps parce que, là aussi, je 
vais me retrouver dans le flux d’une réunion et ça demande une 
attention et … enfin j’ai déjà eu une réunion comme ça, enfin par 
ordinateur, et je trouvais ça plus difficile à suivre’  
(GP 12: M, 39y) 
The meeting dynamics during the MDT meeting:  
Participants expressed their preferences and expectations on three aspects, 
building on the description of the GPs’ current experiences: 
 Time efficiency: 
As time management seems to be very important for GPs, the practical 
organisation of the MDT meeting is fundamental: giving priority to 
patients of participating GPs, structuring the discussion and making 
sure that the necessary specialists are present are factors that have 
been mentioned. 
 Agreements on communication of the MDT meeting results to the 
patient:  
There must be clear agreement on what has to be said to the patient 
and by whom it will be said, in order to avoid conflicts of differing 
messages. 
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 The educational effect of the MDT meeting: 
Some GPs mention the educational significance of a MDT meeting. 
Paying attention to this aspect of the discussion, with information 
delivery tailored to the GPs’ needs, could be important. 
6.4 Discussion 
The overall meaning of the study results can be formulated in this way: 
“GPs are prepared to participate in every MDT meeting, whenever it is 
feasible and whenever it is useful”. 
This phrase summarises the 3 most important findings: 
1. Attendance to a MDT meeting is part of the GP’s work 
2. The practical organisation of MDT meetings and the GP’s practice often 
act as barriers to attendance 
3. The GP’s perceived added value to the MDT meeting is an important 
motivator to participate 
The discussion of these three findings reveals some opportunities and 
starting points to enhance the GPs’ attendance and their participation in the 
MDT meeting. 
These opportunities can be reported using two frameworks: 
 Themes on micro-, meso- and macro-level, referring to the organisation 
of healthcare delivery.74 
 Themes on structural, process and outcome measures, referring to the 
evaluation of the quality of care.75 
An overview of the main results according to these two frameworks is 
presented in Figure 38. 
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Figure 38 – Main themes influencing the GP’s role in the MDT meeting 
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6.4.1 Attendance to the MDT meeting is part of the GP’s work 
Attending the MDT meeting is seen as an integral part of the continuing care 
GPs provide to their patients. As a result, GPs want to take up their 
responsibility and participate in the MDT meeting. 
The rationale for this choice is to be found in the GP core competences, as 
described by the World Organization of Family Doctors (WONCA).k All 
competences have been mentioned by the participating GPs in their 
motivation to attend the MDT meetings. All participants of our study however 
are GPs with MDT meeting experience and therefore this result may be 
influenced by this bias. We do not know whether GPs without MDT meeting 
experience would have responded in the same way. 
These core competences are: 
1. Holistic approach: including psycho-social aspects 
2. Person-centred care: doctor-patient relationship and context-/patient-
centred approach 
3. Primary care management: first point of contact, coordination of care 
4. Comprehensive approach: acute and chronic problems, health 
promotion and well-being 
5. Specific problem-solving skills: impact of prevalence and incidence, 
early/un-differenced stage 
6. Community orientation 
A major topic of concern for the participating GPs is the continuing 
information flow. The patient’s history (medical and non-medical) must 
inform the MDT meeting discussion which in turn must shape the 
organisation of care in the future. The optimisation of this information flow 
may comprise interventions on multiple levels: preparedness to share 
information (micro-process level), organisational aspects of the MDT 
meeting providing time and space (meso-process level), and the practical 
requirements for managing all the information in an accessible way, e.g. in 
a shared online Electronic Health Record (macro-structural level). 
                                                     
k  http://www.woncaeurope.org/gp-definitions 
Other studies confirm the specific tasks and roles of GPs during cancer 
follow-up, thereby stressing the need to install a reliable information flow. 
The tasks and roles mentioned in the literature are: flexible mediator 
(between patient and clinic, interpreting and translating), efficient handyman 
(solving practical problems locally), and personal companion throughout 
illness.76, 77 They are congruent with our findings. This confirms the 
statement that the MDT meeting process is in the scope of action and 
responsibility of the GP. 
6.4.2 The practical organisation of MDT meetings and GP’s 
practice often act as barriers to attendance (Structural 
aspects on micro- and meso-level) 
The majority of the practical aspects of the MDT meeting organisation which 
need improvement, concern time management aspects. Some suggestions 
can be made: to be invited on time, direct contact during the invitation, the 
choice for a protected time period outside consultations and home visits, and 
effective discussion on the time they arrive (without waiting time). This 
practical inconvenience has to be outweighed by the perceived benefit of 
attendance in order for the GP to participate.78 Other authors suggest, 
however, planning enough time during the discussion for each case.79 
The positive interactions during the MDT meeting are based on good 
interprofessional relationships (GP and specialist). In regions with low 
hospital density, the cancer specialist network is smaller and may facilitate 
interpersonal relationships between GPs and the local hospital specialists. 
But as low hospital density is associated with longer distances to other 
entities, this factor plays an inhibitive role for attending MDT meetings in 
more distant hospitals. 
A good relationship enhances GPs’ efforts for attending MDT meetings. It 
might be helpful, e.g. by organising joint CME sessions, to foster 
interprofessional relationships in different ways (macro- and meso-
structural). The literature shows that interprofessional education leads to 
better interprofessional collaboration, which in its turn leads to better patient 
care.80, 81 
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As suggested by the participants, the GPs’ practice organisation may 
interfere with attending the MDT meeting. Group practices, as they share 
care and workload between colleagues, may have an advantage in this.l 
Practice organisation does not seem to influence the continuity of out-of-
hours palliative care provision.82  
6.4.3 The GP’s perceived added value to the MDT meeting 
discussion is an important motivator to participate 
A GP’s self-confidence about his/her contribution to the MDT meeting 
process varies between GPs. The MDT meeting is often perceived as a 
multidisciplinary process focused on medical expertise. Some GPs found it 
difficult to bring non-medical information (psychosocial or patient-context 
related information) into the discussion, as has also been described in the 
literature.83 This might even be more difficult if the GP is not sure whether 
he/she represents the patient’s view, due to lack of an official declaration or 
written statement from the patient, e.g. ACP documents (meso-process). A 
timely invitation, offering the GP enough time and opportunity to contact the 
patient and discuss his/her will before the MDT meeting, might reinforce the 
GP’s participation. Research shows that there is no uniform policy between 
hospitals on how and when GPs are invited. 
In the complex situation of cancer care, collaboration between GPs and 
specialists is a necessity. GPs spontaneously respond to this need by 
getting into direct contact with the oncologist and by using networks of 
trusted healthcare providers.84 In our study, those informal contacts remain 
important and are complementary to the MDT meeting. Building those health 
professional networks is even stated as being an explicit outcome of the 
meetings (meso-process and -outcome). 
GPs recognise that the perceived degree of complexity needs to be high 
enough to motivate him/her to attend the MDT meeting. This statement 
questions the necessity of GPs’ attendance of all MDT meetings where their 
patients are discussed. Another way of sharing information could be 
preferred in the case where treatment choice is less complex.79 Healthcare 
                                                     
l  In the province of Luxembourg, the density of GPs (2009) is the lowest and 
the decrease in home visits (between 2006–2010) the highest in Belgium. 
professionals (e.g. specialised nurses in oncology, MDT meeting 
organisers) calling them before the MDT meeting with specific questions 
(functional status of the patient, patient’s preference or will, specific aspect 
of home care, socio-economic organisation…), so that the GP can fulfil 
his/her role without being present. This puts emphasis on the GP’s specific 
role, and could represent a time-saving procedure for the GP and the other 
specialists. The benefit of a group discussion with other disciplines, 
however, is lost in this way.  
Remuneration is not valued very highly. To our respondents, the financial 
aspect does not outweigh the described barriers. It cannot be concluded 
from this study if the remuneration would gain importance in the case of 
compulsory attendance to a higher frequency of MDT meetings. 
6.4.4 Some suggestions for improvement  
Participants from our study stated their preferences about the MDT 
meeting’s process and results. These are discussed and formulated as 
suggestions for improvement and presented in Figure 22. 
Some advantages have been mentioned about video-MDT meeting: more 
GPs will participate mainly due to the lack of interference with practice 
organisation. A prerequisite for an effective implementation of video-MDT 
meeting is the use of a uniform and simple software package to make it 
acceptable for less IT-minded GPs. Unfortunately, the networking effect, 
recognised as a strong motivation factor by participants, will be lost. 
In addition, there are differing views towards the added value of meeting 
each other during the MDT meeting. There is a range from preferences of 
actually meeting others, through participation through video-MDT meeting, 
to preferences of a private telephone call to the specialist. Depending on the 
prioritisation in the practice (which patients need more attention), the value 
of interpersonal contact, and the ease of participation in a group discussion, 
GPs might be motivated to participate in MDT meetings or not. Exploring 
possible strategies for selecting appropriate patient cases for in-person MDT 
meetings might benefit the tight schedule and speedy meetings. 
Meeus P, Van Aubel X. Performance de la médecine générale, bilan de 
santé. Health Services Research (HSR). Bruxelles: Institut national 
d’assurance maladie-invalidité (INAMI). 2012. D/2012/0401/11 
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The synergy and complementarity between GPs and specialists during the 
multidisciplinary oncological consultation has to be highlighted. The MDT 
meeting’s organisers, the specialists, and the GPs need to be informed and 
convinced of the added value of sharing their expertise. The MDT meeting 
process may benefit form a clarification of each participant’s role, as many 
other studies have shown.84, 85 
Some important information coming from the patient (functional status, 
patient’s will about treatment options) is needed for the organisation of care 
at home (side-effects, extent of the home care for coordination) could be 
systematically integrated in the MDT meeting discussion and translated into 
the MDT meeting report. GPs suggest a more detailed report including 
specific information relating to the GP’s perceived role: information for the 
patient (what has to be said by whom), information for the organisation of 
care at home (what is needed, what can be expected). Other studies have 
emphasised the importance of good communication after the process and 
claim that the report has a good structure.77, 86, 87 In the MDT meeting 
process, as in general, there is an opportunity for GPs and specialists to 
reach an agreement on what a report should include to raise its utility.88 
Standardising the MDT meeting report, with the aid of a shared electronic 
patient health record might optimise the efficiency of the information flow. 
A MDT meeting is an operationalisation of a good concept: interprofessional 
patient care. Embedding the MDT meeting in a continuous process of 
interprofessional oncological care might raise the awareness, conviction and 
commitment of all participants to enhance the effectiveness of the entire 
care process. 
 
Table 27 – Main themes for improvement 
 Structural Process Outcome 
Micro (patient-level) Video-MDT meeting software Preparation of information according 
to MDT meeting agenda and focus 
Patient’s selection 
 
Meso (between primary care and 
hospital) 
Timely invitations  Patient’s selection and concomitant 
level/mode of communication 
MDT meeting report 
Macro (national level) Position of GP in cancer care 
Clarification of role and position of GP 
in MDT meeting 
Stimulation of interprofessional 
collaboration 
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6.5 Strengths and limitations of the study  
6.5.1 Strengths  
This is the first time the GPs’ preferences and experiences have been 
collected and described. The sampling has been done countrywide. 
6.5.2 Limitations  
We cannot exclude a social desirability in some answers, as the participants 
were interviewed by peers (the interviewers were GPs like the participants). 
This may have influenced discussions on willingness to attend and 
discussions on remuneration. However, this is not a risk for the validity of 
the discussions on barriers to attendance. Suggestions for improvement 
focus on overcoming the barriers and are therefore valid. 
We cannot conclude from this study what the opinions are of GPs with no 
MDT meeting experience. GPs without MDT meeting experience may have 
other barriers for attendance than participants from our study. These 
barriers, however, will not originate from lived experiences and may only 
originate from second-hand knowledge (or lack of knowledge) on MDT 
meetings. The results of the QUALICOPC study indicate that 20.1% of 
Flemish GPs and 57.4% of Walloon GPs are not aware of the MDT meeting 
existence (Presentation by Prof dr Sara Willems on the results of the 
QUALICOPC study on 25/03/2014 for the NRKP). 
6.6 Key messages  
GPs have a unique position in health care: 
 This position results form sharing a history of longitudinal care 
with the patient, leading to the acquisition of unique information 
on medical, personal and social patient-related topics. 
 This information and the patient’s expectations render the GP a 
representative of the patient. 
As a result of their unique position: 
 GPs perceive MDT meeting participation as part of their job  
 GPs are willing to make efforts to attend the MDT meetings  
During the MDT meetings, the GPs tasks and roles are dependant on: 
 the complexity of the patient’s case 
 the quality of the interactions with other MDT meeting participants 
 practical and contextual variables 
 task agreements between GPs and hospital specialists 
The GPs’ current experience with MDT meetings are mixed and are 
dependant on: 
 practical factors like the timing and quality of the invitation, timing 
of the MDT meeting during the day, proximity of the hospital, the 
team composition during the meetings  
 interpersonal factors like the quality of the relationship with 
specialists, the feeling of being valued as a person and as a health 
professional, and the educational aspect of the MDT meeting   
Alternative for MDT meetings: 
o MDT meeting through videoconferencing is a valued 
alternative, though difficulties with the use of different software and 
techniques may be an obstacle. 
The MDT meeting process in itself fosters interpersonal contact with 
specialists, eventually leading to better patient care. 
As GPs are willing to take their responsibility in the continuity of 
patient care, they made some suggestions for improvement: 
 the information-flow must be fluid and high-quality, starting from 
the invitation and ending with the report 
 the MDT meeting timing is best at noon to interfere as little as 
possible with the GPs’ practices 
 video-MDT meeting should be made accessible and easy to use 
 during the MDT meeting, attention should be paid towards time-
efficiency, the educational aspects of the MDT meeting and 
towards clear agreements on communicating MDT meeting results 
to the patient. 
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7 CONCLUSION, DISCUSSION AND 
POLICY RECOMMENDATIONS 
Conclusion, discussion and policy recommendation are presented in the 
document entitled “Summary of the scientific report” which is available on 
the KCE website.  
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